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1. Overview of Learning 
 
I am a cancer researcher and a translational medicine practitioner. This doctorate has been 
a challenging journey for me in many ways, not least the requirement to put myself at the 
centre of the work which, for a scientist, is an anathema – or so I thought. To explore in this 
way has itself been a profound learning experience and one I am already disseminating in 
the training of new doctors.  
The doctorate has required of me an exploration of my motives, my way of dealing with 
opposition and how I learn. It has led to me exploring my values and thinking about concepts 
like altruism. I always saw myself as altruistic; now I might describe myself as ethically 
motivated. I have been able to see that my work in today’s complex society requires me to 
be more than a researcher and how much I have needed to improve my knowledge and 
skills in different areas like political lobbying, media, politics and public health. The learning 
threads I have extracted through exploring a selection of my public works all relate to some 
form of transformation or indeed translation. I am a cancer researcher and a translational 
medicine practitioner. The term ‘translational medicine’ reflects the complexities that face the 
movement of what is known in the laboratory to practical application in the clinic. The 
process is long, frustrating and sometimes quite disheartening and the core skill that is 
required is an understanding of and movement between different areas of practice. When I 
look back to the beginning of this doctoral process I see that I had a particular way of dealing 
with the translation, a more battle-focused stance. Now that I have taken the time to stand 
back I believe I have widened my view and see the way forward as collaborating with other 
ethically motivated people and learning more about the agendas of other stakeholders and 
how to deal with them productively.  
So this journey is one of transformation and translation – negotiating understanding, 
changing attitudes and mobilizing actions in oneself and in others. I have spent my life 
researching cancer treatments. I have selected four examples (see Introduction) from 
several dozen to illustrate best the major challenges facing cancer researchers in translating 
their work from the laboratory to the clinic and the changes that have been required in me as 
a professional. They are also the ones that demanded of me the greatest challenge: to 
change the way I was approaching the obstacles or risk becoming marginalized as a brilliant, 
but possibly mad, scientist.  
The following is a summary of my thinking and development to act as a guide through the 
context statement.  
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Scientific obstacles to translation from research to optimal clinical efficacy 
Response: to develop  
1. Personalized treatments 
2. Inhibitors of resistance 
3. Delivery systems. 
Professional learning threads:  
From laboratory to clinic. 
 
Environmental obstacles to translation from laboratory to cancer patients 
Response: to tackle the environmental obstacles more efficiently 
1. The monopoly of the Big Pharma 
2. To share knowledge with practitioners 
3. To convince practitioners of the efficacy through knowledge and training 
4. To convince the media through sound research and lobbying  
5. To collaborate not just on the science but on lobbying through knowledge, 
persuasion and outcomes 
6. To lobby decision makers at the highest level to rethink current methods of 
translation and criteria for trials, etc.  
Personal learning threads: 
From sole campaigner to president of a new association and a new journal.  
 
Personal obstacles to transformation 
1. Challenge the seductive power, for me, of ‘the loneliness of the long-distance runner’ 
2. Reflect on the ‘doing’ with passion and on the personal is political, the personal is 
universal 
3. Giving myself time to reflect on the cost of the drive to save lives in time 
4. Recognizing that ‘the good and the bad’ duality thinking avoids complexity  
5. Transforming opposition into effective strategies 
6. Transforming the energy of the revolutionary into collaborative leadership with others.  
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2. Introduction  
 
The science context  
In my roles of hospital translational medicine practitioner, cancer researcher and President 
of the Hellenic, European and International Society of Molecular and Genomic Medicine and 
Research, I take novel treatments from the laboratory to the clinic. This is done mainly 
through presenting tailored molecular targeting therapeutic approaches, based on -omics 
that analyse the interactions of biological information objects in various omes including 
genome, proteome, metabolome, expressome, and interactome, in plenary sessions or 
invited lectures of international medical congresses. Presenting at congresses is a political 
statement as well as a scientific one that I explain more later, but briefly one does so to 
contribute to open knowledge and thus gives up the patent rights – but no-one else can own 
them either, including the pharmaceutical companies.  
In my field, congresses are the highest level of peer review since work is accepted and 
approved by elite professionals and academics in the field of clinical oncology and 
translational cancer medicine. Congresses are the source of cutting-edge medical 
information for new treatments that are then published in the summit’s proceedings on which 
regulatory agencies base their approvals. This is the ultimate in medical communication 
because it offers the most recent advancements in oncology to participants who can ask 
questions or may ask for future collaborations. Furthermore, by the time a new treatment is 
published in peer reviewed journals it will be out of date, for by then congresses will have 
already published further advances. In addition, medical doctors and oncologists who attend 
these congresses, auspiced by medical universities, earn continuing medical education 
credits that they need for renewing their medical licence.  
I have presented papers more than 2,500 times and have received more than 150 
international awards in personalized medicine. I have become one of the recognized 
pioneers of the last two decades in aiming to eradicate fatal tumours from the start by 
inducing apoptosis, otherwise the tumours become chemo/radio resistant, leading to lethal 
metastasis.  
This congress approach is to ensure independence of research. In my field we know that the 
current approaches by the large pharmaceutical companies known as the Big Pharma tend 
to focus on the ‘one size fits all’, but cancer rsearchers know this is inappropriate and that 
symptom management only uses a small part of the knowledge we have and could go 
forward with. Finding a cure for cancer or effective treatment leading to its eventual 
eradication is not only within our grasp but can be part of a successful business model. This 
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may sound dramatic, but this journey through my work may offer some important information 
and insight into the world my colleagues and I function in daily.  
As a researcher and advocate of individualized treatment, after decades of stagnation in the 
development of effective approaches to cancer treatment my role and goal is to discover 
novel molecular approaches to eradicate tumours and to bring them into clinical use. I have 
to concern myself with where to find funding for clinical research free from conditions of 
patent rights. This is looked at in more detail later.  
Personalized Medicine uses what we call pharmacogenomics. Treatments like 
chemotherapy are administered to all patients without taking into consideration molecular 
level differences, which are addressed by genomics technologies. Chemotherapy can create 
resistant tumour types that proliferate in an unconstrained way due to an enhanced rate of 
DNA repair, activation of drug-efflux pumps and genetic, epigenetic and generally -omic 
alterations that inhibit induction of apoptosis. Furthermore, these conventional 
chemotherapies are extremely toxic, exerting severe side effects because they disrupt 
cellular proliferation and DNA metabolism in fast-growing cells of the human body, including 
those of bone marrow, the gastrointestinal tract and hair follicles. Some severe side effects 
of chemotherapy include cancer such as leukemia due to massive DNA damage; 
chemobrain that involves brain damage and memory loss, impaired orientation, brain 
shrinkage, deterioration of cognitive function and vision problems; systemic toxicity including 
infections due to immunosuppression, toxicity in the liver, kidney, heart and lungs, anemia, 
appetite and metabolic changes leading to cachexia and blood clots.  
http://www.medicinenet.com/script/main/art.asp?articlekey=21716 
http://www.cancervic.org.au/about-cancer/types-treatmentstrials/chemotherapy/ 
side_effects_of_chemotherapy.html http://canceraustralia.nbocc.org.au/breast-
cancer/treatment/side-effects-of-chemotherapy, 
http://www.rethinkingcancer.org/resources/magazine-articles/7_1-2/chemotherapy-side-effects. php  
http://www.telegraph.co.uk/health/healthnews/6690767/Woman-died-after-cancer-drug-side-
effects-were-ignored.html 
 
I have given a lecture at the Annual Meeting of the Surgical Society of Oncology in the 
United States proving that, after surgery to cut out the organs affected by cancer, we have 
enhanced angiogenesis and subsequent metastasis in cancer patients. In addition, radiation 
is as toxic as chemotherapy, enhancing synergistically the risk of developing secondary 
tumours by approximately 300 per cent. A publication in The Lancet by German 
epidemiologist Dr Ulrich Abel from the Oncology Clinic of University of Heidelberg has 
confirmed some of my published results from 1994 to the present, based on exhibition of 
mechanisms of novel therapeutic approaches,1 stating that chemotherapy for advanced 
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epithelial cancer is a ‘scientific wasteland’ because there is no scientific evidence to 
demonstrate that conventional chemotherapy can extend the survival rate of cancer patients 
suffering from the most common epithelial cancers. He had previously made a 
comprehensive review and analysis of every major study and clinical trial of chemotherapy 
ever carried out which he published in The Lancet in 1991, stating that the overall worldwide 
success rate of chemotherapy was ‘appalling’ because there was simply no scientific 
evidence available anywhere that chemotherapy can extend in any appreciable way the lives 
of patients suffering from the most common organic cancers, emphasizing that 
chemotherapy can rarely improve the quality of life.  
http://cancertutor.com/ChemoSp,heill/deathbydoctoring4.htm 
http://www.karinya.com/chemotherapy.htm  
http://just-say-no-to-chemo.blogspot.gr/2011/07/battle-against-cancer-industry.html  
http://icurecancer.ning.com/profiles/blogs/the-battle-against-the-cancer 
 
Furthermore, he states that at least 80 per cent of chemotherapy administered throughout 
the world is worthless and is akin to the ‘emperor’s new clothes’ (http://www.mnwelldir. 
org/docs/fraud/chemo.htm) – neither doctor nor patient is willing to give up on chemotherapy 
even though there is no scientific evidence that it works. Surviving does not prove that it was 
due to the chemotherapy, as there are so many other factors and variables to consider. 
Furthermore, a survey of oncologists at McGill University Cancer Center has reported that 
75 per cent of them would refuse any type of chemotherapy, citing the ‘ineffectiveness of 
chemotherapy and its unacceptable degree of toxicity’, according to Philip Day’s, Cancer: 
Why We’re Still Dying to Know the Truth (Credence Publications, 2000).  
 
http://www.curenaturalicancro.com/2-physicians-refuse-chemo.html 
http://www.cancernetwork.com/display/article/10165/66128 
http://cancercommonsense.com/#/statistics/4538345819  
http://eclinik.wordpress.com/health-tips/why-you-should-refuse-chemotherapy/ 
http://hfs1.com/DOCTORS_ON_CANCER_CURE. php  
http://curezone. com/blogs/fm.asp?i=967954 
http://www.scam.com/showthread.php?t=34028 
http://curezone.com/forums/am.asp?i=1284922 
http://www.curenaturalicancro.com/2-physicians-refuse-chemo.html 
http://salonesoterica.wordpress.com/2007/12/01/why-75-of-doctors-would-refuse-chemothrerapy-
on-themselves/ 
http://www.naturalnews.com/036054_chemotherapy_physicians_toxicity.html 
 
A study published in 2005 by Professor Michael Morgan, Chief of Medical Oncology at 
Australia’s Royal Prince Albert Hospital, reports that, despite the use of new and expensive 
single and combination anticancer agents, the contribution of chemotherapy to five-year 
survival in adult cancer patients was 2.1 per cent in the United States and 2.3 per cent in 
Australia (http://www.icnr.com/articles/ischemotherapyeffective.html).  
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Another researcher, Professor Hardin Jones from the University of California,2 has 
concluded that the survival rate of untreated cancer patients who had refused conventional 
cancer treatments including chemotherapy, radiation and surgery, was enhanced four-fold 
compared to cancer patients who had undertaken these treatments. In addition their quality 
of life was better. Although this finding is quite surprising to the general public, it is not 
considered so by many in my profession, given that our knowledge is greater than that 
communicated to the public through a variety of channels. In my research I have proved 
scientifically the disadvantages of conventional chemotherapy by exhibiting molecular 
mechanisms based on signalling pathways using advanced and state of the art -omic 
technologies. I have been very outspoken at medical congresses about these issues and am 
supported by sound knowledge and research.  
I ensure that I have all the scientific facts for explaining and supporting my research work on 
novel molecular treatments tailored to each patient’s genomic. An example of 
pharmacogenomics in the oncology sector consists of the FDA’s decision to revoke its 
approval of Avastin for use in metastatic breast cancer due to severe side effects including 
internal bleeding, blood clots, heart failure and colon perforation. One of my previous 
research works included the exhibition of VEGF165b as a resistant mechanism for Avastin. I 
presented this in the 2008 Gastrointestinal Cancer Symposium of the American Society of 
Clinical Oncology (Giannios, 2008). Personalized anticancer treatment is completely tailored 
to the requirements of the individual cancer patient using pharmacogenomics (Hu et al., 
2005) or even molecular testing for stratifying cancer patients with shared biological 
characteristics to the most efficient treatment by using one or few molecular biomarkers 
(Jorgensen et al., 2007; Trusheim et al., 2007).  
Another drug, the antidiabetic Avandia, is still on the market with the FDA’s permission 
despite exhibiting serious side effects. Avandia is a drug for type-II diabetes belonging to the 
family of thiazolidinediones. Since its approval in 1999 it has killed about 100,000 diabetic 
patients from heart attacks, strokes and liver problems and still continues to cause more 
than 500 heart attacks and subsequent deaths per month, according to the US Senate 
Finance Committee report.  
http://www.cbsnews.com/8301-504763_162-20009124-10391704.html  
http://www.chicagoinjurylawblog.com/cat-pharmaceutical-litigation.html 
http://www.politicolnews.com/fda-keeps-avandia-for-gsk-profits/ 
http://www.worldwidehealth.com/health-article-Avandia-is-Killing-Americans-FDA-Negligence-
Comes-Front-and-Center.html  
http://www.youhavealawyer.com/avandia/lawsuit-claim/ http://www.bloomberg.com/news/2011-
05-04/glaxo-is-poised-to-settle-about-1-000-suits-over-avandia-drug-lawyer-says.html  
http://www.prweb.com/releases/2012/4/prweb9403970.htm 
http://www.dailyfinance.com/2010/07/13/glaxosmithkline-settles-avandia-lawsuits-fda/ 
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http://www.businessweek.com/news/2012-02-14/glaxo-settles-20-000-lawsuits-over-avandia-
lawyer-says.html  
http://www.fiercepharma.com/story/gsk-resolves-20k-more-avandia-lawsuits-lawyer-says/2012-02-02  
http://www.adrugrecall.com/avandia/lawsuit.html 
http://www.drugwatch.com/avandia/lawsuit.php  
http://www.resource4thepeople.com/defectivedrugs/avandia.html/ http://avandia.legalview.com/ 
 
According to the report, two US senators, Max Baucus and Charles Crassley, even accused 
the company of intimidating physicians, misrepresenting findings and exerting pressure on 
medical researchers to stop publishing the side effects. The New England Journal of 
Medicine published an article in 2007 linking Avandia to a 43 per cent enhanced ischemic 
cardiovascular risk.  
 
http://www.rightinginjustice.com/news/2010/02/22/senators-ask-why-dangerous-avandia-was-not-
pulled-from-market/  
http://www.avandia-legal.com/page/2/?s  
http://www.nejm.org/doi/full/10.1056/NEJMoa072761 
 
The Wall Street Journal reported that Avandia (rosiglitazone) was allowed to continue its 
sales.3 However, in November 2011 the pharmaceutical company involved was ordered to 
settle all the cases and, to date in 2012, it has settled some 25,000 (http://www. 
businessweek.com/news/2012-02-14/glaxo-settles-20-000-lawsuits-over-avandia-lawyer-says.html). 
Issues such as these undermine coinfidence in the Big Pharma.  
A further concern that intensifies doubts about trustworthiness is the Big Pharma’s 
increasing outsourcing policies in the Third World, where people participate in low-cost trials 
and increase further the difficulties in replicating or challenging the findings. According to Dr 
Light’s findings4 presented in Atlanta at the 105th Annual Meeting of the American 
Sociological Association on 17 August, 2010, the phenomenon of enhancing the number of 
patients taking new drugs characterized by low effectiveness and high risks of adverse 
effects is called ‘risk proliferation syndrome’. The Big Pharma argue that the benefits of their 
drugs outweigh their risks, making them valuable treatment options. If the only source of 
funding is the Big Pharma, then many doctors and researchers may believe that something 
is better than nothing in fighting any kind of serious illness, and if they do not bring in funding 
they may not be able to progress in their work and careers. Moreover, if they go against the 
accepted practice for treatment and suggest alternatives they could be sued for malpractice 
in that they did not follow conventional treatment and thus have endangered patients’ lives. 
This is a professional risk few are willing to take.  
I and many of my colleagues wonder why the drug regulators, advocacy groups, politicians, 
the legal system and especially the media do not pay more attention to many of these issues 
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and do something about them. In particular, they could inform people of options through 
creating reliable sources of information to help them make the best choices when faced with 
serious illnesses. For my part, what I have managed to do is to publish many of my novel 
molecularly targeted anticancer treatments, educating the public about the advantages of 
personalized medicine compared to the disadvantages of conventional treatments.5 
I have been fighting for the last two decades as an opinion leader in international oncology, 
cardiology, diabetic and other medical congresses for the establishment for personalized 
medicine which, in my opinion, is the best solution for the rational use of drugs where 
anticancer agents will be prescribed, based on pharmacodiagnostic results.  
However, before we are able to target drugs for each unique genetic profile (Langreth & 
Waldholz, 1999), we must establish stratification of patients who share biological 
characteristics by using pharmacodiagnostic testing to divide patients into biological 
subgroups to be targeted with more effective drugs that exert reduced systemic toxicity. 
Then we can fully move into the realm of personalized medicine to establish a more targeted 
drug therapy, minimizing medication error and high costs to treat drug-related adverse 
effects. In addition to a much more cost-effective drug therapy for patients, personalized 
medicine will be able to reveal mechanisms of the pathogenesis of different diseases and 
their response to drug therapy (Woodcock, 2007) tailored to the individual biology and 
pathophysiology of each patient. This will mean the end of the ‘one treatment fits all’ 
approach that expects the same drug to work in the same way for each patient, because a 
pharmacodiagnostic test will select the drug for each individual.  
By individualized drug treatment tailored to every patient’s unique biology, we will be able to 
administer the right drugs to the right patients with the use of molecular methods such as 
genomics, metabolomics and proteomics. These are affected by genetic variations including 
germine-alterations such as hereditary mutations and somatic ones such as non-hereditary 
mutations. These will improve drug efficacy and minimize side effects in diseases like 
cancer, cardiovascular conditions, infectious diseases, psychiatric illness and respiratory 
diseases currently being treated with a blanket approach in which some patients gain a few 
benefits but most gain little or have added problems (Jorgensen et al., 2007). With the new 
molecular diagnostic methods, we will be able to improve medical treatment in all disease 
areas by achieving the best possible health outcome for each individual. Generally, the drug 
treatments that must be individualized in association with pharmacogenomics in the future 
are the ones characterized today by unmet medical needs such as oncology, infection and 
cardiovascular medicine. Although Sikora (2007) believes the personalized medicine 
approach will significantly reduce the potential subsequent profits for a given drug due to 
market segmentation, the development of pharmacodiagnostics can compensate partially for 
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profit losses and can also cause a reduction in the size of clinical trials that the Big Pharma 
perform for the development of a new drug by minimizing the number of patients who fail to 
respond to a specific therapy (Woodcock, 2007). Thus, the efficiency of any novel 
therapeutic agent can be improved significantly during clinical development with the use of 
predictive biomarker tests, because pharmacodiagnostics may identify those responsive to 
therapy subgroups by reducing the variability of chemosensitivity, especially in cancer where 
chemoresistance is the greatest problem (Hortobagyi, 2004).  
Throughout the last two decades I have seen in the struggle with the Big Pharma over the 
establishment of personalized medicine in oncology that the greatest supporters of the idea 
of individualized medicine are patient advocacy groups, academic groups, some health 
authorities and, surprisingly, some of the health insurance companies that are increasingly 
aware that they pay huge amounts of money for cancer treatments that often fail to work. 
Furthermore, they have to pay for the treatment of the side effects caused by these cancer 
treatments. In addition, health authorities are interested in saving money by moving from a 
blanket drugs approach to new targeted therapies administered in association with 
pharmacodiagnostic tests that will ensure that these novel personalized drugs will be 
administered only to cancer patients with a reasonable chance of being chemosensitive to 
this particular treatment.  
After many years of pressure, regulatory agencies like the FDA have started to support the 
idea of personalized medicine with the formation of initiatives such as the Critical Path6 
because they have come to realize that only personalized medicine can improve the 
efficacy, safety and cost-effectiveness of drug therapy (Lesko, 2007). Not since 2005 have 
they issued guidelines from their concept paper on how future drug diagnostic co-
development should be used for new targeted drugs.  
The principle of personalized medicine has started to spread worldwide, including Australia, 
New Zealand, China, Japan and Europe. In the United States the non-governmental 
Personalized Medicine Coalition (PMC) was formed in 2004 and very active, with members 
from academic medical centers, universities, trade associations, industry such as diagnostic 
companies excluding the Big Pharma, patient advocacy groups, healthcare providers, 
information technology companies, venture companies, health insurance companies and 
government officials. All are all focusing on the understanding, and adoption of personalized 
medicine.  
Cancer researchers like myself have contributed to this shift, but there is still a long way to 
go. I have emphasized in my published work that this transition shan’t be easy. The 
pharmacogenomic methods that must be developed in parallel with the novel drugs for 
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targeting disease mechanisms must be characterized by very high standards of predictive 
performance. This is based on the analysis of genes expressing the targets of drugs 
including signal peptides, proteins, enzymes, non-coding-RNAs, and so on, for the 
identification of responsive biological subgroups and ultimately chemosensitive individuals, 
about whose pathophysiology we must know as much as possible at the molecular level 
(Trusheim et al., 2007).  
Although the personalized pharmacogenomic transition can minimize drug development time 
and subsequent costs for the Big Pharma, it will reduce its huge profit from the blanket 
treatment. It will also require division into smaller units and separation of sales and 
marketing from research and development, which will depend upon the acquisition of 
specialized biotech companies. All these will bring unavoidable changes to how future drugs 
will be developed, marketed and prescribed. However, society must be ready for this new 
system of healthcare by creating a flexible pricing and reimbursement system (Garrison & 
Austin, 2006). Thus, the science behind personalized medicine must be associated with 
pharmacogenomics, politics and adaptable regulatory legislation.  
All the works that I have chosen to reflect upon for this doctorate are examples of novel 
therapeutic approaches based on personalized medicine. The method is to aim to eradicate 
chemo/radioresistant tumours with molecular targeting that minimizes systemic toxicity, and 
not to make tumours more resistant to treatment with associated severe side effects, 
perhaps involving subsequent treatments that might lead to deaths.  
By critiquing my work I hope to uncover and develop other aspects of this translational 
process that I can contribute to more effectively. These include forming and participating in 
more advocacy groups, deepening knowledge of political and social issues, developing 
better communication skills, encouraging more collaboration and lobbying regulatory and 
legislative bodies.  This will more effectively and persuasively bring about a successful 
transition from the ‘blockbuster’ drug era to personalized cancer medicine.  
I must find the most appropriate way to deal with the media, regulation, legislation and 
advocacy. But that is the role of the relatively new profession of translational medicine 
practitioners. I am a scientist, but if we are to get what we know in the laboratory into the 
clinic, it requires the scientist to enter that arena and learn how to change what needs to be 
changed. I have picked up some skills on the way, but this is the first time that I have given 
myself the opportunity to step back and see how I can be better.  
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3. Positioning Myself and My Work  
 
I had never looked too deeply into why I do what I do until I embarked on this doctorate. My 
focus, my obsession even, has been for many years the application and ongoing 
development of my knowledge in the field of cancer research to save lives. This does fit well 
with my values regarding truth and rights.  
I originally applied for this doctorate to explore my work to see if I could be more effective in 
challenging the old paradigm and bringing the new one into centre stage. However I soon 
found myself questioning my own motives, values and beliefs and, through that, realizing 
that efficacy begins with a research on self.  
Before setting out on this critique of my learning through my chosen public works, three 
questions were already at the fringes of my thinking, at the fringes because I am, I believe, a 
man who defines himself by doing, by action in the Nietzscheian sense of having a ‘why’. By 
taking this particular doctoral journey, I believed I might stand still long enough to reflect on 
‘why’ – why do I do what I do? – in the hope that it may reveal to me the answer to the 
second and third questions: what keeps me doing it, and how can I do it better? I believe the 
answers to these three questions need to be brought more centrally into my professional life 
and, by critiquing my work through this lens, I will be able to reframe the steps that I will take 
in the future to counteract the substantial obstacles to achieving the aims of my personal and 
professional life, informed by my values and my epistemological stance.  
I live and work in Athens. I was brought up in a family whose values derive from very hard 
work, education and honesty. I loved literature and was quite good at it but I chose science, 
particularly cancer research, which has a lot to do with my father with some influence from 
my grandfather. During my years of elementary school I was raised by my grandfather. He 
was a lawyer. I was fascinated by his wisdom and his compassion for other people. He 
taught me that I should help people by any means when they need it. He didn’t just talk. He 
was a living example in his guidance to me. He used to help poor people on legal matters 
with no payment. I saw the respect and love that these people had for him. That looked to 
me even at that young age as an excellent reward for kindnesses given. Then when I began 
high school I went to live with my father, who used to work in the Bank of Greece. I 
remember he used to become depressed when a relative or colleague died from cancer. He 
always used to try and help them in any way he could. Not being a doctor himself he often 
ended up frustrated and angry because he could not save them. I later came to understand 
that, as a young man serving with the allies in North Africa during the war, he had killed to 
save others, others had died to save him and some he could not save. This experience 
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influenced his approach to life. His frustration and agony at the death of others affected me 
deeply, making me feel extremely scared and helpless at those times. I remember the 
terrible nightmares I had as a child because I was afraid that my family might get some 
cancer at some time, and I would lose them forever.  
I could not live with this fear for the rest of my life. I promised myself that I would do anything 
to avoid this. The only way to achieve this was by educating myself. Therefore, even when I 
was in high school I used to buy and read medical and oncology books. On high school 
courses like biology, biochemistry, physics and chemistry I used to get straight A+. Then I 
realized that I also had to learn very good English to be able to read the international 
bibliography. This subsequently opened my scientific horizons, because I knew exactly 
which subject I would like to pursue for the rest of my life so I could help people in the best 
way possible.  
I did not know it would be my own father who would put my skills to an early test and, in fact, 
directly influence the path I now follow. He developed lung cancer and, according to his 
physician who also happened to be his sister, he was destined to die from it. I used what 
skills I had and developed more as I was determined to find a therapeutic solution for my 
father to keep him alive as long as possible. I analysed his tumour genotype and phenotype 
on which I tailored a molecular targeting therapy. This is when I observed that his 
chemoresistant mechanisms were circumvented, leading to eradication of his NSCLC cells. 
If he had gone through the conventional treatments offered by the Big Pharma he would not 
have survived because of the systemic toxicity, immunosuppression and activation of cancer 
stem cells, leading to metastasis. When my father had another serious cancer recently, 
diagnosed as hormone refractory prostate cancer, I achieved its eradication by radiation 
therapy. First, however, I circumvented radioresistant mechanisms caused by 
overexpressed antiapoptotic oncogenes and silenced tumour suppressor genes by using 
antisense molecules, antibodies and demethylating agents.  
That is what I have done since. I am the assigned Head of Cancer Research, Molecular and 
Genomic Oncology, and Translational Cancer Medicine in one of the biggest oncology 
hospitals in Europe (Erasinio Hospital) that I have made an International Anticancer Center 
of Excellence even before its opening by developing novel anticancer therapies. These are 
presented and published in international oncology congresses from which I have obtained 
many awards by acting as an opinion leader among my peers.  
I have always been interested in philosophy, more as something to do for pleasure and, as 
for my values, I have carried these within me, never questioning where they came from, 
never seeing the need to. Now I do. Strangely perhaps for a Greek, I did not immediately 
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turn to Greek thought in my enquiry into myself but to the Italian philosopher Antonio 
Gramsci, whose words come closest to how I might describe myself – the pessimism of the 
intellect and the optimism of the will. ‘I’m intellectually a pessimist, but an optimist because 
of will’, will as in will to action. Gramsci wrote these words in a letter from prison during his 
incarceration by Mussolini’s Fascist regime (Gramsci, 1971). Professionally, I feel like I am in 
a state of imprisonment in the middle of a crisis caught between two paradigms, where the 
old, risky and increasingly ineffective ‘blockbuster’ drug cancer policy is dying out and the 
new policy of personalized medicine cannot be born. In fact, like all old paradigms it fights 
harder, knowing its days are numbered. Thus, in the interregnum, a great variety of morbid 
symptoms appear. In the more poetic words of Gramsci, the old world is dying away and the 
new world struggles to come forth: now is the time of monsters like doubt, resistance, 
uncertainty and fear. 
I can also relate to Gramsci on another two levels. Firstly, he was a man of great courage 
who suffered ill health and continued to write through his pain. I meet great courage every 
day in cancer sufferers that motivates me to do what I do. Secondly, he was driven by his 
beliefs and ideals which were, like mine, an obsession. He was held a prisoner by the 
Fascist regime of Italy and the only way his work could reach the public was secretly, 
subversively. I ask myself why we have to be subversive about what is evidenced, ethical 
and can save lives and be forced to behave as prisoners in a domain owned by the 
multinational pharmaceutical companies, with only occasional day release. Like Gramsci, I 
am a multidirectional thinker who fights the current paradigm of cancer treatment with 
evidenced knowledge. I am also energized by this fight. Through a long, painstaking period 
of cancer research I have recognized my own semiotic technologies for making scientific 
meanings that can overturn the present paradigm by dissolving the usual boundaries 
between the rational and irrational, in the Lacanian sense, and taming the beast.7 
I have attempted this, which I will demonstrate in greater detail in critiquing my learning 
through each of my selected works, by establishing myself as an advocate for personalized 
cancer medicine. I need to know how to get better at this. In line with Haraway’s aim for 
science, which is to reveal the limits and the impossibility of its objectivity offering inventive 
analogies that reveal whole new vistas and possibilities for investigation (Elkins,1990), 
during the last decade of the twentieth century and the first decade of the twenty-first century 
I have been concerned with the production of scientific knowledge through cancer research. 
I have acted on that knowledge by aiming to transform the present status of the healthcare 
system against cancer. But scientific knowledge is not enough.  
As Gramsci has contributed much needed insights and correctives to current cultural and 
political work, I try to do the same in influencing significant and crucial changes in the current 
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healthcare approach to cancer. This has proven to be extremely inefficient and, in my 
opinion, is victimizing human lives. Of course, this will never parallel the contributions of 
Gramsci to European political thought, but his work has helped me to position this paradigm 
struggle into a political frame to understand better its complexities, in particular his insights 
into the capitalist formation of the pharmaceutical industry, ‘the contradictory positions that 
constitute subalternity and the importance of arriving at a sense of the multivalent relations 
between economic, cultural and political phenomena’.8 
The agenda of critical theory, especially that of poststructuralist writing over the past few 
decades, has been to address the ways in which modernity and subjectivity are 
interconnected and are crucial to understanding the persistence of certain modes of thought 
and behaviours such as resistance to change. Lacanian theory has complicated the issue of 
ideology in particular, moving it away from notions of false consciousness.9 For instance, my 
ideology and that of several like me involves protection of the lives of cancer patients 
unmotivated by profit. Many colleagues therefore may not be ‘profit’ motivated, but they are 
forced by the old paradigm to be ‘funding’ motivated. There is also the right of the people to 
receive the best that the most advanced knowledge can offer when their lives are at stake. 
Increasingly in the modern global economy, excessive profit for individuals has become a 
right, a kind of ideology that is fought for and protected and is divorced from responsibilities 
to the communities from which this profit is extracted.  
The Althusserian focus on ideology10 has allowed a more complex entry into the difficult 
question of the persistence of dominant ideological practices, a requisite for Marxist thinking 
and for exploring connections between economics, politics and culture reconfiguring 
traditional notions of base and superstructure. It even calls into question distinctions 
between ideology and science. Like Gramsci, Althusser11  insisted on the need to 
disarticulate prevailing and totalizing sociological notions concerning base and 
superstructure. 
In his theorizing about hegemony, however, Gramsci offers more flexible, less monolithic 
and less stratified insights into how the relation of state and civil society produces forms of 
consensus and coercion. Also, borrowing from Gramsci’s notion of cultural hegemony, 
Poulantzas saw a capitalist class that in this case I see represented by the profits of 
conventional anticancer treatment.12 
My ontological position is that continuation with practices involving conventional treatment in 
the face of known advances is anti-knowledge. The fascism that imprisoned Gramsci was 
also anti-knowledge. Ideologically, I can also relate to Althusser, who has been known as a 
theorist of ideology especially with his ‘Ideology and Ideological State Apparatuses: Notes 
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Toward an Investigation’.13 I agree with Althusser’s view on Freud’s and Lacan’s concepts of 
the unconscious and mirror-phase, describing respectively the structures and systems that 
enable the concept of the self. For Althusser, these structures are both agents of repression 
and inevitable.  
Thus, for myself as a cancer researcher the scientific knowledge I learned made two 
impossibilities for me. The first was to support the existing paradigm and the second was to 
ignore what is best for the cancer patient, resulting in me pursuing it no matter what the 
consequences for my personal and scientific life. At this point I have to declare a bias for 
Althusser, who is one of my favourite thinkers because he has examined the contributions of 
the ancient Greeks, Thales on mathematics and Galileo on physics. As Socrates said: ‘Life 
unexamined is not worth living’.  
I do not support Heidegger’s approach to technology with neither praise nor blame – neither 
as an optimist nor pessimist or, in Gramsci’s terms, a pessimism of intellect (Rodriguez, 
2010). Taking action is the optimism of will14 and I am optimistic that personalized cancer 
medicine will take its place in the future.  
However, I do agree with Heidegger that technology’s essence is not technological, but a 
system. As such, technology involved in cancer medicine can be dangerous because it can 
lead to the transformation of the human being by which human actions and aspirations are 
fundamentally distorted. Medical technology can enter the innermost recesses of human 
existence, transforming the way we know and think and will. In my opinion, medical 
technology as a system should be used exclusively for the benefit of the patient and never 
for the profit of big multinational pharmaceutical companies.  
The Hippocratic oath taken by medical practitioners solemnly swears them to practice 
ethically and to save lives. It is an oath that I believe should be extended to and bind all who 
have direct dealings with the translation of scientific findings, from the laboratory to the clinic. 
In today’s world of complex technologies and multidisciplinarity we can no longer look to 
doctors as being the only people to be bound by such an oath, but to all members of the 
system, as medicine today is without doubt a system with many stakeholders.  
This intersection of rights, ideologies and economic structures requires a look at Hegel for a 
frame through which to view them. My situation resembles aspects of his Difference Essay 
(http://socserv.mcmaster.ca/econ/ugcm/3ll3/hegel/1015.pdf), where Fichte failed in the project of 
systematizing. The conventional ‘one size fits all’ treatment will fail in the future due to the 
difference that personalized medicine will bring. Like Hegel, I remain in the remnants of the 
Platonistic idea of a search for ahistorical truths that, combined with his works like the 
Science of Logic (http://plato.stanford.edu/entries/hegel/), can support the idea of personalized 
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cancer medicine. Based on what we know now, the future is in personalized approaches in 
medicine, particularly in cancer and, once the new paradigm can be allowed to function 
without obstacles, it will be profitable and make economic sense. There are, of course, other 
obstacles such as lack of training and equipment that I will deal with in subsequent chapters.  
I also have been inspired by Hegelianism, which offers a metaphysico-religious view of God 
qua or Absolute Spirit (http://escholarship.org/uc/item/3qs0713v#page-4) as the ultimately reality 
that can be known through pure thought processes alone. Like Hegel’s, my philosophy is 
derived from a more religious conception than the critique of pure reason of Kant 
(http://www.highbeam.com/ doc/1G1-276808891.html). I mention religion, because my Christian 
upbringing has always privileged the notion of recognition of pain in others and being 
motivated to action to resolve it. Other Christian perspectives may try to make meaning out 
of pain and see it as some kind of cathartic endurance that expiates sins. I do not. I see it as 
everyone’s responsibility to alleviate pain. I feel pain when I see it in others. If I alleviate 
theirs, I alleviate my own. Thus, with the Absolute Spirit I am trying to introduce an effective 
and life-saving approach of personalized cancer medicine by pure thought processes alone 
ignoring the profitable aspects of this strategy. I support Hegel’s form of idealism that lies in 
the idea that the mind of God becomes actual only through its particularization in the minds 
of his finite material creatures, which consist of simple people and not systems such as our 
industrial ones. So I can personally and professionally relate to his notion that individuals in 
their consciousness of God, serve to realize God’s selfconsciousness. Translated into my 
world and manifested, this is the search for fair treatment for suffering fellow persons who 
have cancer.  
Despite this dominant theological theme, I believe more in existentialism and that everyone 
has the right to try to prolong their existence. That is part of the motivation for what I do.  
It is obvious from my perspective that the old paradigm has not supported nor believed that it 
should support the Hegelian philosophy of ‘ethical life’. 'Ethics' is commonly used 
interchangeably with 'morality', and sometimes it is used more narrowly to mean the moral 
principles of a particular tradition, group, or individual (Deigh, 1995). I can see some 
resonance with what we are trying to do as cancer researchers with Hegel’s philosophy, 
which represents civil resolution or, that will continue to prove that the current paradigm for 
cancer treatment is not only wrong, but dangerous.  
However, this has required sacrifices: professional alienation, marginalization, financial 
sanctions, personal relational sacrifices that I and others like me have felt throughout these 
years. I believe they are motivated by altruism but, as my life has been so defined by this 
fight, I need to get inside what altruism is. My fear is that if I start to deconstruct too much 
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what drives me, it may result in my being less driven or vulnerable. In a fight, if a soldier 
stops to think and reflect it is like taking off the armour that protects him and provides the 
courage to stay in the battle.  
Am I then the altruist, and does it matter? There are many philosophical and psychological 
aspects of altruism that motivate my struggle against this dominant: evolutionary, 
developmental, psychological, social, cultural, political, and religious aspects. I would 
subscribe to the notion that there is no such thing as pure altruism. We all get something out 
of what we do for others, and this motivates us to do it. Perhaps it is in many cases a way to 
respond to fear of uselessness, fear of being a nobody, fear of not belonging, fear of being 
ordinary, and fear of death. I know one day that, through the efforts of many good people, 
altruists or not, we will beat cancer. I hope that my optimism is not Panglossian. I always ask 
myself what assumptions am I making and how do I know what I know? The answer is then 
simple, because I look back to my previous cancer research experience and it is about 
knowledge and transparency. I am known in my field as an opinion leader and that has 
considerable ethical responsibilities. I am uncompromising in my support for evidence-based 
practice, innovative anticancer scientific evidence that can withstand scrutiny. This has been 
recognized globally by the International Oncological and Medical Society especially the 
International Translational Cancer Medicine Society where I am a practitioner.  
Returning to Gramsci, this optimism of will, I think, is what gives me the courage to attempt 
difficult or impossible tasks like fighting the old Pharma paradigm. I believe that my will can 
overcome the odds if I can encourage a collective will. If I did not, I should not have come 
this far. For me, research leads to knowledge but it requires evidence, transparency, honesty 
and criticality not only in carrying out that research but in bringing it into usefulness. There is 
no value in research without that:  
 
All sciences are now under the obligation to prepare the ground for the future task of 
the philosopher, which is to solve the problem of value, to determine the true 
hierarchy of values. (Friedrich Nietzsche)15 
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4. Selected Public Works 
 
The four works I have selected from more than 2,000 that I have presented in international 
medical congresses represent evidence of my contribution to oncology, how the findings 
from one influence the direction and development of the next treatment and illustrate the 
challenges I have had to overcome progressively to arrive at a new way of dealing with both 
the scientific and socio/politcal obstacles. They represent a process of transformation as I 
increased and widened my skills. This process of reflection itself has tied everything together 
resulting in not only changes in myself but culminating in the founding of the Hellenic and 
International Society of Molecular and Genomic Medicine and Research. My presidency is in 
recognition of the contribution of my work and advocacy by my peers. This Society will mark 
its arrival in Greece in October this year with an international conference. I now no longer 
feel I am on my own, and neither do the members.  
Although I lose my intellectual property rights after I publish my work at international 
congresses, independent from any conflict of interest, by acting as an opinion leader I 
influence other researchers to use my novel therapeutic approaches for cancer patients’ 
welfare and take it through all the required clinical stages for achieving regulatory approval. 
This transmission of state of the art and cutting-edge knowledge of novel therapeutic 
approaches such as mine against incurable tumours may spread as a chain reaction in the 
cancer research establishment. Furthermore, this work has been used by cancer advocacy 
groups and even an organization for psychological support for cancer patients. All these 
have numerous implications concerning medical, social, economical, political and regulatory 
issues.  
The work for each novel treatment was deeply challenging because I had to play the main 
role in discovering each one of the new treatments, during which my learning was enhanced 
not only in the usual way for science research in that one discovery leads on to another, but 
in ways I neither expected nor set out to achieve. In science terms the innovations came 
together to offer solutions to many unsolved problems in oncology. I am presenting the first 
one with a summary of technical details. For those remaining, I have put the technical details 
in the appendices.  
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4.1 Public Work 1  
A novel combined and multitargeted therapeutic strategy of chemoradio-
immunotherapy based on a pharmacogenomic approach against advanced and 
metastatic breast cancer (for more technical details see Appendix 1A, and for associated 
public works see Appendix 2A). 
This work was undertaken because hormone refractory breast cancer that metastasizes to the 
lungs, livers and bones is incurable. This is due to overexpressed oncogenes or inactivated 
tumour suppressor genes that are controlled by epigenetic mechanisms such as methylation, 
acetylation, histone variants and so on. I have recently written a book (Giannios, 2011) about 
these. They cause potent chemo and radioresistance, inhibiting programmed cell death 
mechanisms such as type-I or apoptosis. These mechanisms make this tumour type incurable 
and lethal, especially due to metastasis where we have more than a hundred heterogeneous 
tumours.  
As Head of Translational Medicine and Cancer Research of Erasinio Oncology Hospital16 
and now as the President of the Hellenic and International Society of the Molecular and 
Genomic Medicine, I believe it is an imperative of these positions to try always to find 
therapeutic solutions to incurable cancers like the metastatic hormone refractory breast 
cancer. This is currently incurable with conventional therapeutic regimens, which 
complicates the situation by exerting lethal systemic toxicity and creating potent 
chemo/radioresistant mechanisms while activating metastatic mechanisms such as 
angiogenesis or cancer stem cells (Giannios, 2010).  
I presented this work firstly in 2004 at the 18th Annual Meeting of the European Association 
for Cancer Research (EACR) of which I am a founding member. It is a pan-European 
organization representing cancer researchers and belongs to the Federation of European 
Cancer Societies (FECS). This is a Brussels-based organization representing more than 
18,000 cancer professionals in Europe. This work was selected as the best of the congress 
for publication. It was given to the international medical media17 to inform different societies 
that a combined anticancer therapeutic approach against metastatic breast cancer can 
circumvent resistance to treatment mechanisms leading to the eradication of tumour cells by 
induction of apoptosis. This therapeutic approach was translated into many different 
languages from the electronic media. Furthermore, the Greek press, television and radio 
announced this treatment as a medical breakthrough that might save many breast cancer 
patients in the future.  
Since then, I have extended this therapeutic approach to other metastatic cancers, such as 
pancreatic cancer, periampullary cancer, non-small cell lung carcinoma (NSCLC), endocrine 
25 
 
tumours such as anaplastic thyroid cancer. These works were presented in congresses 
including ASCO, British Endocrine Societies (BES), ESGO, ISGIO and others.18 Furthermore, 
they were published in many specialized medical journals such as the International Journal 
of Gastroenterology and Hepatology.19 This work, since its presentation and publication, has 
been followed up by many other researchers who have taken it to multicentre clinical trials 
for many cancers including pancreatic adenocarcinoma, periampullary carcinoma and other 
cancers.20 
This novel therapeutic approach emphasizes the importance of combination therapy under a 
personalized cancer medicine approach with molecular targeting. I was both the innovator 
and project leader, with a number of collaborators and a team of assistants. The role of each 
collaborator or assistant was designed by me to cover each part of the research. They are 
the co-authors of each of my publications and congress presentations. Such co-authorship is 
one of the protocols that I have established for the Hellenic and International Society of 
Molecular and Genomic Medicine where all its members can collaborate to achieve 
publishable results that can benefit cancer patients in the future until regulatory approval is 
granted. It is multidisciplinary research under systems molecular medicine (SMM), the 
science of combining systems biology with molecular analysis and intervention to address 
clinically relevant questions.  
I had concluded that since cancer is an extremely heterogeneous and complex disease, 
especially in metastasis that consists of more than a hundred different tumour types, we 
have to fight it on many different fronts. In this particular case of incurable advanced and 
metastatic breast cancer, I had to detect the chemoresistant mechanism to inactivate 
conventional chemotherapy that exerted only systemic toxicity destroying normal cells. Thus, 
with multitargeted combination therapy using immunotherapy, radiotherapy and genetically 
based antisense therapy, I targeted these chemoresistant mechanisms to circumvent them, 
allowing the conventional chemotherapeutic agent to exert its cytostatic action inducing 
apoptosis and led to the eradication of tumour cells by a bystander killing effect. This novel 
multimodal anticancer therapy should be applied in the future for treating advanced or 
metastatic breast Ca or other incurable cancers.  
This novel combined treatment establishes the foundations of a new era of translational 
cancer medicine in which pharmacogenomics are employed to tailor a molecular therapeutic 
approach to chemoresistant and radioresistant metastatic breast cancer patients. 
Furthermore, this approach allows conventional chemotherapy to exert its antitumour effect 
enhancing therapeutic index and reducing systemic toxicity. One of the main roles of this 
innovative therapeutic approach consists of providing one more proof that cancer research 
changes the face of oncology by emphasizing the significance of functional tumour cell 
26 
 
profiling on which a personalized treatment can be tailored. I have proved that targeting one 
pathway may not be as effective as targeting multiple pathways in a cancer cell. Finally, I 
have proved that when novel therapeutic agents are combined with existing ones they target 
the tumour more effectively by acting synergistically.  
The key for a successful anticancer treatment is the circumvention of chemoresistance or 
radioresistance and effective molecular targeting using nanomedicine and ligands such as 
antibodies that can bind onto specific overexpressed oncogenic receptors, such as 
HER2/neu or EGFR.  
Public Impact: 
Some of the implications of my work have been described in the Introduction and have been 
referenced with the related websites. This public work brought me into more direct contact 
with the media and I found myself wanting to become a journalist to explain better the 
potentials of my work and its implications for cancer treatment. This critical reflection has 
given me the space, in a sense, to be the journalist. How might I explain it to as many 
stakeholders as possible, including the public at large so they can understand? Llike this?  
In their attempts to transmit information to the public, the media have found cancer to be a 
complex disease. The complexity is the key to the approach. It needs to be attacked on 
many fronts. This novel treatment is a combined one, targeting the right drug to the right 
tumour phenotype with the use of pharmacogenomics. This means fewer treatment failures 
leading to cheaper clinical programs and subsequently cheaper drugs. Otherwise, the rise in 
the number and cost of new anticancer drugs will lead to discrimination in treatment: the 
poor will be left to die. My work sets priorities for funding the right combined treatments 
based on a personalized approach.  
Cancer is an enormous socioeconomic problem because conventional treatment, depending 
on the stage of the disease, is mostly ineffective due to complications such as drug 
resistance or acquired mutations after initial therapy. Thus, a novel and drastic multimodal 
anticancer treatment like this, consisting of personalized therapeutic approaches combined 
with conventional anticancer agents is desperately needed to combat cancer especially the 
metastatic type. This could save tax-payers’ money for cancer care.  
I began to look more closely at how cancer issues are reported and found a number that 
were good examples, not because they fitted with my views but because I could see how 
persuasion with scientific evidence, bringing in economic issues supported by facts and 
figures and having a non-aggressive style, was more effective in changing mind-sets. I liked 
the following example.  
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James Gallagher, health reporter for BBC News, published a Lancet Oncology report in 26 
September 2011 stating that most developed countries dedicate up to 7 per cent of their 
healthcare budgets to dealing with cancer. However, few treatments or tests are clear 
clinical winners, with many falling into the category of substantial cost for limited benefit.21 
Furthermore, lead author Professor Richard Sullivan told the BBC that it is not just 
pharmaceuticals. Biomarkers, imaging and surgery are all getting through with very low 
levels of evidence, because the hurdles are set too low. There is also criticism of futile care 
using expensive chemotherapy with no medical benefit in the last few weeks of a patient's 
life. The issue that concerns economists and policymakers is not just the amount of money 
spent on healthcare, but also the rate of increase in healthcare spending or what has 
become known as the cost curve. The report says the UK's total spend on breast cancer has 
increased by about 10 per cent in each of the past four years. Also, it says that the number 
of cancer patients and the cost of treating each one is increasing. A group of 37 leading 
experts from around the world say the burden of cancer is growing and becoming a major 
financial issue because about 12 million people worldwide are diagnosed with cancer each 
year. That figure is expected to reach 27 million by 2030. The cost of new cancer cases is 
already estimated to be about £185bn ($286bn) a year.  
Personalized cancer medicine might circumvent some of these issues because all cancers 
are not the same; not even all breast or lung cancers are the same. Thus, it is hoped that 
better pharmacogenomic testing will bring about this new era of ‘personalized cancer 
medicine’, meaning drugs can be tailored to specific cancers. For instance, testing for the 
KRAS gene in colorectal cancer patients before deciding whether to use a cancer drug 
saves £32m per year in Japan.22 
This approach might reduce DALYs. This measure has been developed by the World Health 
Organization (WHO), and it is the most common yardstick of the cancer burden of mortality 
and disability. One DALY represents one lost year of healthy life, and the burden of disease 
as a measurement of the gap between actual health status, and an ideal situation where 
everyone lives into old age free of disease and disability. Cancer may account for many 
million DALYs lost in the European countries. 23 
I have learned from such journalistic writing and have realized that I have targeted for years 
only my medical peers, but I need to work with others to persuade different target audiences 
to act through finding a way to communicate stem knowledge effectively to those outside of 
the field, but who can nonetheless impact that very field to change. I had once believed that 
the only way to change something was from within. This is not the case. One needs to do 
both.  
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This personalized cancer medicine breakthrough in breast cancer treatment described in this 
public work might improve health cost minimization, benefits, effectiveness and utility. This 
will exert political pressure for implementation of new governmental guidelines for reduction 
of delays and improvements on the development of more effective medical therapies like this 
which create the political challenge of ensuring equal access to innovative anticancer 
treatments for women from deprived backgrounds.  
A medical challenge is also posed to select or stratify the patients who are most likely to 
benefit from this combined multitargeted treatment through molecular profiling. Innovative 
anticancer therapies should be analysed through macroeconomics, the study of the sum of 
individual economic decisions for establishing social benefits through distribution and 
consumption, because cancer has surpassed heart disease as the leading cause of death 
for persons younger than 85.24 The Massachusetts Institute of Technology (MIT) issued a 
report in 2011 stating that cancer recently has replaced heart disease as the leading cause 
of death in the United States.25 Thus, the public impact of this treatment is extremely 
important because the proven activity of many anticancer drugs that have been approved by 
regulatory agencies have little to do with curing heterogeneous chemo and/or radioresistant 
cancers since they are based on finding the tiniest improvement instead of genuine medical 
breakthrough.  
It is like a Greek tragedy where the Fates predetermine the outcome. The worst tragedy is 
that there is a shortage of good ideas on solving the problem of metastasis. This kills breast 
cancer patients because, by the time a tumour is diagnosed, there is extensive metastasis to 
bones, liver, lungs, brain or other vital organs that is sometimes detectable only with –omics’ 
technologies, meaning large-scale studies of bio-molecules to allow us thoroughly to 
investigate diseases with the goal of identifying underlying molecular networks and new 
druggable targets.26 
The Big Pharma focuses on devising drugs that shrink tumours without eradicating them. 
Therefore, the system will remain inefficient, unresponsive, and unduly expensive without 
major changes unless the Big Pharma shifts its focus from incremental improvement to 
developing and producing the new generation of anticancer agents that are based on 
molecular multiple targeting. Combined with traditional chemotherapy, these may eradicate 
metastatic mutant cells by attacking them on multiple fronts.  
However, these treatments are derived from pharmacogenomics where genetic analysis 
may predict drug efficacy or toxicity. Complex bureaucratic and regulatory constraints in 
Europe from agencies such as European Medicines Agency (EMEA) need to be simplified 
for such treatments like mine that aim to circumvent chemoresistance and radioresistance. I 
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think the American Food and Drug Administration (FDA) models such as the Critical Path 
Initiative that helps streamline drug testing and review, and sharpens its focus on methods of 
efficiently identifying and resolving drug safety issues, can ‘fast track’ designation where the 
FDA meets with the sponsor allowing for accelerated approval designation that allows 
approval of the drug based on a surrogate endpoint, such as shrinking tumours and priority 
review.27 
Does it always have to be about the money? 
I believe that part of the communication of our stem knowledge is about accepting the 
economic realities and making an economic as well as a social case. This is part of the art of 
persuasion, as James Gallagher so clearly demonstrated. I really do not want to own the 
intellectual property rights for this therapeutic innovation, because I strongly believe that 
market and knowledge monopolies may hinder the advancement and clinical adoption of 
personalized cancer medicine. Besides, freely accessible innovations may promote further 
innovations.  
Athough my work is self-financed and I could have made a substantial amount of money by 
selling these novel anticancer treatments, I lose the right to patent them after I present them 
in oncology congresses. I do this because I want to act as an opinion leader, educating my 
peers about these innovations. They can modify them according to their patients’ needs or 
even improve them. This creates a chain reaction, spreading the word that there is hope for 
a cancer cure if the cancer policy changes from the ‘blockbuster’ one to the personalized 
cancer medicine. The latter uses pharmacogenomics on which molecular targeting is tailored 
according to the genomic characteristics of each individual tumour.  
I have been able, on the whole, to self-finance much of my work although it has put 
considerable strain on me and my family. I know many potential innovators are not in a 
position to self-finance but, if we could work together to shift our thinking away from 
intellectual property (IP) and money to sharing knowledge, then the effect could cascade.  
For example, when breast cancer patients learn through the media about novel combined 
anticancer treatments consisting of potential multiple targeted agents and conventional 
chemotherapeutic agents, they will be keener to participate in clinical studies. Enhancing 
participation rates will lead to faster and cheaper testing of anticancer combinations. A mass 
media information flow on cancer-related issues and such innovations may induce significant 
changes in health services through planned campaigns and unplanned coverage. Also, the 
manner in which the media portray the issue of any work as hope for the future for breast 
cancer patients may have significant implications on the public’s participation in rationing on 
healthcare resources. Furthermore, the media may suggest the need for a legitimate and fair 
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approach to priority setting for breast cancer patients with innovative personalized 
approaches. Moreover, the media coverage of these may act as a catalyst between 
interdependent external factors like politicians, industry and patient advocacy to change 
delivery of healthcare exerting pressure which influences the decisions of regulatory 
authorities like NICE and EMEA and authorities of anticancer drug funding.  
After the media presented my work, I was approached by interdependent external factors 
such as patient groups, industry and even politicians to commercialize my novel anticancer 
therapy so it could reach the market. The pharmaceutical industry wanted the IP of my 
treatment for profit, the politicians for votes and the metastatic breast cancer patients for 
saving their lives which were in jeopardy.  
The blunt, ‘one size fits all’ approach to cancer treatment is giving way to the individualized 
approach based on theranostics, which uses testing to diagnose a given disease, chooses 
the correct treatment regimen and dose and monitors the patient response to therapy on an 
individualized basis. It is sensible, logical and evidenced in the laboratory yet, like others in 
my position, I am still struggling to complete the regulatory requirements of this treatment 
because: there is a lack of interest in predictive tests from the drug industry due to fear of 
loss of profits; the complexity and monopoly of funding mechanisms; and entrenched 
physician behaviour and unfamiliarity with concepts of genetic factors that influence 
response to drugs. I try to circumvent all these barriers by giving lectures in medical 
congresses.  
The slow pace of translating research discoveries to the clinical arena, combined with lack of 
funding from granting agencies for true translational research, is deeply frustrating and one 
of the few ways left is by applying to European Union grants as a translational medicine 
practitioner. Premium behaviour was not invented by the Big Pharma, it already exists in 
human beings: to pay a premium for what they most desire. It is a question of exploiting the 
situation when what you most desire is your life, or the life of those you care about. 
However, when the Big Pharma is left out of these new therapeutic innovations, they have 
the means to erect obstacles. These include lack of financial resources for scientific attacks 
att medical congresses in the form of questioning by experts representing the interests of the 
Big Pharma. The discussion often reveals their ignorance on the specific theme especially 
when it comes to the molecular aspects of the novel treatment on which mechanisms are 
based. This is something that the Big Pharma lacks because they base their treatments on 
survival rates and not mechanisms. Treatments like mine may enhance the quality of 
healthcare that might increase the number of healthy people and reduce mortality, and 
subsequently improves labour productivity.   
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Reflections:  
It makes me feel great when my hard work can result in potential cures for incurable cancers 
like the metastatic breast cancer. A therapy like this is also very constructive for my 
professional status as an opinion leader in oncology and cancer research. It gives me 
prestige and recognition among my peers. Finally, it gives me public recognition. These 
things mean more to me than money. This public work in which there is so much interest 
presents me with many issues about media and effective use of media, communicating to 
different audiences. In turn, this raised issues of ethics of trials, ethics of withholding and 
ethics of marketing. I realized I needed to get to know how the media works and how to 
persuade them to publish more about the alternatives to the approach of the Big Pharma 
and so on.  
Finally, this work which is a part of my continuous struggle to establish the approach of 
personalized cancer medicine. It has influenced the establishment of the personalized 
cancer medicine era. In the last Annual Meeting of ASCO, its President, Dr George Sledge, 
after addressing thousands of cancer professionals from around the world, talked about the 
impact of the forthcoming era of personalized medicine.28 
I am proud to be playing a part in this through my scientific skills and my values. Through 
this reflective journey I think my efficacy will increase by communicating it out there in a way 
that influences people’s attitudes and behaviour, which is a core driver of change.  
 
 
4.2 Public Work 2 
The invention of a formulation composed of pegylated liposomal anti-eif3c shRNA-
vinorelbine, named after my daughter, Sevina.  
This has led to the eradication of chemoresistant and hormone refractory breast cancer 
(mHRBC) cells by inhibiting oncogenic protein translational initiation and oncogene addiction 
inducing type-I PCD or apoptosis, type-II or autophagy, type-III or necrosis and 
antimetastatic anoikis. This work, still going through the regulatory stages, was carried out 
by me while Head of Translational Cancer Medicine and Cancer Research of Oncology Unit 
of the General State Hospital of Athens.  
The significance of this novel research work, a further development of my previous work, 
was selected by the scientific committee (which includes Nobel Laureates in Medicine such 
as Dr Murad) of the International Modern Drug Discovery and Development Congress (28–
30 November 2007, San Francisco, California), as the best of Congress. It was the first 
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award consisting of an honorary certificate (see Appendix 2B) and a cheque that I invested 
in my next cancer research project.  
The scientific mechanism of this Public Work 2 is included in Appendix 1 B.  
In my previous work I wrote about the media. Public perception is controlled by the media 
and academic perception by academic journals, conferences and congresses. In my 
discussions in this section I draw supporting evidence from the Internet. Many people 
involved in cancer research now publish more through this medium than any other. What is 
challenging for the public is who or what to believe when faced with so many points of view.  
I discuss my learning from this public work towards the end of the chapter. At this point I 
would say that it demonstrates my ongoing learning about the power of the media to bring 
about a change in public perception that in turn can influence both the science and policies 
to take a different direction. Not everyone is invested in the space programme, but everyone 
is or should be invested in cancer. It helped me to think about what could be done to help 
the public differentiate between fact and fiction, reality and hype. This public work also 
emphasized the personal and professional cost of working from within to try to bring about a 
paradigm shift and the power of the Big Pharma, and how there are plenty of challenges on 
the web to the Big Pharma but few changes. Through trawling the websites I became more 
aware of these interfaces of finance, science, politics and public health in a way that went 
beyond the usual concerns of cancer researchers which is in finding funding to progress 
research.  
Cancer science, the Big Pharma and the media 
A full description of how and why I developed this novel anticancer treatment is as follows: 
Firstly, the ‘why’ has been described clearly by many experts such as Morgan et al. (2004), 
who state that conventional chemotherapy has not been proven to be generally effective. 
They cite the overall contribution of curative and adjuvant cytotoxic chemotherapy to five-
year survival in adults was estimated to be 2.3 per cent in Australia and 2.1 per cent in the 
United States. Athough by 2009 the total spent on cancer care, treatment and research 
exceeded $305 billion per year, according to the British Medical Journal, 28 August 2009, 
the five-year survival rate from hepatoma, pancreatic, lung (NSCLC, SCLC), osteosarcoma, 
advanced hormone refractory breast cancer and other solid tumours remains virtually the 
same as it was 25–30 years ago (McColl, 2009). Most cancer patients in the United States 
die of chemotherapy.29 As a result at present there are more than 568,668 cancer deaths per 
year there alone (Kochanek et al., 2011). It is a scientific fact that when chemotherapy is 
administered blindly it does not eliminate metastatic tumours such as colon, lung, or breast 
cancer. Chemotherapists are aware of this. In 2002, the Journal of the American Medical 
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Association reported that, in the previous year, the average oncologist had made $253,000 
of which 75 per cent was profit on chemotherapy drugs administered in his or her office. 
However, surveys of oncologists by the Los Angeles Times and the McGill Cancer Center in 
Montreal show that from 75 per cent to 91 per cent of oncologists would refuse 
chemotherapy as a treatment for themselves or their families. Why? It’s too toxic and not 
effective. Yet, 75 per cent of cancer patients are urged to take chemo by their oncologists.30 
Serious complications with conventional chemotherapy have been associated with a 
weakened immunity system and an enhanced risk of secondary cancers. It is a fact that 
chemotherapy is only rarely curative in solid malignancies, particularly advanced solid 
malignancies. In this kind of environment, the media focus on public figures such as 
Jacqueline Kennedy Onassis and Betsy Lehman, an award-winning health columnist for the 
Boston Globe, and the role of chemotherapy in their deaths. Ralph Moss, the former Director 
of Information for Sloan Kettering Cancer Research Center, said that ‘chemotherapy is 
basically ineffective in the vast majority of cases in which it is given’.31 Dr Ralph Moss in 
2006 reported in Curezone32 that an important paper had been published in the journal 
Clinical Oncology (Morgan et al., 2004) by three Australian oncologists:  
Lead author Associate Professor Graeme Morgan is a radiation oncologist at Royal 
North Shore Hospital in Sydney; Professor Robyn Ward is a medical oncologist at 
University of New South Wales/St. Vincent's Hospital. The third author, Dr. Michael 
Barton, is a radiation oncologist and a member of the Collaboration for Cancer 
Outcomes Research and Evaluation, Liverpool Health Service, Sydney. Prof. Ward is 
also a member of the Therapeutic Goods Authority of the Australian Federal 
Department of Health and Aging, the official body that advises the Australian 
government on the suitability and efficacy of drugs to be listed on the national 
Pharmaceutical Benefits Schedule (PBS) – roughly the equivalent of the US Food 
and Drug Administration.  
The meta-analysis of the Australian oncologists was, ‘the Contribution of Cytotoxic 
Chemotherapy to 5-year Survival in Adult Malignancies was set out to  accurately quantify 
and assess the actual benefit conferred by chemotherapy in the treatment of adults with the 
commonest types of cancer’. This peer-reviewed article (http://www.ncbi.nlm.nih.gov/pubmed/ 
15630849) suggests that the ‘chemo program has been a total failure, a fact which has been 
difficult for the oncology profession to admit’. Although this paper attracted significant 
attention in Australia, ‘it has been greeted with complete silence on the other side of the 
world’ (University of California, San Francisco).33 As oncologist Glen Warner said before his 
death in 2000, after forty years of oncology practice:  
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We have a multi-billion dollar industry that is killing people, right and left, just for financial 
gain. Their idea of research is to see whether two doses of this poison are better than 
three doses of that poison’. This occurs because ‘chemotherapy is an incredibly lucrative 
business for doctors, hospitals, and pharmaceutical companies. The medical 
establishment wants everyone to follow the same exact protocol. They don’t want to see 
the chemotherapy industry go under, and that’s the number one obstacle to any 
progress in oncology.34 
I have presented and published in the Annual Meetings of the International Society of 
Gastrointestinal Oncology (ISGIO), and the American Society of Clinical Oncology (ASCO) 
that conventional chemotherapy may activate cancer stem cells and angiogenesis inducing 
chemoresistance and metastasis (Giannios, 2010). The severe systemic toxicity caused by 
chemotherapy can cause more harm than good according to Dr Alan Nixon, the past 
president of the American Chemical Society, who in 1998 also asked the obvious and logical 
question of how oncologists can ignore this clear evidence (http://www.cancer-treatment-
tips.com/chemotherapy. html). A study published on 23 May, 2011 in the Archives of Internal 
Medicine (Duke et al., 2011) revealed the average number of different side effects for each 
drug is 70, with more commonly prescribed drugs having around a hundred. It has been 
reported that 522 different side effects were reported for just one drug. How in reality can 
any physician know what are the interacting side effects in a patient who is taking five or ten 
prescribed medications simultaneously? Even worse, there are patients who are taking more 
than 15 medications at once.35 
Concerning the term oncologist, it is actually an improper title because it implies an 
understanding of the physiology of tumours. The more accurate nomenclature should be 
chemotherapist.  
Obstacles from research to application  
From our position within the field as cancer researchers and translational medicine 
practitioners dedicated to getting knowledge from the laboratory to the clinic, it is part of our 
work to explore what blocks and what facilitates that route. Passions run high and there are 
many ideas on why knowledge appears to be being blocked.36 
Economics 
The economics of cancer treatment deserve further exploration and to be brought more 
prominently to the public’s attention. The real economics of cancer treatment are exorbitant 
and astounding. Cancer treatment expenditures, for treatment and research, are close to 
$100 billion ($100,000,000,000) per year. The chemotherapy part of that figure, in 1995, was 
approximately, $8.5 billion. These numbers have reached much higher levels today.  
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Cancer deaths are not widely advertised, but are definitely increasing despite some 
fluctuations that prompt media outlets to claim cancer is declining. Thus, cancer has 
overtaken heart disease as America's number one killer. In spite of the best therapy that 
conventional medicine has to offer, over 650,000 Americans suffer and die from cancer 
every year.37 
Conflicts of interest 
There is also the issue of overlapping interests, which are actually conflicts of interests as 
they can compromise independence. One pharmaceutical company owns 12 of the 40 
patents of FDA approved chemotherapy drugs. Senior members of its board past and 
present also hold positions on the board of a cancer centre. This compromises the ethical 
integrity of the centre. This is happening because the boundaries between academic 
medicine—medical schools, teaching hospitals, and their faculty—and the pharmaceutical 
industry have been dissolving since the 1980s, and the important differences between their 
missions are becoming blurred. Medical research, education, and clinical practice have 
suffered as a result, according to a report entitled ‘Big Pharma, Bad Medicine’. This report 
was published in Boston Review last year by Marcia Angell who delivered a talk at Harvard 
University about ethics describing how corporate dollars corrupt medical research and 
education. 38 
Conventional cancer treatment is not addressing the underlying causes of cancer.39 Dr John 
Diamond MD has said that finding a cure for cancer is absolutely contraindicated by profits:40 
Sometimes cancer is treated with the risk of developing secondary tumours, 
according to a study which reports that there is an enhanced risk of leukemia in 
breast cancer patients who take drugs to get a boost in white blood cell growth in 
order to tolerate more aggressive chemotherapy treatments, leading to some 
speculation about Amgen’s Neulasta and Neupogen.41 
Also, antagonists of estrogen receptor such as tamoxifen which are used to prevent the 
recurrence of breast cancer may enhance the risk of developing uterine cancer by 30 per 
cent.42  
German investigators from Friedrich-Schiller University in Jena have shown that paclitaxel 
(taxol), the gold standard of chemo, causes a massive release of tumour cells into circulation 
resulting in extensive metastasis many months or even years later, long after the 
chemotherapy could be suspected to be the cause of the spread of the cancer. This little 
known horror of conventional cancer treatment should be spread far and wide, but it is not 
even listed in the side effects of paclitaxel.43 Thus, sometimes conventional cancer 
chemotherapy may prove to be worse than the disease.44 This observation is confirmed by 
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Dr Allen Levin of University College of San Francisco (UCSF), who states that most cancer 
patients in America die of chemotherapy that does not eliminate metastatic solid tumours 
such as breast, colon or lung cancers. Although this fact has been well documented for over 
a decade, still physicians still use chemotherapy for these tumours.45 
Why nothing changes despite the evidence 
The problem is that conventional chemotherapy suppresses cancer symptoms temporarily 
often converting cancer into a chronic disease. This is then supported by more drugs that do 
not eliminate recurrence or eradicate the root of the tumour, such as cancer stem cells, that 
can be activated by chemotherapy and induce metastasis. I spoke about this in a lecture in 
the plenary session of the Annual Meeting of the International Society of Gastrointestinal 
Oncology in 2010 that took place in the United States (Giannios, 2010).  
A devastating blow to the current cancer establishment was exerted by the legendary cancer 
researcher Ralph W Moss PhD, who concluded that conventional chemotherapy is simply 
ineffective in the vast majority of human cancers.46 Also, Dr Martin Shapiro of University 
College of Los Angeles (UCLA) has stated that cancer researchers, medical journals, and 
the popular media have contributed to a situation in which many people with common 
malignancies are being treated with drugs not known to be effective.47 A report in the 
website CancerResearchInformation.com states that anti-cancer chemotherapy does not work, 
it is costly, it has adverse effects, and it kills cancer patients. Also, this report demonstrates 
the passion and anger felt by many people. There is no-one who is not touched in some way 
by cancer in their lives, either themselves, a relative or friend, or a colleague. It states that 
‘chemotherapy and radiation which share the same resistant mechanisms are very much 
part of conventional medical protocols to “treat” cancer today’. However, they are hideous 
crimes against humanity, and in the near future, humankind will look back on these medical 
Dark Ages and wonder how such brutal and savage methods could ever have passed off as 
‘cancer treatments’.48 
Quoting Benjamin Disraeli, Prime Minister of Britain, Mark Twain wrote there are three kinds 
of lies in the world: ‘lies, damned lies, and statistics’. That statement is even more true (and 
dangerous) when applied to medical studies concerning chemotherapy.49 All the research 
papers relating to chemotherapy and efficacy over a 14-year period have been cited in the 
meta-analysis published in the Australian Journal Clinical Oncology entitled ‘The 
Contribution of Cytotoxic Chemotherapy to 5-year Survival in Adult Malignancies’ mentioned 
earlier. This excellent study was based on an analysis of the results of all the randomized, 
controlled clinical trials (RCTs) performed in Australia and the United States. It measured 
statistically the five-year survival rate from the use of conventional chemotherapy in adult 
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malignancies. The survival data was drawn from the US National Cancer Institute's 
Surveillance Epidemiology and End Results (SEER) registry, and the Australian cancer 
registries, analysing the period between January 1990 and January 2004. For the authors to 
be more than fair, wherever and whenever data was uncertain, they deliberately erred on the 
side of over-estimating the benefit of chemotherapy. Even so, this meticulous study 
concluded that, overall, chemotherapy contributes approximately just 2 per cent to improved 
five-year survival in cancer patients. Despite the mounting evidence for chemotherapy's lack 
of effectiveness in prolonging survival, chemotherapists continue to present chemotherapy 
as a rational and promising approach to cancer treatment that is false.50 
Evidence to support alternatives  
Dr Gregory Foltz discovered that oncologists have been targeting the wrong cells in the 
treatment of cancers such as brain cancer. Cancer stem cells cause the growth of cancer 
cells, and stem cells resist chemotherapy. Dr Foltz explains that this is why ‘standard cancer 
treatments so often fail: those therapies target the wrong cells’. He has created the Center 
for advanced Brain Tumor Treatment at the Swedish Medical Center of Seattle where I have 
given numerous lectures about novel personalized cancer treatments. There he tries, like 
me, to design pioneer and novel personalized treatments for glioblastoma patients. He 
follows my approach, offering to cancer patients the possibility of tailoring their anticancer 
treatment based on their unique genetic makeup of their tumour.51 
I also have carried out a great deal of research concerning cancer stem cells.52 I have 
proved for the first time that chemotherapy may activate cancer stem cells, inducing tumour 
relapse after enhancing angiogenesis and subsequent metastasis in solid tumours.53 The 
new biotech companies recognize that conventional chemotherapy treatments do not work. 
The researchers are starting to ‘think outside the box’, shifting to a systems approach to 
solve the cancer problem. Why wasn’t this shift made years ago, after the failure of 
chemotherapy was first observed?  
Reflections on my efforts 
I can research and invent. This is what I do best. But research and development need 
funding and the complexities of ownership, patenting, trials which are prohibitively 
expensive, and need to be confronted and negotiated. The only group that can afford them 
easily is the Big Pharma. This has strong partnerships and contracts and so on with 
governments, universities and health authorities all over the world. It also has very powerful 
marketing and lobbying groups.  
Some important innovations and discoveries are being accomplished by ‘independents’ like 
myself. The way we circumvent our work being bought up by the Big Pharma and possibly 
38 
 
shelved or developed for huge profit is to go to or be invited to speak at international 
congresses so that the knowledge is shared and can be used, but not patented by anyone. 
So far I have been able to defend my work through knowledge. I took this novel treatment to 
the International Modern Drug Discovery and Development Congress as mentioned above. 
Over the years I have built up a reputation at major congresses such as the American 
Society of Clinical Oncology (ASCO), International Society of Gastrointestinal Oncology 
(ISGIO), European Society of Gynaecological Oncology (ESGO), American Association of 
Cancer Research (AACR) and many others for sound scientific research and, in more recent 
years, also for my stance against the Big Pharma’s approach. I am now seen as an opinion 
leader. This is not my natural arena, but looking at how important this novel treatment is and 
the difference it can make to lives, I believe I can do more to get our work from the 
laboratory to the clinic. I have still much to learn.  
Inside 
I have tried to convince chemotherapists to tailor molecular targeting approaches under a 
personalized therapeutic strategy for incurable cancers like HRBC by detecting 
chemoresistant mechanisms with pharmacogenetics. These must be circumvented by 
inhibiting the dominant signalling pathways that activate them. This is done with genetic-
based therapeutic approaches like the antisense therapy to allow the conventional standard 
chemotherapeutic agents like vinorelbine to exert their cytostatic action. This way we can 
begin to challenge the existing policies of the the Big Pharma with evidence clearly 
demonstrating by comparison just how unnecessary these harmful and distressing adverse 
(side) effects are under their protocols, which cause systemic toxicity and secondary 
tumours.  
The obstacles to the scientifically sound approach that I and others advocate continue to be 
significant. Many obstacles have been put in the way of this progress. Like many 
independents, I have suffered periods of scientific isolation with obstruction of financial 
resources, regulatory pressures and a continuous painstaking struggle to complete my 
research work while I hold down the demands of my official roles.  
Circumventing the obstacles 
My understanding of the opposition to my work, shared by many colleagues in the cancer 
research field, is that it is down to the profit from the massive sales of the drugs all over the 
world. This public work is self-financed. How doctors attending my lectures are awarded 
Continuing Medical Education (CME) credits is that congresses like the Annual Meetings of 
ISGIO are under the auspices of American Universities such as the Medical School of the 
University of Nebraska.  
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The funding issues were extremely challenging and this work was an individual effort. The 
Big Pharma are aware that after I publish my new treatments in medical congresses i have 
no rights to their intellectual property (IP). I publish them because I want to prove my 
scientific point, that personalized cancer medicine is much more effective than the drug 
policy of the pharmaceutical industry for eradicating chemoresistant and radioresistant 
tumour cells exhibiting molecular mechanisms and not just survival rates. The Big Pharma 
knows that without huge financial investment these treatments cannot get through the 
regulatory process. However, by making them known to academics in congresses a change 
in drug policy can be induced that has a chain reaction, spreading the idea of personalized 
cancer medicine to all associated sectors.  
All the novel cancer treatments originate from the cancer researcher and then it is up to the 
translational medicine practitioner to take it from bench to clinic through all the stages of the 
required regulatory process, leading to the drug being approved. This procedure is extremely 
expensive. After this point, the chemotherapists can use this drug on a routine basis. 
Translational medicine practitioners have established a new regulatory tool called Phase 0 
and this can save a great deal of time and money in drug development.  
The most evidenced impact of translational medicine at the moment is educational, keeping 
chemotherapists up to date with what is possible. In cancer research, we move faster than 
regulation hence experience frustration in trying to get anything from the laboratory to the 
clinic. We know things work and will save lives, but we are held up by a complex arena of 
regulation, stakeholders, old paradigms and the required funding that depends upon the 
control of a triad of pharmaceutical companies, government/regulation and cancer 
fundraising organizations that rarely fund independent research. A serious issue that should 
be circumvented is that if a compound is not patentable such as dicholoacetate (DCA) it 
shan’t be accessible to cancer patients, even if it is effective in deadly tumours such as 
glioblastoma. This is simply because the Big Pharma sees relatively little money in 
developing it. Regulatory agencies such as FDA, instead of helping its development process 
for being accessible to glioblastoma patients who really do not have many therapeutic 
options, they create obstacles such as trying to stop DCA being sold.54 These complications 
should be prevented in the future by political intervention that can be motivated by advocacy 
action. In the case of DCA, the local town raised money for the clinical trials.  
With novel molecular targeting therapeutic approaches like mine, the public impact is 
significant because chemotherapists and radiation oncologists in the future will learn how to 
practise personalized cancer medicine. This is radically more efficient than the conventional 
treatments: It provides better differentiated therapeutic solutions and improves the medical 
outcomes, saving the lives or improving the quality of life of many cancer patients who now 
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are destined to die. Treatments like this are set to motivate regulatory authorities like EMEA 
or FDA to be supportive, accelerating their drug approval process, because innovative 
therapeutic methods like personalized medicine may take us in the direction of safer and 
more effective cancer treatment. After regulatory approval, these targeted therapies would 
be widely adopted by chemotherapists and radiation oncologists, because they are 
extremely effective in eradicating tumour cells in a specific subpopulation of cancer patients 
using  -omic approaches.  
A better economic argument 
There is also the issue of common sense economics. For instance, by dramatically 
improving the efficacy of cancer treatments and minimizing systemic toxicity, personalized 
cancer medicine may circumvent the enormous problem of non-compliance. Many cancer 
patients at the present time do not adhere to their prescribed drugs due to severe adverse 
effects. This wastes many millions of pounds for healthcare systems like the NHS, for 
example. It will enhance compliance rates of cancer patients to their prescribed medications, 
for instance chemoradioimmunotherapy such as the one that I presented at the 18th Annual 
Meeting of the European Association of Cancer Research in July 2004. It was reported as a 
breakthrough treatment, giving hope to the future treatment of advanced breast cancer, in 
the cancer/oncology category of the Medical News Today website.55 This work was selected 
as the most significant of the EACR congress by the whole Federation of European Cancer 
Societies (FECS), the Brussels-based organization that represents the interests of almost 
18,000 cancer professionals in Europe. FECS promotes the multidisciplinary aspect of 
cancer care through scientific activities. At that time I was Head of the Radiotherapeutic 
Cancer Research at IASO Hospital, Athens.  
With this successful, and novel, therapeutic technique I managed to kill metastatic breast 
cancer cells by circumventing their chemo- and radioresistant mechanisms (Giannios, 2004). 
Therapeutic approaches like this one may save huge amounts of money because cancer 
patients will have more trust in something that is tailored particularly for their cancer type at 
the molecular level, targeting their individual phenotype and will be more compliant. 
Furthermore, the financial burden of conducting clinical trials will be decimated, significantly 
accelerating the drug development process because clinical trials will be smaller, targeting 
smaller cancer populations. With these tailored drugs, we will get positive results within 
weeks or months instead of years since we will be able to exclude the non-responsive type 
cancer types from clinical trials. We will be able to identify responders by using biomarkers. 
This will allow chemotherapists and radiation oncologists to take a more rational and 
selective approach to their therapeutic decisions.  
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With the new generation of personalized treatments that aim to tailor drugs, specifically 
targeting cancer patients who are likely to respond positively to these specific treatments, we 
can circumvent the presently existing trial and error approach to cancer treatment which is 
associated with high cost, high risk and low efficacy. Thus, by blocking the growth and 
spread of incurable cancers by interfering with specific molecules involved in oncogenesis 
and tumour proliferation, we can save the lives of cancer patients and avoid the huge 
financial waste of ‘one size fits all’ drugs. Furthermore, these treated patients will be able to 
boost the economy by staying in work. This helps society. Standards of social life will be 
greatly upgraded by reaching an optimal level of health. Providers and hospital groups will 
become much more efficient from a welfare perspective. Deficits will be reduced and 
politicians will be more efficient and popular by investing more money in other social needs. 
The pharmaceutical companies will have to learn to accept the end of an era that has been 
financially very successful for them in its ‘one size fits all’ policy, because there are many 
more treatment options for an individual cancer patient.  
Such innovative cancer research like personalized medicine will hopefully or could already 
be influencing medical bodies, health authorities and even pharmaceutical companies to 
focus on grouping disease by mechanisms of action and not to group disease by symptoms. 
It also indicates very clearly to them that they must be prepared to invest money on 
research. This is still needed for the future development of drugs to target oncogenic 
mechanisms instead of organ types, shifting to a horizontal mechanism of action from a 
vertical organ-specific view. With the development and use of pharmacogenetic tests, they 
will be able to accelerate pharma R&D, minimizing financial costs for clinical design and the 
time to market for their innovative products of personalized treatment that will be 
characterized by enhanced efficacy. Taking this particular public work as an example, my 
research that produced the novel treatment indicates that apoptotic cells may be used as 
targets for specific delivery of novel anticancer agents, instead of the blind survival rates that 
the Big Pharma currently uses without knowledge of any mechanism for cytotoxic action. In 
this way, clinical trials may be more efficient and effective, influencing positively the 
regulatory authorities for accelerating their approval because apoptosis is the ultimate end 
result for individualized cancer treatment.  
Personalized Cancer Medicine is a new medicine in the context of healthcare delivery and 
will be very competitive in the future. It will require close and productive collaboration 
between diagnostic and pharmaceutical companies, offering many new jobs that will help 
society. Molecular diagnostics will guide the practice of personalized medicine by targeting 
the right drug to the right patient. Companies must learn that they can capture value by 
delivering value. They must focus on developing innovative medically differentiated cancer 
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products for surviving in the future. I am one of the many scientists and cancer researchers 
who have fought the ‘one size fits all’ anticancer policy of the Big Pharma for more than a 
decade by presenting in International congresses works like the one mentioned above, and 
acting as an opinion leader regularly presenting research work with novel therapeutic 
strategies of personalized cancer medicine. The resistance of the big multinational 
pharmaceutical companies has been extremely strong because they fear that personalized 
healthcare would undercut their revenues. Time will prove them wrong and hopefully soon, 
because cancer patients should be respected and supported to the highest degree possible 
with no compromises involved.  
This work in cancer research has had positive and negative influences on my life and my 
professional development. It requires a patience that can quickly turn to frustration and 
anger when I have to wait for my novel molecularly targeted drugs to be available to cancer 
patients after the procedures of patenting and licensing have been completed. The 
enhanced scientific experience from my recognized work gives me better potential to 
continue with more strength to give lectures in oncology congresses educating colleagues 
about the benefits of personalized medicine for cancer patients. Furthermore, initiating 
collaboration improves my research work, discovering new therapeutic strategies for cancer 
especially metastasis which is very chaotic. In addition, with this international award, one of 
many that I have received, I can influence the Big Pharma to be more interested in the 
personalized healthcare that I strongly believe can offer many more benefits to desperate 
cancer patients, their relatives and to society in general compared to the existing 
conventional ‘blockbuster’ policy. As I always learn from each of my novel anticancer works, 
so can other cancer co-researchers using this knowledge to improve the treatments or use 
them as the basis to develop better treatments or improve their already developed 
treatments. This will make them more advanced and efficient against advanced tumours that 
are currently incurable under the conventional ‘one size fits all’ anticancer policy.  
This work of personalized medicine that uses pharmacogenetics to develop safer, cheaper 
and more effective anticancer drugs, from bench to clinic, as a translational medicine 
approach may contribute to the developing area of sociology of socio-technical expectations 
by creating new technological visions. In itself this will be a challenge to the ‘one size fits all’ 
approach.  
Fear 
When I trawled the web in a more systematic way I was overwhelmed by what I found, and 
as an insider I already knew a considerable amount. I now more than ever know that to bring 
the new paradigm in we need to all work together and to develop a high level research 
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journal and web presence where people can access evidenced findings from oncologists, 
cancer researchers and translational medicine practitioners.  
If I was overwhelmed, then what must it be like for relatives of sufferers trying to find the best 
treatment, a cure even? There are so many charlatans waiting to take advantage of them. It 
was at this stage that I decided that this should be for me a primary goal. It is not only the 
patient who suffers, but all those friends and relatives who care and feel powerless, plus all 
the scientists who know they have the answers to many of the problems but can’t get it to 
them. My thinking began to be around an association, a journal and a website.  
One very positive aspect of our era is that informative dissemination of medical knowledge is 
rapid and widespread due to the existing technological advancements. This can mediate 
cutting-edge medical education of health professionals, cancer patients and their families, 
advocacy groups, policy makers, journalists and society in general that may lead to radical 
policy changes in the way that cancer is tackled in the future. So that people know who and 
what to believe it is vital that cancer researchers and translational medicine practitioners can 
lobby and convince governments of their case which at least gives some seal of approval.  
 
4.3 Public Work 3  
Therapeutic genetic vaccine for HPV 16(+) cervical cancer and oropharyngeal (OSCC) 
cancer  
My novel therapeutic anticancer genetic vaccine, presented at the Annual Meeting of the 
American Society of Clinical Oncology in 2009 under the category of Developmental 
Therapeutics: Immunotherapy-subcategory: Vaccines and citation: J Clin Oncol 27: 15s, 
2009 (suppl: abstr 3062) is as follows:  
Effect on humoral and cellular immunity and on apoptosis in CIN2, CIN3, and HPV16+ 
cervical cancer of therapeutic divalent genetic vaccination with CMV replicon system (CRS) 
delivering HPV16 recombinantly mutated E6 and E7 viral oncogenes targeting p53 and Rb, 
respectively.  
The technical aspects of this work are described in Appendix 1C. Other anticancer vaccines 
I have developed and presented in oncology congresses are in Appendix 2C.  
This work demonstrates what is possible if one is highly motivated and dedicated. Cancer 
has to be managed in a multipronged approach: science, trials, individual and team effort 
and dedication, the media, policies, funding. The science carried out by individuals and 
teams provides the evidence and trials to establish its efiicacy and feedback information on 
such things as optimum delivery and counterindications, dosages and exclusions. This 
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combined evidence needs to be made known to both the general public and decision makers 
like government bodies and funders. Training has to be carried out to help practitioners in 
cancer understand the delivery of the treatment and its combination array to optimize impact. 
This work was motivated not only by the science but by a social conscience. Cancer 
treatment as it exists today has great disparity but if it continues with the Big Pharma 
controlling both doctors and the price of drugs, it will be disastrous for people in the lower 
income groups.  
Description: This therapeutic genetic vaccine against HPV 16(+) derived cancers is the only 
one that exists in medical oncology.  
Its therapeutic significance is substantial because it is independent from chemoresistant and 
radioresistant mechanisms. HPV is the most common sexually transmitted infection in the 
world. HPV type 16 can cause cervical and oropharyngeal squamous cell cancers(OSCC), 
such as soft palate, tonsillar and tongue cancers that rise rapidly with an overall five-year 
survival of about 25 per cent. Other tumour types that HPV 16 causes include anus, vagina, 
vulva and penile cancer. None of the vaccines to date actually treat cancer. The vaccines 
which are used today are only preventive vaccines fighting viral agents that are capable of 
causing cancer. This therapeutic cancer vaccine is an emerging experimental type of 
treatment designed to stimulate the humoral and cellular immune system that are the body’s 
natural defences for finding and fighting cancer cells. This therapeutic vaccine can be 
combined with other cancer treatments including chemotherapy, radiation, surgery, 
antiangiogenesis drugs, and so on. This therapeutic vaccine targets certain molecules such 
as antigens on the surface of tumour cells, never expressed by healthy cells. Thus, this 
therapy circumvents systemic toxicity. For the development of this novel therapeutic vaccine 
which is one of a kind, I have developed a cytomegalovirus (CMV) replicon system (CRPs) 
for the efficient delivery of the HPV16 recombinantly mutated E6 and E7 genes replacing 
part of the CMV genome for the HPV genes which were genetically altered to block binding 
sites for tumour suppressor gene p53 and oncogene Rb. The replicon vectors infected and 
co-transfected CIN and cervical cancer cells derived from HPV16 (+) tumours. After 
vaccination with a needleless injection system the viral E6 oncogene did not degrade 
apoptotic p53 and it blocked activation of telomerase. This induced type-I PCD or apoptosis 
and DNA repair in cervical intraepithelial neoplasia (CIN) and cervical cancer cells. This 
vaccination led to scheduled cell cycle entry, genetic stability and mortalization of tumour 
cells. Cellular and humoral immune responses were exhibited which led to irreversible D2 
apoptotic stage of apoptosis or type-I PCD leading to a bystander killing effect of 
intraepithelial neoplasia, and cervical cancer cells. BrdU and MTT analysis exhibited 
inhibition of DNA synthesis and metabolic activity of vaccinated tumour cells compared to 
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controls. This genetic vaccine coding for E6 and E7 mutations designed to prevent p53 and 
Rb binding sites, activating humoral and cellular immune responses leading to eradication of 
cervical intraepithelial neoplasia (CIN2, CIN3) and cervical cancer cells via induction of 
irreversible D2 apoptosis to give a bystander killing effect. This therapeutic vaccine has 
tremendous potential to stimulate humoral and cellular immunity against HPV16 (+) derived 
tumours.  
My role in it: I was the innovator and developer of this pioneer work. The idea was mine and 
I achieved its realization, although it was painstaking work at considerable expense to my 
personal time and at high risk due to the need to use live human tumour cells from from 
metastatic patients. I also was exposed to the carcinogenic HPV(+) 16 virus with which I 
could have been infected at any time, causing me cancer. Of course all the required 
measures were taken according to the guidelines of good laboratory practice (GLP) and 
good clinical practice (GCP). However, accidents can always occur that carry some risks. I 
do not take unnecessary risks in my work but I think take a balanced view. The outcomes 
are so important that some things are worth the risk, but it is always professional to minimize 
the risk as much as is humanly possible. So yes, I have exposed myself to such risks to 
discover a therapeutic solution to these chemoresistant incurable tumours that kill people 
whose only mistake was to have unprotected sexual intercourse or the wrong blood 
transfusion. Like the other public works, this was presented at international oncology 
congresses where my lectures are approved by the scientific committees and colleagues 
have the chance to ask questions. This is the best way for them to learn that there are 
therapeutic solutions available to patients with incurable cancer but which need to go 
through procedures to arrive in the clinic.  
Public impact: The human benefits of developing cancer vaccines will be of great 
importance – for millions of patients cured, to billions of pounds saved. Unfortunately, so far 
we have only vaccines that offer prophylaxis for the development of cervical cancer. To date, 
none of these approved vaccines actually treat patients who have developed cancer. The 
vaccines that I have developed and have been accepted for presentation in oncology 
congresses prove that gene modified cellular vaccination can be personalized against 
various types of advanced chemo- and radioresistant tumours, leading to apoptosis. 
Furthermore, these genetic vaccinations can be used synergistically with conventional 
chemotherapy under a personalized cancer medicine approach with vaccines derived from 
an individual cancer patient. Analysis of the therapeutic divalent genetic vaccine with CMV 
replicon system that I have developed against chemoresistant HPV16+ cervical cancer is 
facilitated by the intratumoural delivery of HPV16 recombinantly mutated E6 and E7 viral 
oncogenes that target tumour suppressor genes p53 and RB, as follows:  
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It is well known that there is a huge increase of HPV(+)16 derived cancers that can be fatal 
due to the increased incidence of infectious blood transfusions and unprotected sexual 
activity. I must emphasize that although this project was self-financed, as I declared officially 
in the disclosure form of the Annual Meeting of American Society of Clinical Oncology, I 
have completely waived my IP rights so future massive production of my therapeutic vaccine 
can be as economical as possible and be available in the future to deprived cancer patients. 
This production should be by a governmental, not a for-profit, facility. This will benefit 
society. Since the rapid increase in cervical cancer incidence worldwide requires improved 
healthcare access to under-served areas, my affordable HPV therapeutic vaccine aims to 
overcome the socioeconomic barriers associated with this fatal disease, and the other 
HPV(+) derived cancers that spread worldwide, especially in the developing countries where 
there is no available screening.  
The social macroeconomic benefits can be very significant. Society will benefit from better 
health and lower public expenditures for treatment that can be reallocated to other 
productive uses such as pharmacogenomics. The great utility of this therapeutic approach is 
that it is much more effective than conventional anticancer treatment because it may 
circumvent resistant antiapoptotic mechanisms with fewer adverse effects. Immunological 
analysis after vaccination exhibited significant antibody and antigen specific T-cell immune 
responses that were induced against the target E6 and E7 proteins. This led to the apoptotic 
eradication of cervical or vulvar intraepithelial neoplasia, limiting adverse events and 
injection site reactions to mild or moderate that need no treatment. That has a huge clinical 
impact because it can substitute chemotherapy with its associated tremendous systemic 
toxicity, chemoresistance, and development of secondary tumours. The public impact might 
spread worldwide because cervical cancer kills million of women every year, making it the 
second biggest cause of death among female cancer patients globally, according to WHO,56 
because HPV is carried by approximately 450 million people.  
Since HPV is the most common sexually transmitted infection in the world, a genetic 
therapeutic vaccine like mine is a distinctive kind of biotechnological agent, invoking notions 
of containment and contagion. Thus, politics can shape every aspect of the biotechnological 
and/or pharmaceutical life-course consisting of the way of production, use and so forth. 
Therapeutic vaccines like mine may instigate political struggles and social change because 
by curing HPV(+) derived cancer, it embodies the dream of hygienic containment by 
transforming bodies, practices, and institutions. The high-quality healthcare provided by this 
vaccine means that providers can manage a population’s healthcare by timely, skillful 
application of advanced therapeutic technology in a culturally sensitive manner within the 
available resource constraints. Policy interventions can be derived from this novel 
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therapeutic genetic vaccine that can lead to a higher quality process of care and rapidly 
improve a population’s health outcome, which can be cost effective in the long run.  
The news media comprise the channel for making this potential treatment known to the 
public so cancer patients may exert pressure on policymakers, physicians and guideline 
panelists (who define acceptable standards of care) for the immediate development, 
approval and availability of this vaccine. It can save lives and money by substituting toxic 
chemotherapy and/or radiotherapy. When this therapeutic option is known to cancer 
patients, it can circumvent the moral hazard where patients purchase drugs and services 
differently when they have insurance, based on the differences in value decisions and costs. 
Chemotherapy with all its supplementary drugs may be much more expensive than this 
vaccine. Subsequently, it can cut direct costs of cancer care, such as biochemical diagnostic 
tests associated with chemotherapy, hospital and physician fees, and mainly the cost of drug 
therapy paid by the government and other public and private insurers.  
The money saved can be used for other social priorities. For this to take place, new 
legislation should eliminate treatments that are not reasonable and necessary for the 
treatment of cancer. A therapeutic vaccine like this can go against the larger economics of 
the chemotherapeutic policy because, in a private system, investors such as pharmaceutical 
and biotechnology companies or venture capital investors must seek a positive financial 
return for shareholders for their drug development investment regardless of the quality of 
healthcare that they provide to cancer patients. Thus, policymakers must maintain an 
appropriate balance between responsibility for public and private healthcare programs and 
incentives for investments in future health innovations like mine. They should circumvent 
disparities in cancer care where individuals from lower socioeconomic groups, and specific 
racial or ethnic minorities who are characterized by enhanced cancer risk and worse cancer-
related outcome must have free access to innovative, revolutionary and novel treatments, 
like my therapeutic vaccine. This is not easy because the causes for these disparities are 
complex and include economic, cultural and social factors. Even the risk of uninsurance 
reaches the highest levels among those in lower income brackets. This should be 
immediately corrected. The social macroeconomic benefits of my therapeutic vaccine can be 
of huge importance because it can make healthier populations in societies that can increase 
tremendously the levels of human capital by enhancing the capacity to generate wealth. 
Higher quality of healthcare provided by a therapeutic vaccine like mine can increase 
society’s human capital by reducing the number of deaths from cancer, and the amount of 
disability, improving worker productivity. In addition, providers and insurers may benefit by 
avoiding unnecessary or inappropriate healthcare such as ‘blockbuster’ chemotherapy. 
Thus, society may benefit from better health, and cost effectiveness for treatment. Thus, 
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novel therapeutic interventions like mine that can improve quality have an especially high 
social value. This may lead to public dissemination by motivating managers and providers to 
undertake changes that will improve the delivery of healthcare. This vaccine might bring a 
new era of therapeutic genetic vaccination against cancer that may bring real value in 
healthcare, overturning today’s situation where cancer patients are left to settle for a market 
that has sub-optimal equilibrium and a poor quality of healthcare, like the conventional 
‘blockbuster’ chemotherapy. I strongly believe that novel anticancer approaches like my 
therapeutic genetic vaccine may improve tremendously the provider–patient interaction by 
increasing the overall value of healthcare.  
All involved parties in cancer treatment including Big Pharma must understand that the field 
of personalized medicine is rapidly expanding even in the sector of genetic vaccination 
against tumours with viral origin (ie HPV16+), such as cervical intraepithelial neoplasia (CIN) 
2–3, or cervical cancer. The more we learn about the genetic mechanisms of cancer growth 
and cause, the more we can harness this knowledge to improve survival rates, and improve 
quality of life for cancer patients by circumventing unnecessary side effects at affordable 
financial terms.  
My work offers new genetic clues about the effectiveness of therapeutic cancer vaccines 
based on genetics. The development of biotechnological advancements like this genetic 
vaccination against cervical cancer is feasible because it greatly reduces biotechnological 
development costs, ensuring that a high proportion of derived products make it through all 
the phases of development, and subsequently onto the health market. It is a fact that 
genomics-related technology (GRT) mediates the removal of unfavourable biotechnological 
products at the very early stages of development. The current advancements in genomics 
that reveal the detailed molecular basis of cancer may allow cost benefits to be passed onto 
the government agencies that fund healthcare, and cancer patients.  
A very serious ethical issue that I want to emphasize is whether the genomic medicine 
revolution will ever reach the healthcare system in developing countries that cannot afford 
even the cheapest of anticancer treatments already available to their poor and 
immunosuppressed patients due to malnutrition. To be honest, I do not think these 
treatments will ever reach cancer patients in the Third World and this worries me 
considerably. My belief has been confirmed by the WHO, which emphasizes that global 
inequalities are widening in the availability and subsequent use of anticancer treatments 
based on pharmacogenetics including molecular profiling, proteomic profiling, genetic 
testing, and metabolomic analysis.  
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For instance 90 per cent of the global health research expenditure is directed at diseases 
that affect only 10 per cent of the world’s population. Thus, we must stop the divide growing 
between the rich and poor concerning availability of cutting-edge anticancer treatments. Only 
with intensive scientific effort from cancer researchers like myself and political effort, the 
major anticancer advances derived from genetic research will be able to save millions of 
lives, especially in the developing world. Scientific evidence of genomic cancer medicine 
derived from oncology congresses have started to influence policy debates, mainly between 
cancer researchers who invent novel treatments that are followed by chemotherapists, 
radiation oncologists, regulators and company representatives. Only with the positive 
collaboration among them will all these new anticancer treatments be translated from bench 
to clinic, especially for sexually transmitted visuses that may cause malignant tumours, such 
as cervical cancer and oropharyngeal carcinoma (OSCC).  
Influence on my professional life/development: The innovation of this therapeutic genetic 
vaccine opens many doors for me in academia, research and industry. As a matter of fact, 
after this development and presentation I was proposed as Global Vice-President for Lilly 
Oncology in the United States, a position that I turned down. It is more important for me to 
remain independent and this vaccine also enforces my position as a pioneer cancer 
researcher, and gives me the pleasure in persuading and educating my peers about this 
therapeutic option. However, my greatest reward is that this vaccine can really help cancer 
patients in the future, improving their quality of life.  
All my works evoke the same issues about increasing my community of practice’s 
awareness, that of my field, public awareness and that of the media. And I learned from this. 
Until then I had been opposing them, both of us keeping to different sides of the table, they 
trying to undermine me in congresses and me fighting them, primarily with my scientific skills 
and knowledge and often feeling quite isolated. However, this time the approach was at a 
higher level, the offers at a higher level, the techniques persuasive rather than oppositional. I 
decided then that I could learn from this. I needed to be persuasive rather than oppositional, 
I needed to develop a way to impact the media and to influence the Big Pharma’s practice 
through public and expert opinion which could only be achieved through not standing alone 
but through collaboration and our own association.  
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4.4 Public Work 4 
Nanomedicine - Formulation SEVIN-A composed of Pegylated-Nanoparticles of CDP 
bound to multitargeted siRNA molecules against BMI1 and Survivin conjugated with 
miR-373 which targets CD44 overexpressing cancer stem cells (CSCs) of metastatic 
ovarian carcinoma induces Apoptosis/PCD type-I (D2 Stage) circumventing potent 
Chemoresistant-Multifactors caused by Vinorelbine.  
This work was presented at the plenary session of the 8th Ovarian Cancer Research 
Symposium at the University Hospital of Seattle in Seattle, Washington, 28–29 October, 2010.  
This novel treatment received a distinction from the congress committee.  
This novel treatment exhibited eradicating results due to induction of D2 irreversible stage of type-I 
PCD or apoptosis in chemo and radioresistant cancer stem cells of advanced ovarian cancer.  
For the technical aspects of this public work, see Appendix 1D. For a list of all associated 
works developed from this and put into the public domain, see Appendix 2D.  
As a cancer researcher I have to keep up to date with the very latest developments in science, 
to know every part of the body and its functions and to be an expert in genetics if I am to find 
new treatments, and new ways to deliver our treatments that do not damage the patient 
further. In addition, I must learn about particular delivery systems that can bypass the brain 
barrier and to negotiate the complex world of media, finance and politics. This work 
demonstrates my learning at the scientific edge and its application in my field of cancer 
research. In a sense, the good cancer researcher never sleeps. But what is the use of all of 
these novel treatments if we cannot get them to the patients? This work, at the cutting edge, 
confirmed for me that as a group we could be more powerful, more vocal and, most 
importantly, more organized. At one time the doctor and the specialist were highly respected; 
now we are treated like cogs in a wheel of big finance, increasingly separated from our 
patients and indirectly colluding with unethical practices. I no longer need to go on proving 
myself as a scientist, I am a good one: I just need to use the reputation I have built up to be 
more effective in the public arena and this time I do not go into it alone, or even thinking I am 
alone.   
Nanomedicine has great potential for breakthroughs in basic, applied and clinical sciences, 
leading to more efficient and targeted diagnosis, treatment and monitoring of diseases like 
cancer. In my pioneering work I have used colloids, which are lipid-based liposome 
nanoparticlesand niosomes. I use high Tc phospholipids which are combined with 
cholesterol which are located between acyl chains for enhancing stability when the 
nanoparticles interact with the biological milieu. For circumventing opsonin adsorption I 
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pegylate the surface, making it more hydrophilic. This way the nanoparticles carrying 
therapeutic molecules can circumvent elimination by the Reticulo-Endothelial System (RES) 
that consists of the macrophages (Kupffer cells) of the liver and spleen. With these 
nanoparticles I can target specific tumour cells characterized by chemoresistance due to 
overexpressed drug efflux genes such as MDR-1 that encode protein Pgp, which acts as a 
pump by binding drug molecules to its ATPase chains. Molecular Tumor Cell Targeting 
(MTCT) is achieved by linking antigens or other biosensors such as RNA strands to the 
surface of the nanoparticles that detect specialized properties of the tumour cell walls 
delivering their cargo of therapeutic molecules intracellularly by endocytosis circumventing 
chemoresistant efflux pumps. Only then can personalized medicine, which is molecularly 
targeted, be achieved for individual cancer patients by tailoring the treatment specifically to 
their tumour phenotypes.  
Once the target tumour cells have been identified – in my therapy they are the cancer stem 
cells (CSCs) that overexpress CD44 – and they have been activated by the 
chemotherapeutic agent vinorelbine, the nanoparticles that I have designed with high Tc 
phospholipids and pegylation to enhance hydrophilicity and lead to the circumvention of 
biological milieu interactions will bind with the conjugated miR-373 onto the CD44 of tumour 
cells. This will cause the entrance of tumour cells via endocytosis, releasing the therapeutic 
siRNA molecules intracellularly for downregulating BMI1 and survivin and inhibit downstream 
signalling pathways that lead to induction of type-I PCD or apoptosis (D2 irreversible stage) 
and activate a bystander killing effect. The siRNA molecules were protected and their life 
was prolonged during delivery with nanoparticles. Otherwise, the RNA strands would be 
destroyed by cellular mechanisms before reaching their targets.  
Furthermore, specific molecular targeting will aid in the treatment of late phase metastasized 
cancers and hard-to-reach tumours like breast and ovarian tumours. Also, nanoparticles will 
circumvent tumour chemoresistance by overpassing Pgp drug efflux pump. These 
nanoparticles will treat only the tumour, without damaging adjacent healthy tissue. They 
dissolve intracellularly in the endosome, releasing their therapeutic siRNA cargo that 
eradicates endodyploid cancer stem cells after downregulation of Aurora-B. The bottom-up 
construction of these nanoparticles takes advantage of molecular self-assembly for building 
specific structures, based on Watson-Crick DNA base pairing, for building nucleic acids of 
defined structure that will be used for personalized medicine involving molecular targeting. 
The benefits of nanoparticle delivery are extremely significant because they improve 
bioavailability of entrapped therapeutic molecules by targeting specific organs, tissues and 
mainly tumours, providing the highest dose of the therapeutic agent directly and with 
precision where it is needed, in our case to the cancer stem cell that causes metastasis. This 
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will reduce waste and cost due to breakdown prior to the drug binding to its target. 
Nanomedicine is a relatively new area of biotechnology, but the possibilities for novel 
therapies to treat advanced and metastatic cancers seems endless, as you can see from my 
novel anticancer therapies using nanoparticles, as included in the appendices.  
I was the innovator of this novel nanotechnology-based anticancer therapy, targeting cancer 
stem cells that cause metastasis. This work is of importance for the future of nanomedicine 
because currently there are no approved nanotechnology-based drugs or therapies on the 
market. Thus, I have learned to design, manufacture and manipulate biocompatible 
nanomaterials with a molecular understanding of tumour cell function and disease 
development. This way I can target cancerous tissue for transporting drugs into tumour cells 
to induce apoptosis. The main thing is that I prepare them with biocompatible phospholipid 
molecules that are not immunogenic, and intracellularly they are biodegradable. 
Nanomaterials are of great value in oncology and other medical applications because they 
improve the efficacy of cancer treatment tremendously. With the design and use of 
nanosomes I have managed to reduce adverse side effects of chemotherapy, overcome 
biological barriers such as the blood–brain barrier, and circumvent chemoresistant 
mechanisms, thus enhancing the therapeutic index of anticancer agents and reducing 
systemic toxicity.  
I always use drug delivery systems in my novel anticancer therapies, because they 
concentrate the therapeutic molecules in cancerous tissue and significantly reduce the 
collateral damage caused by chemotherapy. Another driver is the low solubility of many 
anticancer agents that prevents their formulation as drugs. I also have extended the life 
cycle of an anticancer agent by using reformulation. Furthermore, I have managed to make 
these nanoparticle drug delivery systems (NDDS) cost effective. My main concern is to 
deliver the right drugs with nanosomes to the right cancer patients, under a personalized 
medicine approach using molecular targeting.  
Public impact:  
The impact of nanomedicine will revolutionize health. The following is a summary; for a fuller 
account, see Appendix 4. Nanomedicine will improve healthcare in future. It is taking place 
now and in conjunction with the personalized treatment –omics approach it poses the most 
major challenge yet to the Big Pharma ‘blockbuster’ policy. The Big Pharma do not possess 
the know-how to produce products based on nanomedicine and must rely on merging with 
biotech companies or buying patents related to nanomedicine. Either way, the group has no 
control over this technology, and it can prove to be extremely costly. Novel nanotechnology-
based therapy will introduce a new market segment that will be established by focusing on a 
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more individualized or personalized medicine using tailored molecular targeting that will be 
developed, and marketed, by medium-sized pharma companies. Nanotechnology can add 
new functionality to anticancer agents, making them more competitive. For instance, 
nanosomes can inhibit chemoresistance by circumventing P-gp (MDR-1) polymorphism 
C3435T, especially in West Africans and African Americans characterized by overexpression 
of this multiple drug resistance gene, according to an article published in The Lancet.57 
Furthermore, they can enhance therapeutic index of entrapped drugs and reduce their 
systemic toxicity. This is the reason that drug delivery systems currently represent the 
largest market in the pharmaceutical industry. There are no general scientific hurdles that 
block nanomedicine products, such as nanoenabled drugs that, combined with 
pharmacogenomics, could change disease costs.  
Commercialization of these products depends upon external factors such as the availability 
of capital, technology transfer management by universities, regulatory issues, and the IP 
landscape. These are complex and fragmented aspects because nanosomes studies have a 
multidisciplinary nature consisting of physics, chemistry, and biology that makes 
categorization difficult. The commercialization of nanoenabled drugs needs companies to 
finance clinical trials for novel drugs and provide the distribution network. However, these 
products are associated with personalized medicine mediated by molecular targeting. These 
mean fewer failures, cheaper clinical programs and potentially cheaper drugs, leading to 
more affordable, high-quality cancer care. Nanotechnology in oncology is seen as an area in 
which there is significant potential for delivering health gain.  
Reflections: 
I started to write this as a scientist, describing accurately the scientific process of arriving at 
this innovation. I then wrote about my role in it. But when it came to public impact and 
potential for the future, I found I could not stop writing. I wrote so much I have had to put a 
large section in the Appendices. This reflects who I am. I am determined, I am angry, I am 
passionate and energetic, and fundamentally I am an optimist. I could not have done what I 
have done without that attitude to life. This optimism is built on the shoulders of the peoples 
of our recent past who sacrificed so much, so that my generation could be free. I have no 
hesitation in sacrificing things in my life so the next generation will benefit and to derive 
satisfaction at the same time, something our war generations could not do as the loss of life 
had been so great.  
This wonderful coalescence of different science disciplines is resulting in new ways of 
thinking and doing things in the world. It fundamentally challenges this insidious movement 
towards the wealthy of access to medicine and appropriate life saving treatments. It also 
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moves us closer to cures, rather than profiting by inhibiting cures by promoting symptom 
management. This coalescence has become a constant inspiration to me to, in a sense, to 
mimic it. I can be a vehicle for achieving a similar coalescence of practitioners from the many 
different areas of cancer medicine and delivery. We can work together to change the 
policies, perceptions and misinformation that are standing in the way of the progress of our 
science. The Big Pharma can resist individuals working alone or in niche groups, it can 
marginalize them; but it cannot resist a huge groundswell of scientifically and strategically 
informed agendas that place human life and values such as social responsibility at the core 
of its activity.  
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5.  From Reflection to Action  
 
I have said at the outset that this doctoral journey has to be more than a critique of my work. 
It has to be a critique that has purpose. I have hoped that through this critical journey I can 
become a more informed and more effective advocate in my field of translational cancer 
medicine. I am aware that I am regarded as passionate and, some would say, even 
obsessive. Passion needs to be harnessed by objectivity achieved through evidence and 
insight for holding particular views and challenging the dualistic thinking of good and evil, 
which is seductive but intellectually lazy. In my busy life in pursuit of bringing laboratory 
research to the clinic, I have been in the past been seduced into such thinking, but this 
journey has helped me take a step back, and may make me more effective rather than less.  
Recently there has been the case of reviving the old tricylic anti depressant clomipramine 
(Parker & Pilkington, 2006) with laboratory evidence and anecdotal evidence to support its 
efficacy in killing brain tumour cells. Brain tumours pose the greatest challenge to 
researchers and clinicians as so many treatments cannot cross the brain barrier and 
debulking of the tumour can cause disabilities.  
In the last year I have been working on a delivery system that can pass through the brain 
barrier and my work is about to be published next year as a part of a book involving 
epigenetic cancer medicine. The researchers and clinicians involved 58 have been unable to 
get funding from the Big Pharma, because the drug is already very cheap and available. 
Clinical trials will now be funded by an independent brain tumour trust. A year ago I would 
have been angry and seen this as just another example of the Big Pharma controlling 
everything. Now I can step back and look at how we can encourage more private and charity 
funding of independent research, as in the case of DCA59 that is funded entirely  by the 
public and directly to the researchers in the United States and how cancer specialists can be 
brought more closely together, not only through congresses but through an association. In 
2011, I received judicial approval for inaugurating the activities of the Hellenic and 
International Society of Molecular and Genomic Medicine that now has more than a hundred 
subscribed members, so that we can not only share knowledge and agree on a strategy for 
the acceleration of individualized treatments, but be able to present united and rigorously 
examined areas of research to be presented to independent funding bodies. It will be 
officially launched at its first conference in October 2012.  
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More Effective Advocacy for personalized cancer medicine (PCM)  
Good and Evil? 
Personalized cancer medicine targeted with pharmacogenomics and pharmaco-epigenetics 
has been established by cancer researchers and translational medicine practitioners with 
resistance from the Big Pharma. This resistance is mostly manifested in the refusal of 
funding and in the practice of conditional funding in which every discovery is patented to the 
Big Pharma. The way that supporters have counteracted this resistance has been through 
public sharing of medical knowledge through congresses where a number of figures, 
including myself, act to change the attitudes and stimulate positive action to advance the 
progress of discoveries from laboratory to clinic.  
When you are part of this oncology world, as in all sub-cultures one is privy to knowledge 
that may enrage you. When related to outsiders, they could be forgiven for believing one is 
suffering from some form of paranoia. For example, there are things that happen at all levels 
of a university’s infrastructure that would not be believed. The same is true for anybody in 
government departments, mental health hospitals or banks. Therefore, it will be no surprise 
to me if readers construe some of what I say as a touch paranoid.  
The Big Pharma’s ‘race for cancer cure’ could be seen as a major sociomedical 
misrepresentation, because its administrators establish cancer non-profit groups but put their 
own executives on their administration boards. It is therefore difficult to assess whether all 
decisions by these cancer non-profit groups are independent of the interests and direction of 
the Big Pharma or whether such groups are inadvertently subsidizing Big Pharma lobbying 
and drug campaigns and whether their research efforts are not fully accountable. Such 
groups depend upon donations by ordinary citizens who deeply believe that all their 
donations are being used responsibly to find cures for the various cancers that have often 
affected members of their own families or friends. For instance, take the non-profit American 
Cancer Society:  
 
http://www.tbyil.com/ACS_Problems_Part3.htm 
http://www.articlesbase.com/cancer-articles/asbestos-mesothelioma-the-questionable-ethics-of-
the-american-cancer-society-do-you-trust-them-2126581.html 
http://www.chelationtherapyonline.com/PreventCancer/index.html  
 
This organization has millions of dollars in cash, a fleet of luxury cars, multimillion-dollar real 
estate and many hundreds of millions of dollars in other assets, while its CEO has an annual 
salary of about a million USDs. The Big Pharma publicity indicates that the only obstacle to a 
cure is money. It is left to extraordinary individuals suffering from cancer like David Schreiber 
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(who recently lost his fight against brain cancer) to spread the word about prevention of cancer 
through books like his best-selling Anticancer (http://en.wikipedia.org/wiki/David_Servan-Schreiber).  
Unfortunately, cancer has been transformed by the Big Pharma into a market-driven industry 
that has a high yield for corporate sponsors, instead of financially supporting independent 
research groups to find innovative strategies for treating cancer. I myself would have no 
issue with the Big Pharma if it devoted much more funding to the development of beneficial 
molecular targeting therapeutic approaches on a personalized basis, using epigenetic and 
genetic treatments establishing circumvention of chemo/radioresistant mechanisms, 
supporting clinical delivery training and guaranteeing that these treatments will be available 
at reasonable prices. However, due to a lack of investment, these PMA approaches are 
currently specialized knowledge that the Big Pharma does not possess. The group has 
recently been trying to fuse or purchase biotech companies to address that deficit.  
Another success for the Big Pharma monopoly of cancer is their influence on legislation. It is 
now illegal to claim anticancer effects by nutritional therapies, medicinal herbs, chemical 
detoxification, and so on. For instance, alternative cancer clinics have been made illegal in 
Western countries, including the United States, where federal criminal law with imprisonment 
applies to these cases. The reasons given are to protect the public from exploitation. Thus, 
everything that is not controlled by conventional cancer medicine is discredited as quackery, 
dictating that conventional doctors disregard all supporting scientific evidence of PMA that 
could show the ‘blockbuster’ drug policy of the Big Pharma as inefficient and dangerous. 
Cancer patients receiving chemotherapy are required to avoid antioxidant nutraceuticals on 
the grounds that they interfere with the drug treatments, while in reality they protect normal 
cells from the chemotherapeutic systemic toxicity that may cause immunosuppression, heart 
failure, brain, liver and kidney damage and even secondary tumours. In these circumstances 
one might be forgiven for thinking that conventional ‘blockbuster’ cancer medicine does not 
aim to eradicate tumours, but to convert cancer into a chronic disease dependent on drugs 
that suppress only the symptoms of cancer and never the disease itself.  
In nothing we do in the congresses and through no strategy developed in our association or 
publications do I want to contribute to repeating the approach of the Big Pharma, not least in 
failing to educate the public in what is possible and what could be available through PMA 
based on –omics, which might actually eradicate tumours. There is no excuse for keeping 
people in ignorance, particularly in today’s global village. It is very hard to censor all 
information in a modern environment, but there are forms of censoring knowledge such as 
buying up patents and therefore preventing their development or, most importantly, the 
timing of their development. To a small team or an individual researcher, the cost to patent 
findings these days is financially prohibitive.  
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Cancer cure is the holy grail of medicine. I ask myself often if that is what drives me, to be 
that person or one of those people that ‘finds’ the cure. I firmly believe that no single person 
will do this, but that the future is in prevention and eradication brought about by individuals 
and teams openly sharing knowledge. I have saved people through my work and lost people. 
It is a humbling experience and at my age I want to contribute to the creating of conditions 
that will support a new way of thinking and save more lives. I regret every day the lives of 
those lost under my care and I am fully aware that it is at those times easier to blame 
something like the Big Pharma than myself or the randomness of life.  
But I also believe, and have and can evidence, the substantial obstacles the Big Pharma 
impose and the powerful monopoly they have in this arena. This prevents a new paradigm 
that can be objectively assessed as more efficient, fairer, sustainable and visionary than 
what we have now. At the moment the patient has no choice but to follow conventional 
treatment. To oncology scientists, that is like cutting off a leg without anaesthetic when we 
know anaesthetic will work yet is not allowed, while the patient does not even know it 
exists.It is like condemning a person to a wheelchair when there are amazing prosthetics, 
yet the company who makes them has set the price too high, or well-publicized incidents 
even within conventional cancer treatments when a patient is denied a treatment because it 
is too expensive yet the clinicians know it will prolong life. If a cancer cure was actually 
discovered, the cancer ‘blockbuster’ policy of the Big Pharma would no longer be the second 
most profitable industry after the petroleum industry. The majority of cancer patients die from 
permanent organ damage caused by conventional chemotherapy 
(http://realhealthtalk.com/chemotherapy.html). I make no apologies as an insider for my anger.  
The future 
One of the biggest challenges for the health sector in the twenty-first century will be to develop 
personalized therapeutic agents specifically tailored to individual cancer patient’s biology and 
pathophysiology. This change from the ‘blockbuster’ cancer medicine (BCM) to personalized 
cancer medicine (PCM), initiated by cancer researchers like myself globally during the last 
decade of the twentieth century, will influence the development, marketing and prescription of 
advanced cancer drugs such as epigenetic inhibitors that can be delivered on an individualized 
basis with nanotechnology. These changes could lead to major changes in cancer treatment, 
such as the stratification of cancer patients into biological subgroups with the utilization of 
pharmacoepigenomics and pharmacogenomics, leading to the development of tailor-made 
personalized treatments for individual cancer patients. It would involve the molecular targeting 
that has been established and presented in oncology congresses by cancer researchers.  
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However, the materialization of personal cancer medicine practice requires the support of 
advocacy groups to influence political decision makers. Thus, advocacy strategies for being 
productive and efficient must focus on a well-conceived advocacy plan for the successful 
monitoring, implementation and evaluation of this change in cancer control policy. Advocacy 
efforts must aim to activate social mobilization through the media and support coalition 
building for a sustained fight against the resistance of the current paradigm. Public 
assistance, including groups and organizations, can influence national and international 
leaders who, in turn, can exert pressure on ministries of health and local authorities to adopt 
new comprehensive cancer control policies or programmes.  
Yet it is up to cancer researchers like myself to prove with publications and lectures at 
international oncology congresses the superior medical advantages of the new personalized 
approach against cancer compared to the old one. This way, the advocacy groups can use 
the medical evidence to engage the support of regulatory authorities in establishing this new 
era of cancer control policy. Thus advocacy groups can put cancer control knowledge into 
action by turning authorities such as health ministries into advocates for influencing other 
regulatory bodies and planners.  
The establishment of a successful and effective advocacy action requires devotion and the 
commitment of a great deal of time, however. Knowledge provided by health experts such as 
cancer researchers will define the current cancer situation by analysing in great depth the 
scientific barriers and opportunities of cancer control; professional advocacy skills are 
needed for careful planning and productive collaboration to achieve a sustained strategy. Pie 
in the sky? A dream too far? As the anthropologist Margaret Mead60 said, even a small 
group of thoughtful, committed citizens can change the world, especially when their 
advocacy strategies are carefully tailored to the cultural, social, economic and political 
milieu.  
Dr Martin Luther King61 said that ‘radical and breakthrough change towards social benefit 
does not roll in on the wheels of inevitability but comes through continuous and painstaking 
struggle against all fronts.’ The fact is that this new paradigm of personalized cancer 
medicine has unfortunately to pass through three stages, according to German philosopher 
Arthur Schoperthauer (1788–1860). He said that ‘all truth passes three stages: First, it is 
ridiculed. Second, it is violently opposed. Third, it is accepted as self-evident.’  
 
http://paganpressbooks.com/jpl/DEFENCE.HTM  
http://plato.stanford.edu/entries/schopenhauer/  
 
As Clarence Darrow (1857–1938) said, ‘I will chase after the truth like all hell and I will free 
myself, even though I never touch its coat-tails’ (http://www.informationphysics.com/truth).  
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International bodies and effecting change 
The guide for effective programmes of cancer control focusing on policy and advocacy 
published by WHO at the end of 2008 has clearly identified barriers to and opportunities for 
comprehensive cancer control and advocacy that must be considered in the planning of 
advocacy strategies in order to establish a personalized cancer policy. The barriers that 
must be circumvented include lack of political will and leadership for developing cancer 
control under a public health approach that could be influenced by the Big Pharma and the 
reliance on symptom control over effective treatment approaches, prevention and early 
detection. Social barriers that must be circumvented include cultural taboos or myths, 
stigma, religious attitudes to cancer and limited understanding or poor need for cancer 
advocacy and mainly lack of advocacy skills. Only if we achieve the implementation of the 
six basic components of cancer control: prevention, early detection, diagnosis, treatment, 
survivorship and palliative care, can we circumvent and cure most of the cancers that 
currently kill approximately ten million people per year.  
I want to emphasize how important is advocacy support in improving the new challenge of 
cancer survivorship care, because currently there are many deficits in cancer care: patients 
become long-term survivors. According to the Continuing Medical Education (CME) course 
at Harvard Medical School on Cancer Survivorship Care, there are four essential 
components that should be improved. They include prevention of recurrent or new cancers 
plus other late effects derived from cancer; organized and effective coordination of oncology 
specialists and primary care providers; intervention for cancer control and its sequelae; 
surveillance of cancer and effective assessment of medical and psychosocial late effects 
(Rowland et al., 2006; Hewitt et al., 2006). This oncology challenge of cancer survivorship, 
up to now was quite unexplored and underestimated, covers the period of time from the 
onset of cancer diagnosis through the remainder of one’s lifespan. More narrowly, it covers 
the period of time after the current forms of cancer treatment that can leave people more 
disabled than they were before diagnosis, exposing them to long-term complications such as 
chemobrain, vital organ dysfunction due to irreversible damage, functional disorders and 
potentially lethal secondary tumours (Horning, 2008; Gilbert, 2008). Thus, cancer survivors 
of current conventional chemotherapeutic agents face potentially disabling physical, mental 
and social complications. All would be improved or circumvented by the introduction of the 
personalized cancer medicine (PCM) approach that can be facilitated by strong advocacy 
action.  
Generally, for implementing improvement of the six basic components of cancer control, we 
must educate policy makers and programme managers on how to advocate, plan and 
implement efficient programmes that are able to control cancer and reduce its incidence, 
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mortality or morbidity, and improve the quality of life for cancer patients, especially in late 
stage IV. This needs to be done by establishing a systematic implementation of evidence-
based interventions for the five basic components of cancer that apply to my selected works 
for the DProf. So what I have done now and will carry into the future is:  
1.  I will go on researching into cancer and safe and effective modes of delivery 
2.  I will launch the Hellenic Association this year and work with my colleagues to bring 
about change based on good science, ethics and values which support social 
responsibility. This association will:  
a.  form a powerful lobby group on policy 
b.  educate the media 
c.  produce collaborative papers  
d.  advocate for social responsibility and all medical practitioners to subscribe to 
the equivalent of the Hippocratic oath. 
There is strength in numbers. We have been fighting and been marginalized as individuals 
for years. I have myself have gone from being an idealist to being a realist. I have gone from 
revolutionary to pragmatist.  
The most important thing I have learned by going through this laboratory to clinic process 
was to be sound in knowledge, patient and diplomatic. What I have learned going through 
this doctoral process is how to be more effective, more persuasive and less dualistic in my 
thinking, that is, we are good and they are bad. I have found a way to gather the 
independents together for a unified voice and to form stronger lobbying. I needed to bring 
cancer researchers and translational practitioners into some organization or body that will 
give their work prominence and recognition. This is not about making money, but doing what 
may seem old fashioned – doing what is right.  
My own learning edge – the art of translation  
It is easy to say what needs to be done and what I will do. I have the skills to do some of 
this, but my learning edge is in knowing how to communicate effectively with different 
stakeholders, particularly those who are outside my normal domain of practice, the general 
public, advocacy groups and the media. I need to find out how to manage communication 
more effectively with those I have seen until now as obstacles that need to be circumvented 
like those doctors who work for the Big Pharma and whom I have termed chemotherapists. 
In this sense, my journey in translational medicine is in its early stages, but I have been 
taking rewarding steps in the right direction and can see how effective this is. For example, 
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as a cancer researcher and translational medical practitioner I believed myself to have all the 
technological and scientific knowledge of importance to the patient. I never gave particular 
attention to the nurses who look after patients and their families, and who have the primary 
relationships with the patient. If I were to caricature myself it would be the scientist who 
walks into the room and, although I care deeply and do not want the patient to die and 
devote all my professional life to finding away to keep them alive, that is not what comes out 
of my mouth. I tend to talk the science. What has been so helpful is talking to the nurses, 
explaining the issues to them and listening to their advice about how to communicate that to 
the patient. Similarly, if a doctor at a congress challenged me, I would respond by using my 
knowledge almost like a weapon. In this way, a skirmish might be won but I lost the battle. 
Now, instead of doing that, I ask if they would like to consider joining my association or 
whether there is a way I can help to elucidate the science. I realize now that before this 
doctorate it was my lack of flexibility in communication style behind the lack of progress in 
getting people on my side.  
If I can learn from my own scientific training, then practice is the answer. First, however, I 
need to become familiar with the language and communication styles of the different 
stakeholders who are part of this translational process from bench to clinic, defining exactly 
the reason for our communication, and what we should discuss at a specific time. If I can’t 
do that, I need to have people who can. These stakeholders consist of my own field that I am 
already familiar with (see Introduction and the role of congresses, and whose proceedings 
are translated to the media) and the various governmental and non-governmental groups 
that impact on public opinion and with whose language I am less familiar. They include:  
a. regulatory officials  
b. government officials, parliament representatives 
c. all the professionals dealing with the healthcare 
d. patient groups   
e. external players such as the media. 
I will be initiated into this process of communication very soon, as I have been invited to give 
a lecture in the World Antibody Drug Conjugate (ADC) taking place in San Francisco this 
year on 23–25 October (http://adc-summit.com/speakers), where all the major stakeholder 
groups necessary for establishing the Personalized Cancer Medicine paradigm will be 
present. I have come to realize that I need to have a strategy for communicating and thereby 
collaborating with this range of stakeholders. It will include an analysis of each group of 
stakeholders, their perspectives, their questions and the content that may both answer their 
questions and at the same time offer them a little more to think about.  
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The challenge, of course, in establishing an effective communication strategy for each group 
is to distinguish the main characteristic differences between them. From an intensive Internet 
search I have found the following considerations that apply to different stakeholder groups. 
They have been written by Suzane McDonald from Ireland and Ann-Elisabeth Hammer from 
Norway (http://www. hma.eu/fileadmin/dateien/HMA_joint/02-_HMA_Topics/02-HMA_ 
Strategy_Paper/Index/Section_III_01_Stakeholders.pdf). I have modified them to the particular 
context of my drive to establish a new paradigm in how we respond to cancer. Common to 
all is to do what we say and say what we do.  
a. communicating with cancer patient groups and the generalpublic requires 
consideration of timing (eg in relation to events in the media, government 
policies, etc), appropriate language, clarity, being concise, non-sensational, 
non-trivial, relevance to audience, actions very clearly defined and feasible 
and contacts provided.  
b. communicating effectively with healthcare professionals involves considering 
the role of each professional, their concerns and contexts in which they have 
to operate as they will have their own cultures, timely access, clear 
recommendations for action, a clear understanding of what is feasible, 
collaboration opportunities and contacts provided.  
c. communicating with peers internally requires establishing confidentiality, pre-
action discussion with relevant colleagues, clear understanding of the vision 
and purpose, a persistent and consistent message and circulation or 
notification of medical information.  
d. communicating with regulatory officials requires having confidentiality 
assured, thorough knowledge of regulation and why it is the way it is, 
evidence-based recommendations, persuasive argument,  
e. communicating with government officials for political action requires accurate 
information, meaningful language and contextual/background information and 
economic advantages.  
I also have to improve my communicative skills to establish effective media relations, which 
is an extremely important issue. Handling this requires sensitivity to and understanding of 
the social and political aspects of public health and how words can be taken out of context.  
If any government is to take action to make novel treatments more accessible to the public, 
then it is public pressure that can make it happen. This requires us as the scientists to 
ensure effective information and collaborative communication to shift them towards the new 
paradigm that aims to protect public health. A major step is the engendering of trust through 
the association’s being independent, not for profit, transparent and thorough in its research 
64 
 
and having at its core the principle of social responsibility. If we are to establish confidence 
and trust between society and our association that may lead to strong advocacy action for 
the benefit of public health, we have to get our message across effectively. As Aristotle 
(384–322 BC), Plato’s student and teacher of Alexander the Great, said: ‘if communication is 
to change behavior, it must be grounded in the desires and interests of the receivers’. We 
are helped in this by the Internet and its use in disseminating accurately and quickly medical 
information-sharing across all the stakeholder groups, leading to the appropriate decision-
making required for the establishment of personalized cancer medicine.  
The art of translation in teaching 
I have recently been engaged to design and deliver Masters in translational medicine and in 
pharmacogenomics and pharmacoepigenetics. I can teach the science but I can become 
more skilled in teaching what ‘translational’ means and the skills of negotiation with different 
stakeholders. To help in this I want to explore taking a PG Higher Education teaching 
certificate if I am to be successful in persuading future doctors to challenge dominant 
paradigms and the Big pharma from a position of knowledge of the complexities as well as 
the specifics.  
To more effectively communicate with the advocacy groups and with the media, I need to 
find a way to translate the complex into the simple in the way that distillation is simple which 
is not the same as simplistic which I now realize is patronizing. For this reason I think that 
our new association will need to look at guest speakers and co authors who are experts in 
lobbying, public relations, public health to better support the shifts for many of us from 
cancer research to translational medicine which is a relatively new discipline. I need to find 
associates and people I know in the press to help me with my presentation skills. When I am 
in my comfort zone which is populated with science and scientists I can face people head on 
and draw confidence from my subject knowledge. When I am not in my comfort zone and 
faced with people who do not know my field but whose lives, or the lives of their relatives 
depend on them understanding what I am saying, I lack confidence and fall back into the 
science which is not helpful.  
I have never been asked to give an account of my work other than in the scientific sense and 
neither have I ever been asked to give an account of myself. I found it challenging and 
turned to philosophy to help me to begin to position my thinking, emotions and behaviours, 
as philosophy is close to science. But now I see philosophy as cognitive and a necessary 
step for someone like me to begin to cross that more difficult bridge of relating. In my 
experience with the nurses, I saw that relating for me has to have a purpose, an outcome. In 
talking further with them, the impact of my science was more effective through them being 
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translators or helping me to translate. I do not think I am going to make some giant leap or 
have an epiphany that will transform me into some highly relational being. I believe it will be 
through a process of collaboration, having more conversations and less didactic encounters, 
recognizing that extensive knowledge of a discipline does not make you superior, especially 
if you cannot communicate it effectively to achieve a successful translation from bench to 
clinic. If cancer researchers like me want to be successful translational practitioners, we 
need to learn the art of translation and be guided by those who have mastery in such skills.  
Hippocrates was an able translator and distilled from his extensive learning a simple oath 
that everyone can understand. It is my aim to encourage all health practitioners in cancer-
related practice to study this oath and undertake it, and for members of our new association 
to build on it together, as translational practitioners of the future.  
I swear... that I will fulfill according to my ability and judgment this oath and this 
covenant: 
To hold him who has taught me this art as equal to my parents and to live my life in 
partnership with him, and if he is in need of money to give him a share of mine, and 
to regard his offspring as equal to my brothers in male lineage and to teach them this 
art – if they desire to learn it – without fee and covenant; to give a share of precepts 
and oral instruction and all the other learning to my sons and to the sons of him who 
has instructed me and to pupils who have signed the covenant and have taken the 
oath according to medical law, but to no one else.  
I will apply dietic measures for the benefit of the sick according to my ability and 
judgment; I will keep them from harm and injustice.  
I will neither give a deadly drug to anybody if asked for it, nor will I make a suggestion 
to this effect. In purity and holiness I will guard my life and my art.  
I will not use the knife, not even on sufferers from stone, but will withdraw in favor of 
such men as are engaged in this work.  
Whatever houses I may visit, I will come for the benefit of the sick, remaining free of 
all intentional injustice, of all mischief and in particular of sexual relations with both 
female and male persons, be they free or slaves.  
What I may see or hear in the course of treatment or even outside of the treatment in 
regard to the life of men, which on no account one must spread abroad, I will keep 
myself holding such things shameful to be spoken about.  
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If I fulfill this oath and do not violate it, may it be granted to me to enjoy life and art, 
being honoured with fame among all men for all time to come; if I transgress it and 
swear falsely, may the opposite of all this be my lot.62 
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APPENDIX 1  PUBLIC WORK SUMMARIES 
1A] SCIENTIFIC MECHANISM OF PUBLIC WORK 1 
This novel therapeutic strategy constitutes a cornerstone in cancer research, because my 
novel chemoradioimmunotherapic approach developed as a personalized cancer medicine 
approach consisting of chemotherapy, radiation therapy and immunotherapy in one. The 
chemotherapy component consisted of cytostatic vinorelbine tartrate, used in the treatment 
of breast and other cancers, the radiotherapy component was provided through the addition 
of high-energy radioisotopes, while the immunotherapy aspect was achieved by attaching 
scFv antibody specific to HER2/neu oncogene onto radioisotopes as well as through the 
inclusion of a separate 21-nucleotide double stranded siRNA generated against 
hypermethylating gene DNMT1 that constituted the genetically based antisense treatment.  
The main problem of advanced and metastatic breast cancer is chemoresistance and 
radioresistance caused by hypermethylation of CpG islands due to upregulated genes such 
as DNMT1 that inactivate tumour suppressor genes responsible for induction of apoptosis. In 
just 24 hours after treatment the novel treatment regime achieved effective targeting of the 
tumour cells by blocking the genetic mechanisms that protect the tumour cells from 
conventional treatment, thus allowing the chemotherapy and radiation therapy components 
to exert their cytostatic and cytotoxic effects. This led to activation of caspases 3 and 9 that 
induced the irreversible D2 stage of apoptosis, with a subsequent bystander killing effect 
leading to the eradication of tumour cells, according to transmission electron microscopy 
results (TEM). This effect is caused when apoptotic bodies are phagocytosed by adjacent 
tumour cells.  
Several diagnostic tests were employed as a pharmacogenomic approach for determining 
the genetic basis for the observed success of the molecularly targeted multimodality 
treatment. This targets multiple pathways in the tumour cells, including the downstream 
signalling pathways. These tests tailored the molecular targeting approach against 
oncogenes essential to the propagation and perpetuation of the tumour cells. Since cancer is 
a complex disease, it needs to be attacked on many fronts. Thus, my multimodal treatment 
worked synergistically against tumour cells by downregulating oncogene HER2/neu as a 
consequence of the antagonizing action of antiHER2-scFv antibody by re-expressing the 
apoptotic tumour suppressor gene BRCA1 as a consequence of the inhibition of the DNMT1 
mRNA, and finally by breaking the DNA strand of tumour cells irreversibly leading to 
induction of type-I programmed cell death (PCD) or apoptosis. This combined treatment has 
proved that, if we target resistant to treatment mechanisms such as antiapoptotic oncogenes 
and re-express silenced tumour suppressor genes by inhibiting methylation of the CpG 
islands with genetically based antisense treatment against methylating genes, we can allow 
chemotherapy to exert its cytotoxic and/or cytostatic action eradicating advanced and even 
metastatic tumour cells which are characterized by extreme heterogenicity. Downregulation 
of oncogenes such as HER2/neu might inhibit the dominant oncogene effect that depends 
on a complex system of downstream signalling pathways.  
Furthermore, administration of radiation by linking the radioisotopes to the anti-HER2 
antibody proved to be much more efficient than conventional external beam radiotherapy, 
because the radiation is targeted specifically on those breast cancer cells that overexpress 
HER2/neu and leave normal cells unaffected, thereby reducing systemic toxicity. This, in 
synergy with the improved therapeutic index of the chemotherapeutic agent, inhibited DNA 
synthesis and metabolic activity, leading to eradication of tumour cells. These results opened 
up the possibility of challenging and circumventing the policy of the Big Pharma by 
combining targeted immunotherapy with chemotherapy and radiation therapy for the 
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successful eradication of resistant to treatment tumour cells under a stratified or 
personalized cancer medicine approach.  
I have applied this approach to other types of cancer characterized by hypermethylation of 
tumour suppressor genes and overexpression of dominant oncogenes such as HER2/neu 
and bcl-2 that activate antiapoptotic downstream signalling pathways. For instance, the 
same treatment with combined antisense gene treatment achieved the eradication of radio- 
and chemoresistant metastatic non-small cell lung carcinoma (NSCLC), which is a currently 
incurable and lethal tumour, proving once more that under a personalized cancer medicine 
approach chemoresistant mechanisms can be circumvented, allowing conventional 
chemotherapeutic agents to exert their cytostatic or cytotoxic actions inducing apoptosis. In 
contrast, the ‘one size fits all’ approach of the Big Pharma exerts the opposite effect in 
cancer treatment.  
1B] SCIENTIFIC MECHANISM OF PUBLIC WORK 2 
My novel treatment of Public Work 1 aims to circumvent chemoresistance after its 
mechanisms have been detected with the use of pharmacogenetics, enabling me to use the 
appropriate molecular targeting strategy under a personalized cancer medicine approach. 
this leads to the eradication of tumour cells by induction of Programmed Cell Death, after 
elimination of the oncogenic antiapoptotic downstream signalling pathways that were 
activated by the phenomenon of oncogene addiction. This Work includes a novel drug 
delivery system based on nanomedicine which, with the proper composition of high Tc 
phospholipids and Chol, has protected the therapeutic molecules from biological milieu 
interactions such as opsonin adsorption that might lead to RES elimination. This results in 
the enhancement of therapeutic index and reduction of systemic toxicity. The novel genetic-
based therapeutic antisense agent (anti-eiF3c shRNA) has enabled the chemotherapeutic 
agent vinorelbine tartrate to exert its cytostatic action by circumventing antiapoptotic 
mechanisms such as oncogene bcl-2, which was phosphorylated, leading to the 
upregulation of tumour suppressor gene beclin-1 that led to autophagy. Other anticancer 
effects observed were anoikis and necrosis. Finally, the induction of irreversible D2 stage of 
apoptosis led to a bystander killing effect, eradicating the chemoresistant tumour cells of 
hormone refractory breast cancer. My work suggests that, although no single drug is likely to 
eradicate cancer, combinations of tailored therapeutic agents that target specific multiple 
sites in the oncogenic biochemical pathway signalling cascade may induce apoptosis even 
in chemoresistant tumour cells. Furthermore, the therapeutic index may be improved with 
the use of drug delivery systems such as colloidal nanoparticles that can mediate molecular 
targeting.  
1C] SCIENTIFIC MECHANISM OF PUBLIC WORK 3 
This therapeutic genetic vaccine against HPV 16(+) derived cancers is the only one that has 
ever existed in medical oncology. Its therapeutic significance is great because it is 
independent from chemoresistant and radioresistant mechanisms. HPV is the most common 
sexually transmitted infection in the world. HPV type-16 can cause cervical and 
oropharyngeal squamous cell cancers (OSCC), such as soft palate, tonsillar and tongue 
cancers that rise rapidly, with an overall five-year survival of about 25 per cent. Other tumour 
types that HPV 16 causes include anal, vaginal, vulval, and penile cancer. To date, none of 
the vaccines actually treat cancer. Those used today are only preventive vaccines, fighting 
viral agents that are capable of causing cancer. This therapeutic cancer vaccine is an 
emerging experimental type of treatment designed to stimulate the humoral and cellular 
immune systems that are the body’s natural defences for finding and fighting cancer cells. It 
can be combined with other cancer treatments including chemotherapy, radiation, surgery, 
anti-angiogenesis drugs, and so on. This therapeutic vaccine targets certain molecules such 
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as antigens on the surface of tumour cells, and they are never expressed by healthy cells. 
Thus, this therapy circumvents systemic toxicity. For the development of this novel 
therapeutic vaccine, which is one of a kind, I have developed a cytomegalovirus (CMV) 
replicon system (CRPs) for the efficient delivery of the HPV16 recombinantly mutated E6 
and E7 genes replacing part of the CMV genome for the HPV genes that were genetically 
altered to block binding sites for tumour suppressor gene p53 and oncogene Rb. The 
replicon vectors infected and co-transfected cervical intraepithelial neoplasia (CIN), and 
cervical cancer cells derived from HPV16 (+) tumours. After vaccination with a needle-less 
injection system, the viral E6 oncogene did not degrade apoptotic p53 and it blocked 
activation of telomerase. This induced type-I PCD or apoptosis and DNA repair in CIN and 
cervical cancer cells. It led to scheduled cell cycle entry, genetic stability and mortalization of 
tumour cells. Cellular and humoral immune responses were exhibited that led to irreversible 
D2 apoptotic stage of apoptosis or type-I PCD, leading to a bystander killing effect of 
intraepithelial neoplasia and cervical cancer cells. BrdU and MTT analysis exhibited 
inhibition of DNA synthesis and metabolic activity of vaccinated tumour cells compared to 
controls. This genetic vaccine coding for E6 and E7 mutations designed to prevent p53 and 
Rb binding sites activated humoral and cellular immune responses, leading to eradication of 
cervical intraepithelial neoplasia (CIN2, CIN3) and cervical cancer cells via induction of 
irreversible D2 apoptosis that led to a bystander killing effect. This therapeutic vaccine has 
tremendous potential to stimulate humoral and cellular immunity against HPV16 (+)-derived 
tumours.  
1D] SCIENTIFIC MECHANISM OF PUBLIC WORK 4 
Nanomedicine has great potential for breakthroughs in basic, applied and clinical sciences, 
leading to more efficient and targeted diagnosis, treatment, and monitoring of diseases like 
cancer. In this novel public work I have used colloids, which are lipid-based liposome 
nanoparticles, and niosomes. I use high Tc phospholipids, which are combined with 
cholesterol, located between acyl chains for enhancing stability when the nanoparticles 
interact with the biological milieu. To circumvent opsonin adsorption I pegylate the surface to 
make it more hydrophilic. This way the nanoparticles carrying therapeutic molecules can 
circumvent elimination by the Reticulo-Endothelial System (RES) consisting of the 
macrophages (Kupffer cells) of the liver and spleen. With these nanoparticles I can target 
specific tumour cells characterized by chemoresistance due to overexpressed drug efflux 
genes such as MDR-1 that encode protein Pgp that acts as a pump by binding drug 
molecules on its ATPase chains. Molecular Tumor Cell Targeting (MTCT) is achieved by 
linking antigens or other biosensors such as RNA strands to the surface of the nanoparticles 
that detect specialized properties of the tumour cell walls, delivering their cargo of 
therapeutic molecules intracellularly by endocytosis circumventing chemoresistant efflux 
pumps. Only then can personalized medicine, which is molecularly targeted, be achieved for 
individual cancer patients by tailoring the treatment specifically to their tumour phenotypes. 
Once the target tumour cells have been identified, where in my therapy they are the cancer 
stem cells (CSCs) that overexpress CD44, and they have been activated by the 
chemotherapeutic agent vinorelbine, the nanoparticles that I have designed with high Tc 
phospholipids and pegylation for enhancing hydrophilicity that leads to the circumvention of 
biological milieu interactions will bind with the conjugated miR-373 onto the CD44 of tumour 
cells. This causes entrance of tumour cells via endocytosis, releasing the therapeutic siRNA 
molecules intracellularly for downregulating BMI1 and survivin inhibiting downstream 
signalling pathways that led to induction of type-I PCD or apoptosis (D2 irreversible stage) 
activating a bystander killing effect. The siRNA molecules were protected and their life was 
prolonged during delivery with nanoparticles, otherwise the RNA strands would be destroyed 
by cellular mechanisms before reaching their targets. Furthermore, the specific molecular 
targeting will aid the treatment of late-phase metastasized cancers and hard to reach 
tumours like breast and ovarian tumours. Also, nanoparticles will circumvent tumour 
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chemoresistance by overpassing Pgp drug efflux pump. These nanoparticles will treat only 
the tumour, without damaging adjacent healthy tissue. They dissolve intracellularly in the 
endosome, releasing their therapeutic siRNA cargo that eradicates endodyploid cancer stem 
cells after downregulation of Aurora-B. The bottom-up construction of these nanoparticles 
takes advantage of molecular self-assembly for building specific structures based on 
Watson-Crick DNA base-pairing for building nucleic acids of a defined structure that will be 
used for personalized medicine using molecular targeting. The benefits of nanoparticle 
delivery are extremely significant because they improve bioavailability of entrapped 
therapeutic molecules by targeting specific organs, tissues and mainly tumours, providing 
the highest dose of the therapeutic agent directly and with precision where it is needed. In 
our case this is to the cancer stem cell that causes metastasis, reducing waste and costs 
due to breakdown prior to a drug binding on its target. Nanomedicine is a relatively new area 
of biotechnology, but the possibilities for novel therapies to treat advanced and metastatic 
cancers seems endless, as you can see from my novel anticancer therapies using 
nanoparticles, attached.  
I innovated this novel nanotechnology-based anticancer therapy for targeting cancer stem 
cells that cause metastasis. I repeatedly have used nanosomes for molecular targeting of 
nanoscale therapeutic antisense nucleic acids, DNA, proteins and chemotherapeutic 
molecules that can circumvent chemoresistant mechanisms, leading to the eradication of 
metastatic tumour cells, as you can see in Appendix 2D where I have developed novel 
anticancer treatments that have been accepted by the scientific committees of international 
congresses for presentation. This work is of huge importance to the future of nanomedicine, 
because currently there are no approved nanotechnology-based drugs or therapies on the 
market. Thus, I have learned to design, manufacture and manipulate biocompatible 
nanomaterials with a molecular understanding of tumour cell function and disease 
development. This way I can target cancerous tissue for transporting drugs into tumour cells 
for induction of apoptosis. The main thing is that I prepare them with biocompatible 
phospholipid molecules that are not immunogenic, and intracellularly they are 
biodegradable. Nanomaterials are of great value for oncology and other medical applications 
because they improve the efficacy of cancer treatment tremendously. With the design and 
use of nanosomes I have managed to reduce adverse side effects of chemotherapy, 
overcome biological barriers such as the blood–brain barrier and circumvent chemoresistant 
mechanisms, enhancing the therapeutic index of anticancer agents and reducing systemic 
toxicity. I always use drug delivery systems in my novel anticancer therapies because they 
transport selectively and safely the therapeutic molecules in the targeted cancerous tissue, 
and significantly reduce the collateral damage caused by chemotherapy. Another driver is 
the low solubility of many anticancer agents that prevents their formulation as drugs. I have 
also extended the life cycle of an anticancer agent by using reformulation. Furthermore, I 
have managed to make these nanoparticle drug delivery systems (NDDS) cost effective. My 
main concern is to deliver the right drugs with nanosomes to the right cancer patients under 
a personalized medicine approach using molecular targeting.  
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APPENDIX 2  SELECTED PAPERS AND AWARDS 
2A] SELECTED PAPERS ASSOCIATED WITH PUBLIC WORK 1 
I have extended the therapeutic approach of Public Work 1 in other cancers including 
pancreatic cancer, periampullary Ca, non-small cell carcinoma, endocrine-tumours such as 
anaplastic thyroid Ca. These works were presented in annual congresses of medical 
societies including American Society of Clinical Oncology (ASCO) as follows: 
Giannios, J., Antisense chemoradioimmunotherapy consisting of anti-IGF-I/HGF bs-
scFv linked onto high-energy radioisotopes and TFO targeted to DNMT1 and 
conjugated to vinorelbine induce ADCC, apoptosis and anoikis in metastatic NSCLC 
characterized by radio and chemoresistance. Meeting: 2006 Gastrointestinal Cancers 
Symposium of the American Society of Clinical Oncology (ASCO).  
 
Additional presentations include societies such as British Endocrine Societies (BES), 
International Society of Gastrointestinal Oncology (ISGIO), European Gynecological Society 
(ESGO) and many others. Furthermore, related papers were published by myself in many 
specialized medical journals such as the International Journal of Gastroenterology and 
Hepatology, The Journal of Breast Cancer Research of impact factor 5.79, etc. This work 
since its presentation and publication has been followed by many other researchers who 
have taken it to multicentral clinical trials for many cancers including pancreatic adeno Ca, 
periampullary Ca, B-lymphomas etc.  
2B] AWARD OF PUBLIC WORK 2 
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2C] SELECTED PAPERS ASSOCIATED WITH PUBLIC WORK 3 
Other anticancer vaccines that I have developed and presented in oncology congresses are 
as follows: 
Multi-vaccine SEVINA Composed of Vinorelbine Apoptotic Tumour Cell Lysate 
(VATCL), Cationic Colloidal 25 mer ISS CpG Oligonucleotide (ODN) Adjuvant and 
Recombinant Chaperone GRP94/gp96+HER2 Differentiation Antigen Vaccine 
Induces Formation of Exosomes from APCs and Humoral Cellular Immune 
Responses Leading to Vaccine Induced Apoptosis (VIA) in Chemoresistant Distal 
Breast, Lung, Prostate and Ovarian Cancer. 
This was published in the Journal of Immunotherapy: November/December 2005, 28(6), 
655-656. 
 
Abstracts: Abstracts for the 20th Annual Scientific Meeting of the International Society 
for Biological Therapy of Cancer: TURNING IMMUNIZATION INTO TUMOR 
REGRESSION: OBSTACLES AND STRATEGIES.  
This work was presented in the plenary session of the ISBTC Congress in Washington DC, 
USA.  
 
Effect of gene modified cellular vaccine (GMCV) composed of autologous adipose-
derived mesenchymal stem cells (AADMSCs) transfected with lipid-cation Hsp70 on 
innate and adaptive immunity after targeting primary and metastatic breast Ca cells 
inducing secondary-necrosis and lethal bystander effect, while injured cells were 
renewed.  
This work was presented in the 2009 Breast Cancer Symposium of the American Society of 
Clinical Oncology (ASCO).  
 
Gene modified cellular vaccine (GMCV) composed of autologous adipose-derived 
mesenchymal stem cells (AAD-MSCS) transfected with lipid-cation Hsp70 activated 
innate and adaptive immunity after targeting metastatic pancreatic Ca cells.  
Speaker/Presenting Author: John N Giannios,1* Translational Cancer Medicine, 
Erasinio Oncology Hospital, Athens, Greece.  
This work was presented at the Congress of the British Society of Gastroenterology (BSG) in 
2011 as an oral presentation under the category of Neoplasia and Cancer Pathogenesis 
BSG11-ABS-2453.  
Humoral and cellular immunity induces apoptosis in CIN2-3, HPV16+ cervical Ca 
after genetic vaccination with CRS targeting p53 and Rb.  
This work was presented in the Congress of International Gynaecological Cancer Society 
(IGCS) in 2010.  
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Gene-Modified Cellular Vaccine (GMCV) Transfected with Lipid-Cation Hsp70 
Activates Innate and Adaptive Immunity in Primary and Metastatic Gastric Cancer 
Cells.  
This work was presented as a lecture in the Annual Meeting of the International Society of 
Gastrointestinal Oncology (ISGIO) in USA.  
 
Gene Modified Cellular Vaccine of Autologous Adipose-derived Mesenchymal Stem 
Cells transfected with lipid-cation Hsp70 activates innate and adaptive immunity in 
metastatic ovarian Ca.  
This work was presented in the meeting of the European Society of Gynaecological 
Oncology where I am a founding member in Italy (2009).  
 
Eradication of unresectable chemo/radioresistant hilar cholangiocarcinoma with 
gene-modified cellular vaccine (GMCV) composed of autologous adipose-derived 
mesenchymal stem cells (AADMSCs) which was transfected with lipid-cation Hsp70 
activated innate and adaptive immunity, and induced secondary-necrosis leading to a 
lethal bystander effect.  
This work was presented in the plenary session and received a grant award of the Annual 
Meeting of the International Society of Gastrointestinal Oncology (ISGIO) in 2011 in USA.  
 
Pegylated liposomal formulation with linked anti-DNMT1/HDAC2 bispecific single chain 
Fv molecules (bs-ScFv) and encapsulated vinorelbine induces PCD and ADCC in 
chemoresistant gastric carcinoma (GC) characterised by HDAC2 overexpression and 
5'CpG island hypermethylation of growth regulators, signal transducers, TSGs, 
invasion/metastasis suppressor genes, DNA repair genes, hormone and kinase 
receptors, angiogenesis inhibitors, tumour antigens, GTP proteins and apoptotic genes.  
This work was presented in the session of Cancers of the Esophagus and Stomach (Upper 
GI Cancer) of the 2004 Gastrointestinal Cancers Symposium (Abstract 81) of the American 
Society of Clinical Oncology (ASCO).  
Two more works selected from the many developed by myself on immunostimulation against 
various incurable cancers are as follows: 
Eradication of osteolytic and osteoblastic metastases of breast cancer inhibiting 
proliferation of tumour associated (TAEC) and bone microvascular endothelial cells 
(BMEC) inducing antibody dependent cellular toxicity (ADCC), antibody mediated 
phagocytosis, and D2 stage of PCD type-I/apoptosis.  
This work was presented in the session of New Systemic Agents---New drugs and targets 
(includes antiangiogenics) of the 2007 Breast Cancer Symposium (Abstract No: 170) of the 
American Society of Clinical Oncology ASCO).  
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This last work is very important because it shows of how immunotherapy can act 
synergistically with conventional chemotherapy to circumvent antiapoptotic mechanisms, 
while it enhances therapeutic index minimizing systemic toxicity.   
 
Immunochemotherapy consisting of rhuMAb HER-2/neu, docetaxel and vinorelbine 
eradicates aneuploid metastatic breast carcinoma (MBC) from sentinel lymph nodes 
(SLN) overexpressing cyclin D1, HER-2/neu and Ras via ADCC, CMC, anoikis, PCD 
and inhibition of angiogenesis.  
This work was presented in the Sub-Category: Molecular/Ligand Targeted Therapies of 
Category: Biologic and Targeted Therapies of the 2002 American Society of Clinical 
Oncology (ASCO) Annual Meeting. Citation: Proc Am Soc Clin Oncol 21: 2002 (abstr 1913).  
 
2D] SELECTED PAPERS ASSOCIATED WITH PUBLIC WORK 4 
The novel treatment of Public Work 4 also exhibited eradicating results due to induction of 
D2 irreversible stage of type-I PCD or apoptosis in chemo and radioresistant cancer stem 
cells of advanced breast cancer, entitled: ‘Effect of pegylated-nanoparticles of CDP bound to 
multitargeted siRNA molecules against BMI1 and survivin conjugated with miR-373 (termed 
as SEVIN-A), which targets CD44 overexpressing cancer stem cells (CSCs) of advanced 
breast cancer (ABC) on apoptosis and circumvention of chemoresistant multifactors caused 
by vinorelbine- tartrate.’ 
This work uses combined nanomedicine with antisense gene therapy to circumvent tumour 
igenesis induced by cancer stem cells activated by conventional chemotherapy, and was 
presented in the Sub-category: Novel Targets – Category: Prevention, Survivorship & Health 
Policy in the Meeting: 2010 Breast Cancer Symposium of the American Society of Clinical 
Oncology. It was reported as Abstract No: 231 in the proceedings of the congress, and it 
was granted an exception in accordance with ASCO's Conflict of Interest Policy because this 
work was self-financed, with absolutely no commercial attachments. Thus, it was designated 
with a caret symbol (^) in the print version.  
ANTISENSE TREATMENT WITH PEGYLATED LIPOSOMAL-OVARIAN TUMOR 
MULTITARGETING WITH MABS AGAINST GP38, MUC1, AND TAG72 ON PEGYLATED 
APOPTOSIS NANODELIVERY PLATFORM OF CYLD AND RIP-1 LEADS TO 
NECROPTOSIS. 
MULTITARGETED SIRNA AGAINST UBCH5, C-SRC, AND HSP90 COMBINED WITH 
BEVACIZUMAB ERADICATED HORMONE REFRACTORY BREAST CA (HRBC) BY 
INDUCTION OF APOPTOSIS/PCD TYPE-I  
PEGYLATED-NANOPARTICLES OF CDP BOUND TO MULTITARGETED SIRNA 
AGAINST BMI1 AND SURVIVIN CONJUGATED WITH MIR-373 (SEVIN-A) ERADICATES 
METASTATIC OVARIAN CARCINOMA  
IMMUNOCHEMOGENIC TREATMENT WITH STEALTH – NANOPARTICLE 
FORMULATION CONSISTING OF CLAMP PNA AGAINST MRNA-FOXC2, ANTI-CD44 
CHIMERIC-MAB, AND TAXOTERE ERADICATED ADVANCED OVARIAN EPITHELIAL CA  
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LNA MODIFIED OLIGONUCLEOTIDES TARGETING MRNA-DICER IN PEGYLATED 
COLLOIDAL NANOPARTICLES WITH LINKED ABS AGAINST CD44 ERADICATE 
OVARIAN CANCER STEM CELLS (OCSCS)  
ADMINISTRATION OF GENE-MODIFIED-CELLULAR-VACCINE COMPOSED OF 
AUTOLOGOUS- ADIPOSE-DERIVED MESENCHYMAL-STEM-CELLS TRANSFECTED 
WITH LIPID-CATION-HSP70 ACTIVATES INNATE AND ADAPTIVE IMMUNITY 
ERADICATING METASTATIC OVARIAN CA  
COLLOIDAL-CDNA ENCODING RECOMBINANT PROTEINS-RMDVA COMPRISING 
DISINTEGRIN/CYSTEINE-RICH-DISULFIDE BOND 2RGD, AND C-TERMINAL DOMAIN, 
METALLOPROTEASE-DOMAIN, AND DIMERIC DISINTEGRIN/MLD-VGD DOMAIN 
(VADD) INDUCED APOPTOSIS IN OVARIAN CA  
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APPENDIX 3  Curriculum Vitae 
Name: JOHN N. GIANNIOS  
Translational medicine practitioner, cancer researcher, molecular oncologist and genetic 
counsellor  
President of the Hellenic and International Society of Molecular and Genomic Medicine and 
Research (HISMGMR)  
Editor of the official journal of the Hellenic and International Society of the Molecular and 
Genomic Medicine and Research  
Head of the Department of Personalised Cancer Medicine, Head of Department of 
Translational Cancer Medicine and Cancer Research, Head of Regenerative Medicine, 
Erasinio Oncology Hospital, Athens, Greece  
Translational Cancer Medicine Practitioner, Molecular Oncologist, Cancer Researcher and 
Genomic/Epigenomic Counsellor in the Dept of Clinical Oncology, General State Hospital of 
Athens with the Head of the Department, Dr E Michailakis  
Translational Cancer Medicine Practitioner, Genetic Counselor, and Head of Cancer 
Research and Molecular Oncology in the Dept of Clinical Oncology of St Andreas Hospital, 
Patras  
Translational Medicine Practitioner and Genetic Counselor in Immunology dept, Mediteraneo 
Hospital, Athens  
Translational Medicine Practitioner and Genetic Counselor in the Dept of Gynecologic 
Surgery in Lito and Mitera Hospital with gynaecological surgeon Dr J Peristeris  
Translational Cancer Medicine Practitioner, Molecular Oncologist, Cancer Researcher and 
Genetic Counsellor in the Dept of Clinical Oncology with director Dr G Samelis of 
Hippokration Hospital, Greece  
Translational Cancer Medicine Practitioner, Molecular Oncologist, Cancer Researcher, and 
Genetic Counsellor in the Dept of Radiotherapeutic Oncology and Gynecologic Surgery in 
IASO Hospital, Athens  
President of Medical Biomics, Balkan Cancer Research Center  
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American Society of Nuclear Medicine 
American College of Chest Physicians 
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Accreditation Council for Continuing Medical 
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Baylor College of Medicine 
American Society of Critical Care Medicine 
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Degrees, Certificates, Fellowships and Memberships  
Diploma in English (New York University, USA)  
BSc in Chemistry and BSc in Biology, American University in Athens, Greece  
Certificate in Oncology/Hematology (American College of Physicians)  
Certificate with Distinction in Good Clinical Practice (UK), Postgraduate Diploma in 
Translational Medicine with Distinction (A3) at the Medical School of University of Edinburgh  
Postgraduate Certificate in Translational Medicine with Distinction (A3) of the Medical School 
of the University of Edinburgh  
MSc in Translational Medicine of the Medical School of University of Edinburgh. Grade 71  
Completion of four years (120 credits) of Professional Pharmacy Degree in New York, School 
of Pharmacy (LIU)  
Postgraduate Cancer Research in University of London  
Completion of 78 online medical courses in Medical School of Harvard University  
Founding and active member of 183 American and European Professional Oncology and 
Medical Societies or Associations  
Completion of more than 2000 Continuing Medical Education Credits after passing exams 
above 75% online  
Genetic Counselor creating the new guidelines of perioperative medicine genomics in the 
Dept of Breast Surgery, Kapodistriakon University of Athens, collaborating with Professor 
Zografos  
 
Medical Awards:  
First Poster Award at 3rd Annual Modern Drug Discovery and Development Summit (M3D), 
28-30 November, 2007, San Francisco, CA., from Nobel Laureate F. Murad  
Awards from 2000 to present at ISGIO Congresses in USA  
Awards from 2002 to present at International Ovarian Ca Congresses in Seattle from the 
Swedish Medical Center and the University of Seattle  
Certificate of Award for Ovarian Ca, National Institute of Health, 1995, USA 
First research prize of the Fourth International Conference on Small Cell Lung Cancer, 
Ravenna, 25-26 April, 1996  
Young Scientist Award of the First Balkan Congress of Oncology, Athens, 3-7 July, 1996  
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Best Research Prize of the First Balkan Congress of Oncology, Athens, 3-7 July, 1996  
First Research Award of the 16th Annual Hellenic GastroenterologyCongress, Athens, 12-16 
October, 1996  
Best Cancer Research Study Award of the International Congress on Cancer Research in 
the year 2000, Athens, May 6-10, 1997  
First Research Prize, International Laser Congress, Athens, 25-28 September, 1996  
Brupbacher Young Investigator’s Award, Third Scientific Symposium of Novel Approaches to 
Cancer Therapy, Zurich, 13-14 March, 1997  
Best Cancer Research Study Award of the International Congress on Clinical Advancements 
of Cancer Research, Athens, 2-5 May, 1997  
First Research Prize, 23th Annual Hellenic Medical Congress with International Participation, 
Athens, 13-17 May, 1997  
Award of Highest Grading in Medical Research Study, 23th Annual Hellenic Medical 
Congress, Athens, 13-17 May, 1997  
First Research Prize, 6th Annual Hellenic Congress of Clinical Oncology with International 
Participation, Athens, 3-5 April, 1997  
First Research Prize, 6th International Congress of the Hellenic Society for Breast Cancer 
Research, Alexandroupolis, 12-15 June, 1997 
Laudation for the Best Research Study of the 9th Hellenic Oncology Congress, 12-15 
November, 1997  
Highest Scientific Award in Breast Cancer, International Congress of IABCR and HSBCR, 
Thraki, 12-16 June, 1997  
Lecture of Distinction in the Frontiers of Gynaecological Cancer, Figo, Copenhagen, 1997  
Best Cancer Research Award, 8th International Congress on Anti-Cancer Treatment, Paris, 
February, 1998  
Frst Research Award of the 18th Annual Hellenic Gastroenterology Congress, Athens, 25-28 
November, 1998  
Poster of Distinction selected from more than 3000 submitted by the Scientific Committee for 
presentation during the 7th United European Gastroenterology Congress (UEGW) Rome 
1999 
First Cancer Research Award of the 7th Hellenic Congress of Mastology with International 
Participation, Athens, 16-19 March, 2000  
Selected inclusion in the prestigious registry of the 6thEdition of Marquis Who’s Who in 
Science - The Definite Register of Outstanding Scientific Professionals 
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Selection as one of the 2000 Outstanding Intellectuals of the 21st Century, 2nd Edn-Honours 
List from the International Biographical Centre, Cambridge, England  
Election as Deputy Director General of the International Biographical Centre, Cambridge, 
England  
Horonary position on the distinguished Research Council of IBC  
Invited lecturer at plenary session of the ASCO Molecular Therapeutics Symposium 
(Educational Program) Angiogenesis Section, 2001, chimeric antibodies targeting the SH2 
domain of Grb2 and p85a of PI3-K linked on ILD induced ADCC, ADMC, complement-
fixation  
Reviewer of Medical Congresses for Current Drugs Ltd. Universal Award of Accomplishment, 
American Biographical Institute Inc, ABI, 11 October, 2002  
Selection by the Board of American Biographical Institute as one of the 500 Leaders of 
Science for achievements during the 20th and 21st centuries, 27 September, 2002  
Selection in the book of Living Legends edited by the International Biographical Centre, 
Cambridge, England, celebrating its fortieth anniversary  
Award ($1000) for the best lecture in UEGW 2002, 10th United European Gastroenterology 
Congress and the Annual Congress of the European Society of Gastroenterology, Swiss 
Society of Gastroenterology Professionals, European Association of Gastroenterology and 
Endoscopy, European Association for the Study of the Liver, European Pancreatic Club, 
European Society of Gastrointestinal Endoscopy, European Society for Paediatric 
astroenterology, Hepatology and Nutrition, International Society of Digestive Surgery 
(European Chapter, European Society of Gastro-Intestinal and Abdominal Radiology, 
European Digestive Surgery, European Association for Endoscopic Surgery, European 
Society of Neurogastroenterology & Motility, European Society for Primary Care 
Gastroenterology, ‘Replication-incompetent AdvCMV-Smad4, vinorelbine tartrate and 
docetaxel reconstitute transcriptional response of TGF-b and phosphorylate bcl-2 inducing 
apoptosis in chemoresistant pancreatic ductal adenocarcinoma (PDAC)’  
Invitation to submit medical articles in BioMed Central  
Invitation as an author of leading scientific research for BIOSIS  
Fellow of the International Biographical Association, Cambridge  
Invited lecturer in ASCO International Symposium in Old Quebec, 19-21 November, 2002  
Invited lecturer in the 1st Interamerican Breast Cancer Conference, 25-27 July, 2002, 
Cancun, Mexico  
Invited lecturer at plenary session of 55th Annual Cancer Symposium of the American Society 
of Surgical Oncology, March 14-17, 2002, Breast Cancer Session, ‘Metastatic tumour growth 
inhibition after open surgery in patients with primary infiltrating ductal breast carcinoma 
(IDBC) by adenoviral transfection against VEGFmRNA’  
Selection and inclusion in the book Great Minds of the 21st Century, by the American 
Biographical Institute  
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Invited lecturer at the Annual Congress of the American Association for the Study of Liver 
Diseases, American Gastroenterological Association, American Society for Gastrointestinal 
Endoscopy, Society for Surgery of the Alimentary Tract, 19-22 May, 2002, San Francisco, 
California, USA, Pancreatic Cancer: Bench to Bedside, ‘Eradication of chemoresistant 
aneuploid pancreatic adenosquamous carcinoma characterised by overexpression of K-
Ras and hypermethylation of CpG islandsof p16 (INK4a) after chemogene treatment with 
vinorelbine, docetaxel and recombinant adenoviral type 5 transfection’  
Invited lecturer at the World Conference in Breast Cancer, Victoria, BC, Canada, Victoria 
Conference Centre, 4-8 June, 2002, ‘Combined chemogenetreatment of cyclinD1 antisense 
ORN(SV-22), vinorelbine and docetaxel eradicatesby PCD chemoresistant aneuploid 
metastatic breast carcinoma (MBC) over-expressing Ras and HER-2/neu’  
Invitation to join the Science Advisory Board, an international group of more than 10,000 life 
science and medical professionals, as a Scientific and Medical Expert  
Invited lecturer at plenary session of the 55th Annual Cancer Symposium of the American 
Society of Surgical Oncology, 14-17 March, 2002, Breast Cancer Session, ‘Metastatic 
tumour growth inhibition after open surgery in patients with primary infiltrating Ductal Breast 
Carcinoma (IDBC) by adenoviral transfection against VEGFmRNA, Denver, Colorado, USA  
Elected member of MEG/AACR ‘The molecular epidemiology working group of the American 
Association for Cancer Research’  
Invited lecturer at 3rd Congress of Clinical Oncology, 10 Feb 2002, Greece, 
‘Immunochemogene treatments against solid and hematologic malignancies’. Elected 
Faculty Member of the Center for Biomedical Continuing Education (CBCE) accredited by 
the Accreditation Council for Continuing Medical Education (ACCME)  
Nomination as International Scientist of the Year 2002, by the International Biographical 
Centre, Cambridge, England  
Invited lecturer at the Breast Cancer Treatment in the 12th International Congresson Anti-
Cancer Treatment, 4-7 February, 2002, ‘Synergistic antiangiogenic and antitumour activity 
inducing ADCC, CMC, anoikis and PCD after immunochemo- gene treatment consisting of 
vinorelbine combined with pegylated colloidal complex (SEVINA) of anti EGFR Mabs and 
bcl-2 antisense oligonucleotides in chemoresistant metastatic breast carcinoma (MBC)  
Invitation to publish my research work in BioMed Central’s online journals  
Invited lecturer at Congress of GI, Malignancies can be prevented and treated: from the 
bench to the bedside, Meeting in Israel, 17-18 January, 2002 ‘Eradicationof chemoresistant 
gastrointestinal stromal tumour (GIST) cells and lymphatic/vascular endothelial cells by 
induction of D2 apoptotic stage leading to bystander killing effect (BKE) after treatment with 
rhu Mab KDR/Flk-1 (VEGFR-2) linked onto pegylated liposomal vinorelbine tartrate (PLVT)’  
International Biographical Institute, UK  
Invitation to International Order of Merit between 500 personalities worldwide 
Selection in the International Register of Profiles, 12th edition, IBC, Cambridge 
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Invited lecturer at ASCO PAN Asia cancer conference (A-PACC), 21-23 September 2001, 
New Delhi, India, ‘ILT induces ADCC, ADMC, complement-fixation, anoikis and apoptosis in 
chemoresistant metastatic breast carcinoma (MBC)’ 
Nomination to ABI’s distinguished Research Board of Advisors  
Horonary position seat on board International Panel of American Biographical Institute 
Nomination for the United Cultural Convention’s (UCC) International Peace Prize  
Received the International Biographical Centre Lifetime Achievement Award from the 
International Biographical Centre, Cambridge, England  
First Award, Annual Meeting of the International Society of Gastrointestinal Oncology, 2004, 
Washington, USA  
First Award, Annual Meeting of the International Society of Gastrointestinal Oncology, 2005, 
Washington, USA 
 
Active Involvement in Cancer Congresses: 
President of the 1st Panhellenic Congress of the Hellenic and International Society of 
Molecular and Genomic Medicine and Research, ‘From basic research to clinical practice in 
Melanoma, Lung Cancer, Gastrointestinal Tumors, and Breast Cancer, 12-14 October, 
2012, Volos, Greece  
President of Organizing Committee of International Congress on Cancer Research in 2000, 
Athens, 6-10 May, 1997  
President of Organizing Committee of World Congress on Clinical Advancements in Cancer, 
Athens, 2-5 May, 1997  
Invited Commentator in the Meeting of International Association for Breast Cancer Research 
(IABCR), Thraki, 12-16 June, 1997  
President of Scientific Committee, First European Congress ofOncology (Multimodality 
Treatment in Malignancies), Athens, October, 1997  
Member of Scientific Committee, International Congress of the Hellenic Society for Breast 
Cancer Research, Greece, 12-16 June, 1997  
Panelist in Satellite Update on Hepatobiliary, Pancreatic and Gastric Cancer, International 
Conf. of Gastro-Surgical Club and WHO, Athens, 5-7 December, 1996  
Invited author for Recent Results in Cancer Research Journal  
Invited lecturer for the section New Frontiers in Oncology, 4th Postgraduate Course in 
Hepatobiliary, Pancreatic and Gastric Diseases, Athens, 5-7 December, 1996  
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Invited lecturer at plenary session of Frontiers in Gynaecological Cancer, Figo, Copenhagen, 
1997  
Invited lecturer at Novel Approaches in the Treatment of Gynaecological Cancers, 10th 
Seminar of Gynaecological Cancer, University of Patras, Greece, 3-5 October, 1997  
Invited lecturer at plenary session of the Scientific Program of the10th International Meeting of 
Gynaecological Oncology, Coimbra, 26 April-1 May, 1997  
Invited lecturer at plenary session, Antioncogene Therapy of Pancreatic Cancer, 6th UEGW 
Birmingham, 1997  
Invited lecturer at plenary session of 2nd International Congress on Lung Cancer, Greece, 9-
15 November, 1996  
Invited lecturer at plenary session of 7th International Congress On Anticancer Treatment, 
Paris, 3-6 February, 1997  
Invited speaker in plenary session of International Congress on Cancer Research, Athens, 6-
10 May, 1997  
Invited speaker at plenary session of Clinical Advancements in Cancer Research, Athens, 2-
5 May, 1997  
Member of Scientific Committee of 22nd International Congress of IABCR, Athens, 25-28 
September, 1998  
Invited lecturer at two main plenary sessions of 22nd Congress of the International 
Association for Breast Cancer Research, Athens, 25-28 September, 1998  
Member of Scientific Committee, 2nd Mediterranean Congress of International Diagnosis and 
Treatment for Thoracic Diseases, Athens, 26-30 November, 1997  
Invited lecturer at two main plenary sessions of 22nd Congress of the International 
Association for Breast Cancer Research, Athens, 25-28 September, 1998  
Member of Scientific Committee, 2nd Mediterranean Congress of International Diagnosis 
and Treatment for Thoracic Diseases, Athens, 26-30 November, 1997  
Invited Speaker at the plenary Session of 18th Annual Congress of Panhellenic 
Gastroenterological Association, Athens, 26-28 November, 1998  
Invited speaker at plenary session of 7th Hellenic Congress of Breast Cancer with 
International Participation, Athens, 16-19 March, 2000  
Member of the Scientific Committee of 7th Panhellenic Congress of Breast Cancer with 
International Participation, Athens, 16-19 March, 2000  
Invited speaker at 9th International Congress on Anticancer Treatment, Paris, February 
1999  
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Invited speaker at 10th International Congress on Anticancer Treatment, Paris, February 
2000  
Invited speaker at Eurogin 2000 Congress, Global Challenge of Cervical Cancer Prevention 
Human Papillomavirus & Genital Ca  
Invited lecturer at the Symposium on Diagnostic and Therapeutic Advancements in 
Oncology, Patras, 3-4 February, 2001  
Invited lecturer and member of the Scientific Committee of 8th Panhellenic Congress of 
Breast Cancer with International Participation, Salonika, 7-10 March, 2002  
Invited author, examiner and contributor for editorials in peer-review medical journals such 
as Clinical Lung Cancer Journal  
Tumour Targeting, EJC, Archives of Hellenic Medicine, Gene Therapy & Immunotherapy, 
European Journal of Gynaecological Oncology, etc  
Invited author for Recent Results in Cancer Research Journal  
Lecturer at plenary session of the 5th International Conference on Head and Neck Cancer, 
San Francisco, 29 July-2 August, 2000  
Lecturer at plenary session of XXXII World Congress of the International College of 
Surgeons, 8-12 October, 2000, Singapore  
Lecturer at plenary session of 1st Multidisiplinary Colorectal Cancer Congress, 17-20 April 
2001, Netherlands  
Lecturer at plenary session of 11th International Congress on AntiCancer Treatment, Paris, 
February 2000  
Lecturer at plenary session of ESSO 2000-FECS Conference, Brussels, Belgium  
Invited lecturer and member of Scientific Committee, 8th Panhellenic Congress of Mastology 
with International Participation, 7-10 March 2002, Thessaloniki  
Invited lecturer and coordinator of Round Table of Genetics in Breast Cancer, 1st Congress 
of the World Society for Breast Health, 22-26 September, 2001, Istanbul, Turkey  
Lecturer in the Annual Meeting of the American Society of Surgical Oncology  
Award candidate and published work in the Annals of Surgical Oncology, 14-17 March, 
2002, Denver, USA  
Invited teaching lecturer in Oncology Congress of Clinical and Molecular Foundations in the 
Prognosis and Therapy of Lung Cancer, Patras, 2001  
President of Frontiers of Novel Targets in Molecular Oncology, UICC, 2004  
Fellow of Research Council of International Biographical Centre, Cambridge  
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Induction in the American Hall of Fame, 19 December, 2003, American Biographical 
Institute  
Member of International Who’s Who of Professionals, 20 February, 2004  
Advisor to the Research Board, American Biographical Institute  
American Medal of Honor, 9 May, 2003  
Leading Intellectuals of the World, American Biographical Institute  
International Biographical Centre, Lifetime of Scientific Achievement Award  
The order of International Fellowship, IBC  
2000 Outstanding Intellectuals of the 21st Century, Cambridge, England  
World Medal of Honor, American Biographical Institute, ABI  
Inclusion in the Contemporary Who’s Who, USA, 24 January, 2003  
Nomination for the Governor’s Award, American Biographical Institute  
Vice-Consul, International Biographical Centre, Cambridge, England  
International Order of Merit, International Biographical Centre  
The Presidential Seal of Honor, American Biographical Institute, 29 August, 2003  
International Biographical Centre Living Legends, Cambridge, England  
Invited lecturer at 16th Asia Pacific Cancer Conference, Manila, Philippines, 18-21 
November, 2001  
Invited lecturer and Session Chairman in ten international oncology congresses in China 
 
Teaching Experience in Molecular Oncology: 
From 9 February 1996 to the end of 1998: I taught medical oncologists PCD in the 
Oncology Hospital, St Anargiri, as an appointed Scientific Advisor. This included all aspects 
of chemo- and radio-resistant mechanisms in cancer and their circumvention, molecular 
diagnosis, gene therapy, immunotherapy, biological therapy, chemotherapy and innovative 
approaches of developmental cancer therapeutics such as ECT and. Also, I established a 
Cancer Research Center at the hospital that, under my supervision, gained cancer research 
awards from oncology congresses. I taught lectures concentrating in gynaecological 
cancers in Mitera Surgical Center. Until 1999 I was project leader in cancer research and 
experimental cancer therapeutics in Department of Gynaecology, Medical School University 
of Patras where I delivered many lectures when the Chairman was Professor Tsigounis. I 
acted as Scientific Advisor and Head of Cancer Research in the oncology clinic of St. 
Andreas Hospital, where I have given many oncology lectures. I was invited by the 
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International Academy of Cytology as a cytopathology cancer expert for the people’s 
mission to China.  
1994-1998: I attended in Metaxa Oncology - Surgical procedures for Lung Cancer in the 
Lung Surgical Oncology Dept of Dr Antypas where lung with cancer lesions were removed 
surgically or photodynamic treatment or surgical laser was performed. Furthermore, I led 
research protocols which were presented at Int Medical Congresses. Also, at that time I led 
research projects in St Anargiroi Hospital, teaching all the Clinical Oncologists and those 
from other hospitals about molecular oncology principles every Thursday for five hours.  
1999-2009: General State Hospital of Athens - I contributed as a cancer research consultant 
in the Clinical Oncology Hospital of Dr Michailakis E where chemotherapies on a 
personalized basis were performed. Also during that time I contributed as a research 
consultant in IASO Radio-Oncology Dept of Dr Maragudakis where radiotherapeutic 
procedures were performed on a personalized basis, and in the Dept of Dr Xepapadakis and 
Dr J Peristeris where breast and gynaecological surgical procedures were performed with 
perioperative genomics. Also perioperative medicine aspects have been described in my 
article of the official journal of the Hellenic and International Society of Molecular and 
Genomic Medicine and Research, where I am the President and Editor.   
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APPENDIX 4  Other Supporting Evidence 
Publications, Presentations in Oncology Congresses, and Online Exam Passes on 
Medical Courses, Earning Continuing Medical Education Credits 
I have presented lectures in oncology congresses and published work in cancer research. 
Many have been selected by Internet search engines such as Medline, Pubmed, Yahoo, 
Google Scholar, and so on.  
1 .  
Effect of stem cell therapy with mesenchymal stem cells on apoptosis in 
inflammatory breast cancer, and effect of vinorelbine on epithelial mesenchymal 
transition and metastatic spread – ASCO 
  
Abstract 2009 Breast Cancer Symposium – Category: Treatment - Other: 
Treatment  
  
Background: Inflammatory breast carcinoma is a lethal variant of locally advanced 
breast Ca with no specific clinical treatments available at the present time. 
Methods: We obtained IBC cells from patients with FNA biopsy, and we developed 
animal.. 
 2.  
Effect of vinorelbine on chemoresistant cancer stem cell renewal in colorectal 
cancer (CRC) and on metastasis. - ASCO 
  
Abstract 2010 Gastrointestinal Cancers Symposium - Category: Cancers of the 
Colon and Rectum - Translational research  
  
Background: Vinorelbine, which is an anticancer cytostatic agent, may shrink 
tumors but it stimulates production of more cancer stem cells, which then 
metastasize as a way to survive the cytostatic action of this drug. Colorectal Ca  
 3 .  
Use of liposomal siRNA against Msi1 combined with docetaxel to eradicate 
advanced gastric adenocarcinoma after inhibition of angiogenesis, proliferation, 
migration, invasion, and metastasis of cancer stem cells, cancer progenitor cells, 
and tumor cells. - ASCO 
  
Abstract 2010 Gastrointestinal Cancers Symposium - Category: Cancers of the 
Esophagus and Stomach - Translational research  
  
Background: We aim to eliminate metastatic recurrences of the advanced gastric 
adenocarcinoma by eradicating cancer stem cells with antisense molecular 
targeting, while with conventional chemotherapy we aim to eradicate tumor cells.  
 4 .  
Use of induced pluripotent stem cells (iPSCs) encoded with anti-GRP78 shRNA, 
which induces apoptosis after a gene-silencing bystander to circumvent vinorelbine 
induced angiogenesis, and metastatic spread in advanced gastrointestinal stromal 
tumors (GIST). - ASCO 
  
Abstract 2010 Gastrointestinal Cancers Symposium - Category: Cancers of the 
Esophagus and Stomach - Translational research  
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Background: Vinorelbine in advanced GIST cells induces tumor relapse with 
enhanced angiogenesis and metastasis by inducing an innate cancer cellular 
stress response, which enhances the expression of GRP78 that blocks cell death 
o. . . 
 5 .  
Antisense immunochemogene therapy (AICT) composed of siRNA targeting 
angiostatic VEGF-A165b mRNA (SEVINA-VI), antiVEGFMAb (bevacizumab), and 
vinorelbine inhibited VEGF mediated desmoplastic response, angiogenesis, and 
lymphangiogenesis inducing maturation of DCs, ADCC, CMC, autophagy, and 
apoptosis in PDAC cir 
  
Abstract 2008 Gastrointestinal Cancers Symposium - Category: Pancreas, Small 
Bowel, and Hepatobiliary Tract - Translational research  
  
Background: In pancreatic ductal adenocarcinoma, the desmoplastic response is 
predominant. VEGF-A165b causes resistance to bevacizumab. Methods: We 
established a clinically relevant model of PDAC in animals by orthotopically 
inoculating human PDAC ce. . . (More)  
 6 .  
Eradication of metastatic breast cancer resistant to trastuzumab and cetuximab 
following immunochemogene treatment with SV-IV, a stealth nanoparticle 
formulation composed of clamp PNA against mRNA of sGCa1/b1, vinorelbine, and 
antiMUC1 chimeric MAb - ASCO 
  
Abstract 2008 Breast Cancer Symposium - Category: Treatment - New Systemic 
Agents – New drugs and targets (includes anti-angiogenics) - Other  
  
Introduction: The unmet medical need for metastatic breast cancer (Ca) is very 
high because of potent chemoresistance. We aim to circumvent these resistant 
factors. Methodology: We obtained surgically tumor cells from patients with stage 
IV breast  
 7 .  
Use of pegylated liposomal multitargeted siRNA against UbcH5, c-Src, and HSP90 
combined with bevacizumab and vinorelbine-tartrate to circumvent oncogene 
addiction, transactivation, and acquired resistance due to VEGFR ubiquitination, 
and mutations/deletions in the kinase domain of VEGFR inducing apoptosis in m 
  
Abstract 2009 Genitourinary Cancers Symposium - Category: Genitourinary 
Cancers - Bladder  
  
Introduction: Metastatic transitional cell carcinoma (mTCC) of the bladder can 
develop resistance to bevacizumab. We aim to circumvent this resistance and 
eradicate mTCC with vinorelbine (VRL). Methods: mTCC cells were obtained from 
patients with meta. . . (More)  
 8 .  
Cetuximab combined with multi-targeted siRNA against HSP90, UbcH5, and c-Src 
circumvented oncogene addiction, transactivation, and acquired resistance as a 
result of EGFR ubiquitination, and mutations/deletions in the kinase domain of 
EGFR in mCRC. - ASCO 
  
Abstract 2008 Gastrointestinal Cancers Symposium - Category: Colon and Rectum 
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- Translational research  
  
Introduction: CRC cells develop resistance to cetuximab through insertion 
mutations at exon 20, ubiquitination, and c-Src which activates EGFR in the 
absence of ligand despite treatment with cetuximab. We aim to circumvent this 
acquired resistance.  
 9 .  
LIP-rMDVA+VRL composed of liposomal cDNA encoding recombinant multimodular proteins rMDVA 
comprising disintegrin/cysteine rich disulfide bond 2RGD, and C-terminal domain (ammodystatin), 
metalloprotease-domain (ammodylysin), and dimeric disintegrin/MLD-VGD domain (VADD) isolated 
vipera ammodytes with VRL e 
  
Abstract 2009 Genitourinary Cancers Symposium - Category: Genitourinary 
Cancers - Early/Localized disease, Locally Advanced/Recurrent/Advanced 
disease, and Biology  
  
Introduction: We investigate if venom proteome of vipera ammodytes can induce 
apoptosis in HRPC. Materials and Methods: We developed a large scale 
expression system with prostate cell line (PCL), which we modified genetically by.. 
 10 .  
(AS-CRI) antisense chemoradioimmunotherapy consisting of anti-CaSm scFv 
linked onto high-energy radioisotopes, vinorelbine and 21 nucleotide double 
stranded siRNA targeted to DNMT1 induce apoptosis (PCD) in pancreatic and 
periampullary Ca characterised by hypermethylated tumour suppressor RASSF1A, 
RAR-b2, B 
  
Abstract 2005 Gastrointestinal Cancers Symposium - Category: Pancreas, Small 
Bowel, and Hepatobiliary Tract - Multidisciplinary Treatment  
  
Introduction: Failure of tumour cells to undergo PCD cause resistance to 
chemoradiological therapies due to overexpression of oncogenes and 
transcriptionally repressed apoptotic TSGs due to methylation. Methods: We 
obtained surgically 19 pancreatic Ca. 
 
11 .  
Effect on humoral and cellular immunity and on apoptosis in CIN2, CIN3, and 
HPV16+ cervical cancer of therapeutic divalent genetic vaccination with CMV 
replicon system (CRS) delivering HPV16 recombinantly mutated E6 and E7 viral 
oncogenes targeting p53 and Rb, respectively. - ASCO  
  
Abstract 2009 ASCO Annual Meeting - Category: Developmental Therapeutics: 
Immunotherapy - Vaccines  
  
Background: Prophylactic vaccines have no therapeutic capacity for all the women 
who are already infected with HPV16 and have developed cervical intraepithelial 
neoplasia (CIN) or cervical cancer. Approximately 300 million women with CIN .. 
 12 .  
Effect of LNA-modified oligonucleotides targeting mRNA of DICER in pegylated 
colloidal nanoparticles with linked abs against CD44 on prostate cancer stem cells 
(PCSCs) and hormone-refractory prostate cancer cells (HRPC): Role of induction of 
PCD after inhibition of oncomir machinery leading to downregulation o  
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Abstract 2010 Genitourinary Cancers Symposium - Category: Prostate Cancer: 
Early/Localized disease, Locally Advanced/Recurrent/Advanced disease, and 
Biology - Prostate Cancer: Early/Localized disease, Locally Advanced/Recurrent/ 
Advanced disease, and Biology  
  
Background: HRPC is incurable due to chemoresistance caused by cancer stem 
cells due to overexpression of oncomirs which upregulate oncogenes and 
hypermethylation in CpG islands which inactivates tumour suppressor genes.  
 13 .  
RhuMAb Anti-HER2/Neu Peglyated Immunoliposomes with Incorporated Vinorelbine 
Tartrate Induces P53 Independent PCD and ADCC in Chemoresistant NSCLC 
(Meeting abstract). - ASCO  
  Abstract 1999 ASCO Annual Meeting - Category: Lung Cancer - Lung Cancer  
  
At diagnosis NSCLC are usually resistant to apoptosis or PCD after chemotherapy 
due to overexpression of HER-2/neu protooncogene. Tumour cells were derived by 
FNA from a patient with advanced stage IV NSCLC. Tumour cells were paraffin .. 
14 .  
Paclitaxel exacerbates doxorubicin induced cardiac mitochondrial dysfunction 
leading to apoptosis of human cardiomyocytes. - ASCO  
  Abstract 2002 ASCO Annual Meeting - Category: Clinical Pharm- Clinical Pharm 
  
There is high incidence of congestive heart failure after combined administration of 
doxorubicin and paclitaxel. Doxorubicinol (dxol) is the major metabolite formed in 
cancer patientsÆ hearts who are treated with doxorubicin. Enzymatic reduction at t.  
 15 .  
Effect of gene modified cellular vaccine (GMCV) composed of autologous adipose-
derived mesenchymal stem cells (AADMSCs) transfected with lipid-cation Hsp70 on 
innate and adaptive immunity after targeting primary and metastatic breast Ca cells 
inducing secondary-necrosis and lethal bystander effect, while injur 
  Abstract 2009 Breast Cancer Symposium - Category: Treatment - Other: Treatment  
  
Background: Metastatic breast Ca leads to fatalities due to resistance in 
conventional anticancer therapies. Methods: Animal models characterized by 
metastatic breast Ca refractory to conventional treatment were developed and  
16 .  
Pegylated liposomal anti-eIF3c shRNA-vinorelbine tartrate formulation (SEVINA-V) 
inhibits oncogenic protein translational initiation, and oncogene addiction inducing 
PCD type-I, II, and III in NSCLC chemoresistant to taxanes. - ASCO 
  
Abstract 2008 ASCO Annual Meeting - Category: Lung Cancer--Metastatic Lung 
Cancer - Metastatic Lung Cancer  
  
Background: eiF3c is required for the initiation of protein translation, and directly 
interacts with mTOR activating eIF4e, which is overexpressed in NSCLC. mTOR 
activates the PI3K/AKT signal transduction pathway, which mediates cell 
proliferation throug. . . (More)  
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 17 .  Effect of vinorelbine on chemoresistant cancer stem cell renewal . . .  
  
Virtual Presentation 2010 2010 Gastrointestinal Cancers Symposium - Track: 
Cancers of the Colon and Rectum - Session: General Poster Session C Cancers of 
the Colon and Rectum (General Poster Session)  
  
2010 Gastrointestinal Cancers Symposium Presentation. Session: General Poster 
Session C Cancers of the Colon and Rectum (General Poster Session).  
 18 .  Effect of pegylated-nanoparticles of CDP bound to multitargeted . . .  
  
Virtual Presentation 2009 2010 Breast Cancer Symposium - Track: Systemic 
Therapy - Session: General Poster Session D (General Poster Session)  
  
2010 Breast Cancer Symposium Presentation. Session: General Poster Session D 
(General Poster Session).  
 19 .  Effect on humoral and cellular immunity and on apoptosis in CIN2 . . .  
  
Virtual Presentation 2009 2009 ASCO Annual Meeting - Track: Developmental 
Therapeutics - Session: Developmental Therapeutics Immunotherapy (General 
Poster Session)  
  
2009 ASCO Annual Meeting Presentation. Session: Developmental Therapeutics 
Immunotherapy (General Poster Session).  
 20 .  Use of liposomal siRNA against Msi1 combined with docetaxel to . . .  
  
Virtual Presentation 2010 2010 Gastrointestinal Cancers Symposium - Track: 
Cancers of the Esophagus and Stomach - Session: General Poster Session  
 31. ASCO Speaker 
32 .  ASCO Speaker 
 33 .  ASCO Speaker 
 34 .  
Chimeric Antibodies Targeting the SH2 Domain of Grb2 and p85a of PI3-K Linked on 
PEG-SUVs with Entrapped Vinorelbine Induced ADCC, ADMC, Complement 
Fixation, Anoikis, Apoptosis and Inhibition of Ras/Raf/MEK/MAPK and PI3K/AKT 
Pathways in Chemoresistant Breast Ca Overexpressing HER-2/neu. - ASCO  
  
Abstract 2001 ASCO Annual Meeting - Category: Immunobiology and Biologic 
Therapy - Gene Therapy  
  
Breast cancer cells with high HER-2/neu expression use Grb2 to transduce signals 
to MAPK and AKT via binding of pTyr to SH2 domain propagating mitogenic signals. 
Breast tumour cells characterised by overexpression of HER-2, Ras and Akt were 
obtained . . . (More)  
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35 .  Reception and General Poster Session B: Prostate Cancer - ASCO 
  
Chair: Alan Pollack, MD, PhD; Chair: Howard I. Scher, MD; Presenter: Sheila M. J. 
Aubin, Ph. D; Presenter: John R. Day, Ph. D.; Presenter: Jacek K. Pinski, MD, PhD; 
Presenter: Shreya K. Shah, MD; Presenter: Jack Groskopf, Ph. D; Presenter: David 
G. McGowan, MB. ChB, FRCPC; Pres: Karim Fizazi, MD, PhD;  
  
Meeting Session 2010 Reception and General Poster Session B: Prostate Cancer 
(General Poster Session)2010 Genitourinary Cancers Symposium - Track: Prostate 
Cancer: Epidemiology, Risk factors, Prevention, and Health Services Research  
  
|PRESENTATION 1: Fellows Poster Walk. |PRESENTATION 2: Fellows Poster Walk. 
|PRESENTATION 3: Urine measurement of TMPRSS2:ERG for the early detection of 
significant prostate cancer. |PRESENTATION 4:. . . (More)  
36. 
Presenter: Austin Duffy, MD; Presenter: Robert R McWilliams, MD; Presenter: 
Cristina Ferrone, MD; Presenter: Christopher Aoki; Presenter: Jessica Hwang, MD, 
MPH; Presenter: Jessica P Simons, MD; Presenter: Mitsuo Shimada, MD, PhD; 
Presenter: Kashif Ahmed, MD; Presenter: Charles C Hsu, PhD; Pres: V J Pi 
  
Meeting Session 2008 General Poster Session C (Poster Presentation)2008 
Gastrointestinal Cancers Symposium - Track: Colon and Rectum  
  
|PRESENTATION 1: Pancreatic adenocarcinoma (PAC) in a younger patient 
population: 10-year experience at Memorial Sloan Kettering Cancer Center (MSKCC). 
|PRESENTATION 2: CFTR mutations and risk for pancreatic adenocarcinoma.  
 37 .  
Evaluation of an antisense antibody drug conjugate (SEVINA) co-administered with 
gamma-irradiation (IR) for the treatment of HMTV and HERV (+) advanced breast Ca  
  
Abstract 2007 Breast Cancer Symposium - Category: Treatment - New Systemic 
Agents---New drugs and targets (includes antiangiogenics)  
  
Introduction: HMTV viruses cause tumors by insertional mutagenesis in patients with 
breast Ca. Also, HERV viruses exist in the 2. 9 billion base pairs of silent regions in 
breast Ca cells. Methods: HMTV and HERV at the latent form were detected in 96%.  
 38 .  
Antisense chemoradioimmunotherapy eradicates metastatic pancreatic CCa 
characterised by hypermethylation of oncosuppressor genes and overexpression of 
antiapoptotic oncogenes - ASCO 
  
Abstract 2006 Gastrointestinal Cancers Symposium - Category: Pancreas, Small 
Bowel, and Hepatobiliary Tract - Translational research  
  
Introduction: Metastatic pancreatic Ca is resistant to almost all cytotoxic drugs and 
radiation making it one of the most aggressive malignancies in human with the worst 
mortality. Materials and Methods: We obtained surgically 96 metastatic 
 39 .  
Bispecific nanobody targeting DNMT1 and SHH conjugated to vinorelbine inhibit DNA 
methylation, hedgehog-patched (PCTH) receptor signaling protein smoothened and 
hTERT expression leading to re-expression of apoptotic tumor suppressor genes and 
inductio - ASCO 
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Abstract 2007 Prostate Cancer Symposium - Category: Locally 
Advanced/Recurrent/Advanced Disease - Developmental therapeutics (molecular 
therapeutics, immunotherapy, cytotoxic chemotherapy)  
  
Introduction: HRPC is incurable due to continued evolution of the cancer stem cells 
(CSC) which give rise to metastatic cells and further drug resistance. Stem cell self 
renewal and survival requires signaling from molecules which we aim to..  
 40 .  
Liposomal vinorelbine with linked PyMT MAbs inhibited VEGF-mediated human 
telomerase reverse transcriptase (hTTTERT), c-Src, Ras, PI3K, VEGF-A, MMP-2, 
and integrins a1, 2, 6 inducing apoptosis in pancreatic cancer - ASCO 
  
Abstract 2006 Gastrointestinal Cancers Symposium - Category: Pancreas, Small 
Bowel, and Hepatobiliary Tract - Translational research  
  
Pancreatic Ca cells from a metastatic patient were obtained and they were treated 
with liposomal vinorelbine tartrate with linked PyMT Mabs. Staining of tumor cells with 
β:-galactosidase was used a marker of cell senescence. Flow...  
41 .  
Eradication of osteolytic and osteoblastic metastases of breast cancer inhibiting 
proliferation of tumor associated (TAEC) and bone microvascular endothelial cells 
(BMEC) inducing antibody dependent cellular toxicity (ADCC), antibody mediated 
phagocyt - ASCO 
  
Abstract 2007 Breast Cancer Symposium - Category: Treatment - New Systemic 
Agents---New drugs and targets (includes antiangiogenics)  
  
Introduction: Bone metastasis is a complication of breast Ca for which only palliative 
treatment is available. We aim to inhibit the cycle between tumor cells and the bone 
microenvironment, which results in increased tumor burden and bone destruction. . . 
 42 .  
Pegylated colloidal anti-eIF3c shRNA-vinorelbine formulation (SEVINA-V) inhibited 
oncogenic protein translational initiation, and oncogene addiction inducing 
apoptosis in HRPC chemoresistant to taxanes. - ASCO 
  
Abstract 2008 Genitourinary Cancers Symposium - Category: Genitourinary 
Cancers - Prostate  
  
Introduction: eIF3c is required for the initiation of protein translation, and interacts 
with mTOR activating eIF4e, which is overexpressed in HRPC. Bcl-2 
overexpression inhibits apoptosis causing oncogene addiction, and 
chemoresistance. Materials and .  
 43 .  
Multi-vaccine (SEVINA) composed of vinorelbine-apoptotic tumour cell lysate 
(VATCL), cationic colloidal 25 mer ISS CpG oligonucleotide (ODN) adjuvant and 
recombinant chaperone GRP94/gp96+HER2 differentiation antigen vaccine induces 
formation of exosomes from APCs and humoral cell immune responses l  
  
Abstract 2006 Gastrointestinal Cancers Symposium - Category: Pancreas, Small 
Bowel, and Hepatobiliary Tract - Translational research  
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Introduction: In this study, we try to eradicate chemoresistant metastatic tumours by 
activating immune responses of the host. Materials & Methods: We established 
growth of distal tumours after injection of chemoresistant human pancreatic tumour  
 44 .  
Diabody vinorelbine conjugate (DVC) composed of vinorelbine-tartrate conjugated 
to anti-DNMT1/SHH di-diabody induce ADCC, CDC, AMP and inhibit DNA 
methylation. - ASCO 
  
Abstract 2007 ASCO Annual Meeting - Category: Breast Cancer--Metastatic Breast 
Cancer - Metastatic Breast Cancer  
  
Background: Hormone refractory breast cancer (HRBC) is incurable due to 
malignant stem cells, which represent a potential nidus for the recurrent cancer that 
arises after treatment failure. Methods: From 126 metastatic HRBC patients, we 
obtained CSCs  
 45 .  
Chimeric LNA/DNA antisense oligonucleotides against DNA MeTase and 
vinorelbine-tartrate encapsulated in pegylated liposomes induce apoptosis in 
chemoresistant advanced colon carcinoma characterised by 5'CpG island 
methylation of RUNX3, MLH1, MGMT, p16INK4A, CDH1, LKB1, HIC1, CDX1, FHIT 
and RAR-β2 genes. - ASC 
  
Abstract 2004 Gastrointestinal Cancers Symposium - Category: All - Colon and 
Rectal Cancers  
  
Colon cancer is a leading cause of death in developing countries. Mortality is high 
because the majority of colon tumours have already at the time of diagnosis. The 
available drug therapies for colon cancer are largely ineffective due to.  
 46 .  
Combined administration of hydrophilic antimitotic desoxyepothilone B and 
vinorelbine induce PUMA, suppression of microtubule dynamics, development of 
hypodiploidy and multinucleation, cell cycle perturbation at G2/M and apoptosis in 
advanced breast carcinoma (ABC) characterised by MDR-1 (Pgp), bcl-2 and 
mutant 
  
Abstract 2004 ASCO Annual Meeting - Category: Developmental Therapeutics - 
Cytotoxic Chemotherapy - Drug Resistance  
  
Introduction: Low aqueous solubility of VRL is a high substrate for ATP dependent 
drug efflux proteins such as MDR-1(Pgp) and MRP2(ABCC2) inserted in plasma 
membrane of tumor cells. Furthermore, b-tubulin mutations are cross-resistant to 
VRL. Methods: . . . (More)  
 47 .  
Pegylated liposomal formulation with linked anti-DNMT1/HDAC2 bispecific single-
chain Fv molecules (bs-ScFv) and encapsulated vinorelbine induces PCD and 
ADCC in chemoresistant gastric carcinoma (GC) characterised by HDAC2 
overexpression and 5'CpG island hypermethylation of growth regulators, signal 
transducers 
  
Abstract 2004 Gastrointestinal Cancers Symposium - Category: All - Upper GI 
Cancer (Esophageal and Gastric)  
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Gastric carcinoma is one of the most aggressive type malignant tumors. Failure to 
trigger apoptosis due to changes in DNA methylation and histone acetylation 
causes chemoresistance in gastric malignancies. DNMT1 interacts with HDAC2  
 48 .  
Antisense chemoradioimmunotherapy consisting of anti-IGF-I/HGF bs-scFv linked 
onto high-energy radioisotopes and TFO targeted to DNMT1 and conjugated to 
vinorelbine induce ADCC, apoptosis and anoikis in metastatic NSCLC 
characterised by radio and chemoresistance. - ASCO  
  
Abstract 2005 ASCO Annual Meeting - Category: Lung Cancer - Non-Small Cell 
Lung Cancer  
  
Introduction: Metastatic NSCLC is resistant to almost all cytotoxic drugs and 
radiation. Materials and Methods: We obtained surgically 132 metastatic NSCLC 
specimens from patients. MS-PCR ehibited hypermethylation of oncosuppressors 
VHL, p63, p53, IGF. . . (More)  
 49 .  Biology of the estrogen receptor, GPR30, in triple-negative breast cancer. - ASCO 
  
Abstract 2010 Breast Cancer Symposium - Category: Prevention, Survivorship & 
Health Policy - Novel Targets  
  
Background: Triple-negative breast cancer currently has no targeted therapy 
because the growth signals are poorly understood. One theory is that a non-
classical ER receptor is present in some tumors, driven by estrogen in 
premenopausal women. GPR 30, . . . (More)  
 50 .  General Poster Session B - ASCO 
  
Presenter: William Fraser Symmans; Presenter: Sherene Loi; Presenter: Joseph A 
Sparano; Presenter: Allen S Melemed; Presenter: Guillermo L Lerzo; Presenter: 
Stacy L Moulder; Presenter: John W Smith; Presenter: Rupert Bartsch; Presenter: 
Lee S Schwartzberg; Presenter: Cathy Van Poznak; Presenter: Jose J Illarramen  
  
Meeting Session 2007 General Poster Session B (General Poster Session) 2007 
Breast Cancer Symposium - Track: Treatment  
  
|PRESENTATION 1: A 200-gene endocrine sensitivity index (SET) predicts survival 
for patients who receive adjuvant endocrine therapy, but not for untreated patients. 
|PRESENTATION 2: Gene expression profiling identifies potential therapeutic ta. . .  
 
 51 .  General Poster Session C: Cancers of the Colon and Rectum - ASCO 
  
Presenter: Kavitha P Raj, MD; Presenter: Sarah Kraus, PhD; Presenter: Stephen C 
Lloyd, M. D., Ph. D. ; Presenter: Kueiyu Lin, MD, MPH; Presenter: Kathleen Mary 
Wesa, MD; Presenter: Ticiana A. B. Leal, MD; Presenter: Inna Naumov, MSc; 
Presenter: Winson Y. Cheung, MD, MPH; Presenter: Michel Houde, PhD; Aude  
  
Meeting Session 2010 General Poster Session C: Cancers of the Colon and Rectum 
(General Poster Session)2010 Gastrointestinal Cancers Symposium - Track: 
Cancers of the Colon and Rectum  
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|PRESENTATION 1: Role of dietary polyamines in a phase III clinical trial of DFMO 
and sulindac for prevention of metachronous colorectal adenomas: A potential target 
for colon cancer chemoprevention. . |PRESENTATION 2: Use.. 
 52 .  Immunobiology and Biologic Therapy : Immunobiology and Biologic Therapy  ASCO  
  
|ABSTRACT 1: Immunotherapy of Multiple Myeloma Using Idiotype-Loaded 
Dendritic Cells (APC8020). . |ABSTRACT 2: Immunologic Gene Therapy of 
Melanoma: Phase I Study of Therapy with Autologous Dendritic Cells Transduced 
with Recombinant Adenoviruses En. . . (More)  
 53 .  Immunobiology and Biologic Therapy - ASCO 
  
Presenter: Abraham Mittelman, MD; Presenter: Alfredo Velasco, MD; Presenter: 
Andrea L. Veatch, MD; Presenter: Antoine Yver, MD; Presenter: Antoni Ribas, MD; 
Presenter: Ben Guo, MD; Presenter: Candelaria Gomez-Manzano, MD; Presenter: 
Carsten Nieder, MD; Presenter: Charles S. Hesdorffer, MD; Presenter: Christine Od  
  
Meeting Session 2001 Immunobiology and Biologic Therapy (General Poster) 2001 
ASCO Annual Meeting - Track: General Oncology  
  
|PRESENTATION 1: A Human Blood Dendritic Cell Purification Platform For Clinical 
Applications . |PRESENTATION 2: A Phase I And Pharmacokinetic Study Of 
Intravenous (iv) P53 Gene Therapy With Rpr/ingn-201 In Patients (pts) With 
Advanced Cancer. . . (More)  
 54 .  Cancers of the Esophagus and Stomach - General Poster Session - ASCO 
  
Presenter: Aldo Iop, MD; Presenter: Ayumu Hosokawa; Presenter: Bach Ardalan; 
Presenter: Barbara Burtness, MD; Presenter: Charles Blanke, MD; Presenter: Dana 
E Rathkopf, MD; Presenter: Desiree Pantalone, MD; Presenter: Esther Chuwa; 
Presenter: eva galizia; Presenter: Giannios N John; Presenter: Hiromichi Ito, MD;  
  
Meeting Session 2004 Cancers of the Esophagus and Stomach - General Poster 
Session (Poster Presentation)2004 Gastrointestinal Cancers Symposium - Track: 
2004 Gastrointestinal Cancers Symposium  
  
|PRESENTATION 1: A phase I/II study of epirubicin, cisplatin, high dose 24-hour 
infusion 5-fluorouracil and sodium folinate (ECSF) for advanced gastroesophageal 
carcinoma. . |PRESENTATION 2: A phase I/II trial of docetaxel, capecitabine, and ..  
 55 .  ASCO Speaker 
 56 .  
Effect of temsirolimus on the growth inhibitory effect of trastuzumab in HER2-
positive breast cancer cell lines. - ASCO 
  
Abstract 2010 Breast Cancer Symposium - Category: Prevention, Survivorship & 
Health Policy - Novel Targets  
  
Background: The mammalian target of rapamycin (mTOR) is a central regulator of 
G1 cell cycle protein synthesis that precedes commitment to normal cellular 
replication. Temsirolimus binds to the immunophilin FK506/rapamycin-binding.. 
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 57 .  Cancers of the Colon and Rectum - General Poster Session - ASCO 
  
Presenter: Adrian G Dan; Presenter: Alok Khorana, MD; Presenter: Barbara Jung, 
MD; Presenter: Barry Mirtsching, MD; Presenter: Bruce J Giantonio, MD; Presenter: 
C. Richard Boland; Presenter: Carol Townsley, MD; Presenter: Cheryl Ho, MD; 
Presenter: Claus-Henning Kohne; Presenter: Derek J Jonker, MD; Presenter: Dom  
  
Meeting Session 2004 Cancers of the Colon and Rectum - General Poster Session 
(Poster Presentation)2004 Gastrointestinal Cancers Symposium - Track: 2004 
Gastrointestinal Cancers Symposium  
  
|PRESENTATION 1: A multicenter phase II study of ‘adjuvant’ irinotecan following 
resection of colorectal hepatic metastases. . |PRESENTATION 2: A proposed 
mechanism for the induction of chromosomal instability (CIN) by JC virus (JCV) . . .  
58 .  Biologic and Targeted Therapies : Molecular/Ligand Targeted Therapies - ASCO 
  
|ABSTRACT 1: KIT mutational status predicts clinical response to STI571 in patients 
with metastatic gastrointestinal stromal tumors (GISTs). |ABSTRACT 2: A rationally 
designed, targeted tumor treatment approach: a phase II study of imatinib mesylate . 
. . (More)  
 59 .  
Inhibition of AKT- and VEGF-signaling pathways by targeting both VEGF-R and 
ErbB-2 in breast cancer cell lines. - ASCO 
  
Abstract 2010 Breast Cancer Symposium - Category: Prevention, Survivorship & 
Health Policy - Novel Targets  
  
Background: Deregulation of PI3K/AKT pathway occurs commonly in breast cancer, 
and is associated with ErbB-2 amplification as well as activating PI3K mutations. 
Trastuzumab have potent antiproliferative effects in ErbB-2-positive human breast 
tumors . . . (More)  
60. Basic science and Bench to bedside (lab) (Abstract No. 43-
74) Ann. Onc., Oct 2002; 13: 13 - 20. solid tumors 
Christopher Souder (1), John H. Marx (1), Kim Leitzel (1), 
Suhail. . . Hochhauser (2), Berend Tolner (2), John Hartley 
(2) (1) Royal Marsden Hospital. . . overexpressing EGFR, 
Ras, MDR-1 & PGE2 JohnGiannios (1), Emmanuel 
Michailakis (1) (1. . . . . . 
 
61. CANCER THERAPEUTICS: POSTER PRESENTATIONS: 
Pegylated liposomal anti-eIF3c shRNA-vinorelbine 
formulation (SEVINA-V) inhibits oncogenic protein 
translational initiation and oncogene addiction inducing 
apoptosis in HRBC chemoresistant to taxanes John 
Giannios and P. Ginopulos 
AACR Meeting Abstracts, Nov 2007; 2007: C26. 
First AACR Centennial Conference on Translational Cancer 
Medicine-- Nov 4-8, 2007; Singapore John Giannios, P. 
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Ginopulos GSHA, Athens, Greece, IH, Athens, Greece C26 
Introduction: eIF3c is required for the initiation. . . . . . 
62. ANTIANGIOGENIC/ANTIVASCULAR AGENTS: POSTER 
PRESENTATIONS: 
Antisense immunochemogene therapy (AICT) composed of 
siRNA targeting VEGFA-165b mRNA (SEVINA), 
bevacizumab, and vinorelbine inhibited VEGF mediated 
desmoplastic response, angiogenesis, lymphangiogenesis, 
and osteoblastic/osteolytic skeletal metastasis inducing 
maturation of DCs, ADCC, CMC, autophagy, and apoptosis 
in HRBC, circumventing Trousseau's syndrome.  
JohnGiannios, E. Michailakis, and N. Alexandropulos 
AACR Meeting Abstracts, Oct 2007; 2007: A9. 
 
63.  AACR-NCI-EORTC International Conference: Molecular 
Targets and Cancer Therapeutics-- Oct 22-26, 2007; San 
Francisco, CA JohnGiannios E. Michailakis N. 
Alexandropulos GSHA, Athens, Greece, IH, Athens, Greece 
A9 Background:. Bevacizumab blocks. 
Find more like 
this. . 
64. EGFR/HER2/RAS/RAF/MAPK PATHWAYS: POSTER 
PRESENTATIONS: Multi-targeted siRNA against c-Src, and 
HSP90 combined with Cetuximab circumvented oncogene 
addiction, transactivation, and resistance due to mutations, 
and deletions in the kinase domain of EGFR in mCRC. 
JohnGiannios and Emmanuel Michailakis AACR Meeting 
Abstracts, Oct 2007; 2007: B126. 
. . . . . AACR-NCI-EORTC International Conference: 
Molecular Targets and Cancer Therapeutics-- Oct 22-26, 
2007; San Francisco, CA JohnGiannios Emmanuel 
Michailakis GSHA, Athens, Greece B126 Introduction: CRC 
cells can develop resistance to Cetuximab through.  
. 
65.  CANCER INITIATING CELL THERAPEUTIC POTENTIAL: 
POSTER PRESENTATIONS: 
(BNT) Bispecific nanobody targeting DNMT1 and SHH 
conjugated to vinorelbine-tartrate (anti-DNMT1/SHH bsNAb-
VRL) inhibit DNA methylation, Hedgehog(HH)-
Patched(PCTH) receptor signaling protein smoothened 
(SMO) and hTERT expression leading to re-expression of 
apoptotic tumor suppressor genes and induction of type-I, II, 
III PCD in HRBC stem progenitor cells (CSCs).  
JohnGiannios, Esmeralda Seraj, Philip Lambrinos, and 
Nick Alexandropulos AACR Meeting Abstracts, Apr 2007; 
2007: 1334.  
Find more like this 
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Cancer after Breast Augmentation Surgery. . . .  
theo_kononas. tripod.com/present.htm - Προσωρινά αποθηκευμένη - Παρόμοιες [PDF] 
Cancer Vaccines 2005: Barriers, Endpoints, and Opportunities 
Μορφή αρχείου: PDF/Adobe Acrobat 
Our Regional Medical Research Ethics Committee approved the . . . . . . Giannios J, Dept. 
of Clinical Oncology and Radiation-Oncology and Radiogenomics, PHSA and . . .  
www.cancerresearch.org/WorkArea/linkit. aspx?LinkIdentifier=id. . . 3138 
Abstracts: 10th Conference on Cancer Therapy with Antibodies and . . .  
από DM Goldenberg - 2004 
Eric Wong, Beth Israel Deaconess Medical Center/Harvard Medical School, . Boston, 
Massachusetts . . . . Andrew M. Scott, Ludwig Institute for Cancer Research, Austin 
Hospital, . Melbourne, Australia . . . Elmurad Akbarov, Scientific Centre of Oncology of 
Republic of Uzbekistan, . . . John Giannios, GSHA, Athens, Greece . . .  
www.liebertonline.com/doi/pdf/10. 1089/cbr. 2004. 19. 503 [PDF] 
Final Program - iSBTc: International Society for Biological . . .  
Μορφή αρχείου: PDF/Adobe Acrobat -  
John Giannios, General State Hospital of Athens. Kimberley Jones. Queensland Institute of 
Medical Research. Maria Jure-Kunkel, PhD . . .  
www.isbtc.org/UserFiles/file/iSBTc-AM09-Final-Program. pdf [PDF] 
Μορφή αρχείου: PDF/Adobe Acrobat - Quick View 
6Shanghai Changzheng Hospital, Shanghai, China, 7Russian Cancer Research Center, . . . 
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. . . Giannios J1, Lambrinos P2, Alexandropoulos N3. 1ACR Oncology, Attiki . . .  
www.worldgicancer.com/. . . /WGI_TOC_041306_with_Titles. pdf -  
International Drug Discovery Science and Technology 2009 . . .  
The Institute of Cancer Research, UK The University of Queensland, Australia . . . . . . Dr 
John N. Giannios, Head of Translational Medicine-Erasinio Oncology. . .  
www.the-infoshop.com/. . . /scientificprogram. shtml - Ηνωμένες Πολιτείες της Αμερικής -  
21st Annual San Antonio Breast Cancer Symposium — December 12–15 . . .  
Boltzmann Institute for Gynecological Oncology; University of. Vienna, Vienna, Austria. . . . . 
. Giannios J, Ginopoulos PV. University oi Patras, Greece. . . . . . Cabot MC, Giuliano AE, 
Han TY, Liu YY, Senchenkov A. Saint John's. . . Henry's Institute of Medical Research, 
Clayton, Victoria, Australia. . . .  
www.springerlink.com/index/Q217045748675047. pdf [PDF] 
Liposome Technology 3rd ed Vol 3. pdf - UNAIR | Universitas Airlangga 
Μορφή αρχείου: PDF/Adobe Acrobat 
John Giannios (Greece), Dmitry Genkin (Russia), Maria Georgiou (Cyprus), . . . . . 
.combinations evolved from the pioneering work by medical oncologists in . . .  
mirror. lib. unair. ac. id/. . . /Liposome%20Technology%203rd%20ed%20Vol%203. pdf 
Bcl-2 - AuthorMapper 
Medical Oncology (1998) 15: 234-240, December 01, 1998 . . . Breast Cancer Research 
(2005) 7: P13, May 27, 2005. By Giannios, J; Lambrinos, P; Maragudakis, E; . . .  
www.authormapper.com/search. aspx?. . . subject%3AOncology. . . -  
The use of paclitaxel and platinum-based chemotherapy in uterine . . .  
The University of Texas, MD Anderson Cancer Center, Department of Gynecologic Medical 
Oncology, 1515 Holcombe Boulevard, Houston, TX 77030, . . .  
lib. bioinfo. pl/paper:10419744 - Προσωρινά αποθηκευμένη 
Antibody Engineering 
από BA Therapy - 1998 
Civic Hospital Research Centre and Department of Pathology, McMaster . . . Massachusetts 
General Hospital and Harvard Medical School. . . . . . S. K. Chatterjee, W. J. John, K. A, 
Foon. The Lucille Parker Markey. Cancer Center and The Department of . . . . J. Giannios, 
P. Ginopoulos, Department of Internal Medicine, Oncology. . .  
www.liebertonline.com/doi/abs/10. 1089/cbr. 1998. 13. 51 
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New Agents in Development : Journal of Immunotherapy 
από NK Cells - 2003 
J Giannios, E. Michailakis, N. Alexandropoulos, T. Kononas. . . . . dosimetry values 
calculated according to Medical Internal Radiation Dosimetry (MIRD) of the . . . 1Christie 
Hospital, Cancer Research UK Centre, Manchester, United Kingdom; . . . . . 1Hematology, 
Oncology and BMT Research Center, Tehran University of Medical. . .  
journals. lww.com/. . . /New_Agents_in_Development. 12. aspx -  
A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular 
immunotherapy in combination with a fully human anti-CTLA antibody (MDX- … 
W Gerritsen, F van den Eertwegh, TD de … - Journal of …, 2006 - journals. lww.com 
. . . Ras siRNA Combined With Vinorelbine Inhibits Oncogenic Signals and Reverses DNA 
Methylation 
Causing Re-Expression of Tumor Suppressor Genes Leading to PCD Type-I, II and III in 
Chemoresistant Metastatic Cutaneous Malignant Melanoma (CMM) JohnGiannios. . . .  
 
Liposome technology: Liposome preparation and related techniques, G Gregoriadis - 2006 - 
TAYLOR & FRANCIS USA 
 
Pegylated-colloidal with linked anti-DNMT1/HDAC2 bispecific single-chain Fv molecules (bs-
ScFv) and encapsulated vinorelbine induces apoptosis in chemoresistant … 
JN Giannios - of the American Association for Cancer …, 2004 - aacrmeetingabstracts.org 
Failure to trigger PCD due to changes in DNA methylation and histone acetylation is a 
contributing factor in chemoresistance of IDC. DNMT1 interacts with HDAC2 causing gene 
silencing which interferes with therapeutic and diagnostic procedures. Our cohort consists of 
126 samples . . . P-341 Immunochemotherapy consisting of vinorelbine and IFNa2b induced 
synergistic TRAIL-mediated apoptosis with caspase-3 release after activation … 
JN Giannios, E Michailakis, N Alexandropoulos - Lung Cancer, 2003 - Elsevier 
P-609 Vinorelbine, fostriecin, genistein and celecoxib induced anoikis and PCD leading to 
bystander killing of chemoresistant advanced lung … 
JN Giannios, E Michailakis - Lung Cancer- …, 2003 - Amsterdam, Netherlands: Elsevier, [ 
Multi-vaccine SEVINA Composed of Vinorelbine Apoptotic Tumour Cell Lysate (VATCL), 
Cationic Colloidal 25 mer ISS CpG Oligonucleotide (ODN) Adjuvant and … 
J Giannios, P Lambrinos, N … - Journal of …, 2005 - journals. lww.com 
Preclinical Study of mAb-siRNA Combination Anti-Angiogenesis Therapy for Treatment of 
Colorectal Cancer Patrick Y. Lu, QQ Tang, FY Xie, J. Xu, Y. Liu, PV Scaria, A. Aslam, MC 
Woodle. Intradigm Corporation, Rockville, MD. Cancer and many other serious diseases are 
characterized . . .  
63 Combined chemogene treatment of cyclinD1 antisense ORN (SV-22) and vinorelbine 
eradicates by PCD chemoresistant aneuploid NSCLC … 
JN Giannios, E Michailakis - Lung Cancer, 2003 – Elsevier Antibody-guided cytokine 
therapy (AGCT) chemoresistant human breast cancer 
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J Giannios, L Ioannidou-Mouzaka, M … - European Journal of …, 1997 - Elsevier 
Breast cancer constitutes one of the most lethal malignancies due to limited effects of  
chemotherapy, radiotherapy and immunotherapy. A high metastatic chemoresistant human 
breast cell line has exhibited overexpression of MDR-1 and MRP mRNA by both RT-PCR. .  
Liposomal Ras siRNA Combined With Vinorelbine Inhibits Oncogenic Signals and Reverses 
DNA Methylation Causing Re-Expression of Tumor Suppressor Genes … 
J Giannios - Journal of Immunotherapy, 2006 - journals. lww.com 
Targeted Therapy: Magic Bullet. . . . or Shot in the Dark Tim Eisen. Royal Marsden Hospital, 
London, United Kingdom. We entered the era of targeted therapies some years ago. 
However, many questions remain as to how best to develop these therapies. In this talk I . . .  
P1-295: ADM. of exosomal c-cbl E3-ubiquitin ligase inhibited SRC-tyrosine kinase Fyn 
blocked phosphorylation of tau tyr18 and phosphorylation of … 
J Giannios, P Lambrinos, N … - Alzheimer's and …, 2006 - alzheimersanddementia.com 
Alzheimer's & Dementia: The Journal of the Alzheimer's Association, Volume 2, Issue 3, 
Pages S183, July 2006, Authors:John Giannios; Philip Lambrinos; Nick Alexandropoulos.  
 
P-608 rhuMAb HER-2/neu and vinorelbine eradicates aneuploid and chemoresistant NSCLC 
overexpressing cyclinD1, HER-2/neu and Ras via ADCC, … 
JN Giannios, E Michailakis - Lung Cancer, 2003 - Elsevier 
P-340 Immunochemotherapy consisting of vinorelbine encapsulated in pegylated liposomes 
with linked anti EGFR chimeric Mabs (SV/22/00) exert … 
JN Giannios, E Michailakis - Lung Cancer, 2003 - Elsevier 
Combined adminstration of antisense chemoradioimmunotherapy (ACRIT) consisting of 
antiHER2 scFv linked onto high energy radioisotopes and triplex forming … 
JN Giannios, P Lambrinos, E … - … of the American …, 2005 - aacrmeetingabstracts.org 
Introduction: Metastatic breast Ca (MBC) is resistant to almost all cytotoxic drugs and 
radiation making it one of the most aggressive malignancies in human with the worst 
mortality. The failure of tumour cells to undergo apoptosis cause resistance to 
chemoradiological therapies . . .  
 
P-609 Vinorelbine, fostriecin, genistein and celecoxib induced anoikis and PCD leading to 
bystander killing of chemoresistant advanced lung … 
JN Giannios, E Michailakis - Lung Cancer, 2003 - Elsevier 
Catalytic cleavage of HER2mRNA induces D2 stage of PCD into chemoresistant ESCC after 
recombinant defective adenovirus mediated transfer of … 
J Giannios, P Ginopoulos - Gastroenterology, 2000 - Elsevier 
Combined administration of hydrophilic antimitotic desoxyepothilone B and vinorelbine 
induce PUMA, suppression of microtubule dynamics, development of … 
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GN John, J Giannios, E Michailakis, S … - ASCO Meeting …, 2004 - meeting. 
ascopubs.org Introduction: Low aqueous solubility of VRL is a high substrate for ATP 
dependent drug efflux proteins such as MDR-1(Pgp) and MRP2(ABCC2) inserted in plasma 
membrane of tumor cells. Furthermore, b-tubulin mutations are cross-resistant to VRL. 
Methods: We treat . 
Diabody vinorelbine conjugate (DVC) composed of vinorelbine-tartrate conjugated to anti-
DNMT1/SHH di-diabody induce ADCC, CDC, AMP and inhibit DNA … 
Giannios N John, et al. Meeting …, 2007 - meeting. ascopubs.org 
Background: Hormone refractory breast cancer (HRBC) is incurable due to malignant stem  
cells, which represent a potential nidus for the recurrent cancer that arises after treatment  
failure. Methods: From 126 metastatic HRBC patients, we obtained CSCs from recurrent  
Peptide Targeting of EphA2 in Epithelial Ovarian Cancer 
EB Dickerson, M Akhtar, LB Kapa, NJ … - Journal of …, 2006 - journals. lww.com 
. . . Ras siRNA Combined With Vinorelbine Inhibits Oncogenic Signals and Reverses DNA 
Methylation Causing Re-Expression of Tumor Suppressor Genes Leading to PCD Type-I, II 
and III in Chemoresistant Metastatic Cutaneous Malignant Melanoma (CMM) 
JohnGiannios. . . .  
Targeted Therapy: Magic Bullet [horizontal ellipsis]. or Shot in the Dark 
T Eisen - Journal of Immunotherapy, 2006 - journals. lww.com 
. . . Ras siRNA Combined With Vinorelbine Inhibits Oncogenic Signals and Reverses DNA 
Methylation Causing Re-Expression of Tumor Suppressor Genes Leading to PCD Type-I, II 
and III in Chemoresistant Metastatic Cutaneous Malignant Melanoma (CMM) 
JohnGiannios. . . .  
Activated Human B Cells can Secrete Granzyme B and Gain Cytotoxic Potential in 
Response to Interleukin 21 
…, SE Blackwell, JE Wooldridge, J Huang, … - Journal of …, 2006 - journals. lww.com 
. . . Ras siRNA Combined With Vinorelbine Inhibits Oncogenic Signals and Reverses DNA 
Methylation Causing Re-Expression of Tumor Suppressor Genes Leading to PCD Type-I, II 
and III in Chemoresistant Metastatic Cutaneous Malignant Melanoma (CMM) 
JohnGiannios. . . .  
[HTML] Esophageal cancer 
nih. gov[HTML]GY Yang - ncbi. nlm. nih. gov 
. . . Disintegrin/MLD-VGD Domain (VADD) Isolated From Vipera Ammodytes, Exerted 
Synergistic Action with Vinorelbine Tartrate Against Metastatic Esophageal Squamous Cell 
Cancer, Circumventing Chemotherapy-Mediated SystemicToxicity Giannios, Head, Cancer  
Liposome Technology, Volume III: Interactions of Liposomes with the Biological Milieu, G 
Gregoriadis - 2006 - Informa HealthCare 
 
Liposome Technology: Entrapment of drugs and other materials into liposomes, G 
Gregoriadis - 2006 - Informa HealthCare 
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[PDF] Forthcoming Conferences and Meetings 
kma.org. kw [PDF]STD Intensive - KUWAIT MEDICAL JOURNAL, 2008 - kma.org. kw 
. . . info@CCTatConcord.com 1st International Congress of Translational Oncology 
May 24-25, 2008 Kastro Kyllinis, Greece Contact: Dr JohnGiannios Tel: 
69-74-711-158 E-Mail: jng@otenet. gr 18th Annual Anatomic Pathology . . .  
Προβολή ως HTML - Όλες οι 4 εκδοχές 
Abstracts: 10th Conference on Cancer Therapy with Antibodies and Immunoconjugates 
DM Goldenberg, SJ DeNardo, JFM … - Cancer Biotherapy & …, 2004 - liebertonline.com 
. . . Ductal Carcinoma (IDC) Characterized by HDAC2 Overexpression and 5!CpG Island 
Hypermethylation of the FHIT, RAR- 2, BRCA-1, APC, p16(CDKN2A), RASSF1A, CDH1(E-
cadherin),  
14-3-3-s (stratifin), HIC1 and MDG1 Tumour Suppressor Genes Giannios, GSHA, Athens . .  
[PDF] Forthcoming Conferences and Meetings 
kma.org. kw [PDF]FWI St Martin - KUWAIT MEDICAL JOURNAL, 2005 - kma.org. kw 
. . . International Congress on C ancer C hemop revention and Control with Ta ilo re 
d Molecular Targeting Feb 15-18, 2006 Ancient Epidavros, Greece Contact: Dr 
JohnGiannios Tel: 69-74-711-158 E-Mail: jng@otenet. gr 9TH . . .  
Προβολή ως HTML - Όλες οι 2 εκδοχές 
[PDF] Cancer vaccination 
oxfordjournals.org[PDF] JML Vega, M Valladares, L Calvo, M … - Annals of …, 2000 - Eur 
Soc Med Oncology 
. . . ADCC. JohnGiannios. Emmanuel Michailakis Depl of Oncology, General Hospital of 
Athens, Athens, Greece About 50% of women with breast cancer develop distant 
metastases within 5 years after primary treatment. Early . . .  
Όλες οι 2 εκδοχές 
Antisense chemoradioimmunotherapy consisting of anti-IGF-I/HGF bs-scFv linked onto high-
energy radioisotopes and TFO targeted to DNMT1 and conjugated to … 
…, N Alexandropoulos, J Giannios - ASCO Meeting …, 2005 - meeting. ascopubs.org 
Introduction: Metastatic NSCLC is resistant to almost all cytotoxic drugs and radiation. 
Materials and Methods: We obtained surgically 132 metastatic NSCLC specimens from 
patients. MS-PCR exhibited hypermethylation of oncosuppressors VHL, p63, p53, IGFBP4, 
p16, RASSF1A, RAR . . .  
Όλες οι 2 εκδοχές 
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1. International Society of Gastrointestinal Oncology 
2009 Gastrointestinal Oncology Conference . . . Methodist Dallas Medical Center, 
Dallas, TX . . . JohnGiannios, Emmanuel Michailakis, John Papanikolaou, Nick 
Alexandropoulos, www.isgio.org/isgio2009/program.html - Cached 
2. Chemoradioimmunotherapy for advanced breast cancer: hope for . . .  
. . . by Dr JohnGiannios, . . . Note: Any medical information published on this website 
is not intended as a substitute . . . Discuss issues relating to cancer / oncology . . . 
www.medicalnewstoday.com/articles/10412. php - Cached 
3. Calendar of Events 
International Medical Care and Diagnostic Conference and Exhibition - IMD Dubai 2008 
. . . The First International Congress of Translational Oncology. Dr JohnGiannios 
www.ams.ac.ir/aim/08112/0027.htm - Cached 
4. H. Lee Moffitt Cancer Center & Research Institute - H. Lee . . .  
Contact Dr JohnGiannios, . . . Contact Office of Continuing Medical Education, 
University of Minnesota, Radisson Hotel Metrodome, . . . c/o Institute of Oncology, . . . 
www.moffittcancercenter.com/moffittapps/ccj/v4n2/ca. . . - Cached 
5. Chemoradioimmunotherapy for advanced breast cancer 
. . . by Dr JohnGiannios, . . . Please note that medical information found on this 
website is designed to support, . . . Oncology, www.news-medical. 
net/news/2004/07/08/3165. aspx - Cached 
6. [PDF] Calendar of Events 
Adobe PDF - View as html 
Arch Iranian Med 2008; 11 (2): 246 Archives of Iranian Medicine, Volume 11, Number 2, 
March 2008 246 Methodology of Clinical Trials in Oncology CESAR Central European 
Society . . . www.ams. ac. ir/aim/08112/0027. pdf 
7. Search results for 'Radioisotopes' 
. . . a pharmaceutical group specialized in medical imaging, . . . by circumventing their 
chemo and radioresistant mechanisms was by presented by Dr JohnGiannios, Head . . 
. Oncology www.news-medical. net/search. aspx?q=Radioisotopes - Cached 
8. Esophageal Cancer 
JohnGiannios Head, Cancer Research, Erasinio Oncology Hospital, Athens, Greece . 
. . Department of MedicalOncology, Kidwai Memorial Institute of Oncology, Bangalore, 
India, www.ncbi. nlm. nih. gov/pmc/articles/PMC2663375 
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9. [PDF] 
Second Annual ISGIO Meeting Marked by Rising Attendance . . .  Adobe PDF - View as 
html 
WASHINGTON, DC— The International Society of Gastrointestinal Oncology (ISGIO) 
played host to more than 500 of the world's top res earchers and physicians from 14 . . . 
www.isgio.org/newsletters/GIONC-2-3. pdf 
10. Breast Cancer: Chemoradioimmunotherapy may hold promise for . . .  
. . . medical industry professionals and women patients together, . . . JohnGiannios, 
head of Radiotherapeutic Cancer Research at the IASO Hospital, Athens, Greece, . . . 
Gynecological Oncology www.obgyn. net/newsheadlines/womens_health-
Breast_Cancer. . . - Cached 
11. Marsha Rivkin Center For Ovarian Cancer Research - Ovarian . . .  
Victor Levenson • Rush University Medical Center . . . JohnGiannios • Erasinio 
Oncology Hospital (Greece) 4:30: Closing Remarks. Site Map Contact Us 
www.marsharivkin.org/events/symposium_agenda.html - Cached 
12. Chemoradioimmunotherapy for advanced breast cancer: hope for . . .  
. . . their chemo- radioresistant mechanisms was by presented by Dr JohnGiannios, . . . 
for graduate students in medical physics, radiation oncology and for therapy 
radiographers. www.brightsurf.com/news/headlines/9641/Chemoradio. . . - Cached 
13. Tumour Suppressor Current Events 
Medical Fields . . . Oncology . . . technique to kill metastatic breast cancer cells by 
circumventing their chemo- and radioresistant mechanisms was by presented by Dr 
JohnGiannios, Head . . . www.brightsurf.com/search/r-a/Tumour_
Suppressor/1/Tumour. . . - Cached 
14. Chemoradioimmunotherapy for advanced breast cancer: hope for . . .  
. . . Biology News And Medical News Biology News 2 Health News 2 Biology News 3 
Health News 3 . . . by Dr JohnGiannios, . . . novel oncology targets for . . . novel 
therapeutics agents directed . . . news. bio-medicine.org/biology-news-2/Chemoradio.  
15. [PDF] Forthcoming Conferences and Meetings Adobe PDF - View as html 
K UWAIT M EDICAL J OURNAL March 2008 84 Internal Medicine: Current Clinical 
Topics for the Primary Care Setting Mar 01-31, 2008 Sarasota, FL, United States 
Contact: Eva or Cristina . . . www.kma.org. kw/KMJ/Issues/mar2008/Forthcoming%20. .  
16. American Society of Clinical Oncology 2001 
John N. Giannios, . . . Department of MedicalOncology, Melbourne, Australia; Centre 
for PET, Melbourne, Australia; Department of Haematology, Melbourne, Australia. 
www.mindcull.com/preview/ASCO_2001. php - Cached 
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17. International Drug Discovery Science and Technology 2009 . . .  
Dr Philipp le Coutre, Professor, Medical Clinic m. S. Hematology and Oncology, . . . Dr 
John H. Van Drie, President, John H Van Drie Research LLC, USA www.the-
infoshop.com/conference/iddst09/scientific. . . - Cached 
18. Annals of Oncology - 2000,Volume 11, Issue 
Giannios, John; Michailakis, Emmanuel. HTML. 42 Active immunization of colorectal 
carcinoma patients . . . 25th Congress of the European Society for MedicalOncology 
pt.wkhealth.com/pt/re/anon/toc.00002352-200000004-00000. . . - Cached 
19. cancer cells radioresistant: Topics by WorldWideScience.org 
. . . and medical regimens . . . a, b, 2 William F. Blakely, c John R. Fike, d Thomas J. 
MacVittie, . . . b Department of Experimental Radiation Oncology, UCLA Medical 
Center, 19833 LeConte Avenue, . . . worldwidescience.org/topicpages/c/
cancer+cells+radio. . . - Cached 
20. ASCO Meeting Abstracts -- Table of Contents (22 /14S - July . . .  
. . . between genetic markers and oncology patient quality of life (QOL) . . . versus A 
and cyclophosphamide (C) as primary medical therapy (PMT) in women with breast 
cancer meeting. ascopubs.org/content/vol22/14_suppl - Cached 
21. American Society of Clinical Oncology 2007 
Evaluation of local control in patients with non-metastatic Ewing sarcoma of the bone: A 
report from the Children's Oncology Group. S. G. DuBois, . . .  
www.mindcull.com/preview/ASCO_2007. php - Cached 
22. Annals of Oncology - October 2002, Volume 13, Issue 
Are you affiliated with a leading medical or academic institution? . . . Annals of 
Oncology. Current Issue . . . Giannios, John 1; Michailakis, Emmanuel 1 
pt. wkhealth.com/pt/re/anon/toc.00002352-200200005-00000. . . - Cached 
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BRITISH SOCIETY OF GASTROENTEROLOGY 
BSG ANNUAL MEETING 14 - 17 MARCH 2011 
ICC Birmingham 
Dear John GIANNIOS  
We are pleased to inform you that your paper has been accepted for oral presentation at 
this meeting. Below you will find instructions regarding your presentation.  
Details of your presentation are as follows: 
Title: GENE MODIFIED CELLULAR VACCINE (GMCV) COMPOSED OF AUTOLOGOUS 
ADIPOSE-DERIVED MESENCHYMAL STEM CELLS (AAD-MSCS) TRANSFECTED WITH 
LIPID-CATION HSP70 ACTIVATED INNATE AND ADAPTIVE IMMUNITY AFTER 
TARGETING METASTATIC PANCREATIC CA CELLS 
BSG11-ABS-2453 
Programme Number: OC-042 
Session: NEOPLASIA & CANCER PATHOGENESIS FREE 
PAPERS 
Date and time of presentation: Tue 15. 03. 2011 15:30 
Place of presentation: Hall 6 
Length of Presentation: 10 minutes presentation + 5 minutes discussion 
IT IS THEREFORE IMPORTANT THAT YOU 
REHEARSE YOUR PAPER TO KEEP TO THIS 
Presentation Order 5 
Speaker guidelines: See below 
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Presenting Author: John Giannios 
BSG ANNUAL MEETING 14 - 17 MARCH 2011 
ICC Birmingham 
Dear John GIANNIOS,  
We are pleased to inform you that your abstract has been accepted for poster presentation 
at this meeting. Below you find instructions regarding necessary preparation. The details of 
your presentation are as follows: 
Title: BIOLOGIC ANTICANCER ACTIVITY OF DESIGNED ANKYRIN REPEAT 
PROTEINS (DARPINS) TARGETED AGAINST DNMT1 AND CONJUGATED TO 
DOCETAXEL LEADS TO ERADICATION OF CHEMORESISTANT MUTATED 
SQUAMOUS CELL EPSOPHAGEAL CANCER STEM CELLS.  
BSG11-ABS-2388 
Programme N°: PTU-102 
Date of poster presentation:  Tue 15. 03. 2011 
Time of poster round: Please stand next to your poster board between 12:30 
and 14:00 
Hanging of poster: 09.30 on the morning of the presentation day 
Removal of poster: Before exhibition close on the same day 
Poster Board size: 2m wide by 1m high (landscape format) 
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Presenting Author: John Giannios 
BSG ANNUAL MEETING 14 - 17 MARCH 2011 
ICC Birmingham 
Dear John GIANNIOS,  
We are pleased to inform you that your abstract has been accepted for poster presentation 
at this meeting. Below you find instructions regarding necessary preparation. The details of 
your presentation are as follows: 
Title: APOPTOTIC EFFECT OF PEGYLATED-NANOPARTICLES OF CDP BOUND TO 
MULTITARGETED SIRNA MOLECULES AGAINST BMI1 AND SURVIVIN CONJUGATED 
WITH MIR-373 (TERMED AS SEVIN-A) WHICH TARGET GASTRIC CANCER STEM 
CELLS (GCSCS) OVEREXPRESSING CD44 AFTER CIRCUMVENTION OF CHEMO 
BSG11-ABS-2376 
Programme N°: PTU-101 
Date of poster presentation:  Tue 15. 03. 2011 
Time of poster round: Please stand next to your poster board 
between 12:30 and 14:00 
Hanging of poster: 09. 30 on the morning of the presentation 
day 
Removal of poster: Before exhibition close on the same day 
Poster Board size: 2m wide by 1m high (landscape format) 
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Presenting Author: John N Giannios 
BSG ANNUAL MEETING 14 - 17 MARCH 2011 
ICC Birmingham 
Dear John GIANNIOS,  
We are pleased to inform you that your abstract has been accepted for poster presentation 
at this meeting. Below you find instructions regarding necessary preparation. The details of 
your presentation are as follows: 
Title: ANTISENSE CHEMORADIOIMMUNOTHERAPY CONSISTING OF ANTI-CASM 
SCFV LINKED ONTO HIGH ENERGY RADIOISOTOPES, DOCETAXEL, AND 21 
NUCLEOTIDE DOUBLE STRANDED SIRNA TARGETED TO DNMT1 INDUCE 
APOPTOSIS/PCD TYPE-I IN PANCREATIC AND PERIAMPULLARY CARCINOMA 
BSG11-ABS-2419 
Programme N°: PTU-104 
Date of poster 
presentation:  
Tue 15. 03. 2011 
Time of poster round: Please stand next to your poster board between 12:30 
and 14:00 
Hanging of poster: 09. 30 on the morning of the presentation day 
Removal of poster: Before exhibition close on the same day 
Poster Board size: 2m wide by 1m high (landscape format) 
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Presenting Author: John Giannios 
BSG ANNUAL MEETING 14 - 17 MARCH 2011 
ICC Birmingham 
Dear John GIANNIOS,  
We are pleased to inform you that your abstract has been accepted for poster presentation 
at this meeting. Below you find instructions regarding necessary preparation. The details of 
your presentation are as follows: 
Title: TUMORIGENIC EFFECT OF VINORELBINE ON CHEMORESISTANT CANCER 
STEM CELL RENEWAL IN COLORECTAL CANCER (CRC) AND ON METASTASIS.  
BSG11-ABS-2428 
Programme N°: PTU-105 
Date of poster presentation:  Tue 15. 03. 2011 
Time of poster round: Please stand next to your poster board between 
12:30 and 14:00 
Hanging of poster: 09. 30 on the morning of the presentation day 
Removal of poster: Before exhibition close on the same day 
Poster Board size: 2m wide by 1m high (landscape format) 
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Presenting Author: John Giannios 
BSG ANNUAL MEETING 14 - 17 MARCH 2011 
ICC Birmingham 
Dear John GIANNIOS,  
We are pleased to inform you that your abstract has been accepted for poster presentation 
at this meeting. Below you find instructions regarding necessary preparation. The details of 
your presentation are as follows: 
Title: USE OF INDUCED PLURIPOTENT STEM CELLS (IPSC) ENCODED WITH ANTI-
GRP78 SHRNA INDUCES APOPTOSIS/TYPE-I PCD AFTER A GENE-SILENCING 
BYSTANDER EFFECT FOR CIRCUMVENTION OF VINORELBINE INDUCED 
ANGIOGENESIS, AND INHIBITION OF METASTATIC SPREAD IN ADVANCED GIST 
BSG11-ABS-2399 
Programme N°: PTU-103 
Date of poster 
presentation:  
Tue 15. 03. 2011 
Time of poster round: Please stand next to your poster board between 12:30 
and 14:00 
Hanging of poster: 09. 30 on the morning of the presentation day 
Removal of poster: Before exhibition close on the same day 
Poster Board size: 2m wide by 1m high (landscape format) 
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Presenting Author: John Giannios 
BSG ANNUAL MEETING 14 - 17 MARCH 2011 
ICC Birmingham 
Dear John GIANNIOS,  
We are pleased to inform you that your abstract has been accepted for poster presentation 
at this meeting. Below you find instructions regarding necessary preparation. The details of 
your presentation are as follows: 
Title: ANTISENSE IMMUNOCHEMOGENE THERAPY COMPOSED OF SIRNA 
TARGETING VEGF-A165B MRNA, ANTIVEGFMAB, AND TXT INHIBITED VEGF 
MEDIATED DESMOPLASTIC RESPONSE, ANGIOGENESIS, AND 
LYMPHANGIOGENESIS INDUCING MATURATION OF DCS, ADCC, CMC, AUTOPHAGY, 
AND PCD IN PDAC 
BSG11-ABS-2518 
Programme N°: PTU-108 
Date of poster presentation:  Tue 15. 03. 2011 
Time of poster round: Please stand next to your poster board between 12:30 
and 14:00 
Hanging of poster: 09. 30 on the morning of the presentation day 
Removal of poster: Before exhibition close on the same day 
Poster Board size: 2m wide by 1m high (landscape format) 
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Presenting Author: John Giannios 
BSG ANNUAL MEETING 14 - 17 MARCH 2011 
ICC Birmingham 
Dear John GIANNIOS,  
We are pleased to inform you that your abstract has been accepted for poster presentation 
at this meeting. Below you find instructions regarding necessary preparation. The details of 
your presentation are as follows: 
Title: ERADICATION OF METASTATIC GASTRIC CA OF THE ANTRUM RESISTANT TO 
TRASTUZUMAB AND CETUXIMAB FOLLOWING IMMUNOCHEMOGENE TREATMENT 
WITH SV-IV, A STEALTH NANOPARTICLE FORMULATION COMPOSED OF CLAMP 
PNA AGAINST MRNA OF SGCA1/B1, DOCETAXEL, AND MUC1 CHIMERIC MAB 
BSG11-ABS-2536 
Programme N°: PTU-109 
Date of poster presentation:  Tue 15. 03. 2011 
Time of poster round: Please stand next to your poster board between 12:30 
and 14:00 
Hanging of poster: 09. 30 on the morning of the presentation day 
Removal of poster: Before exhibition close on the same day 
Poster Board size: 2m wide by 1m high (landscape format) 
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Presenting Author: John Giannios 
BSG ANNUAL MEETING 14 - 17 MARCH 2011 
ICC Birmingham 
Dear John GIANNIOS,  
We are pleased to inform you that your abstract has been accepted for poster presentation 
at this meeting. Below you find instructions regarding necessary preparation. The details of 
your presentation are as follows: 
Title: CHEMOGENE TREATMENT CONSISTING OF RECOMBINANT ADENOVIRAL 
TRANSFECTION OF P16CDNA (SVN-22/3), AND DOCETAXEL ERADICATES 
CHEMORESISTANT ANEUPLOID PANCREATIC ADENOSQUAMOUS CA 
CHARACTERISED BY OVEREXPRESSION OF K-RAS AND HYPERMETHYLATION OF 
CPG ISLANDS OF P16 
BSG11-ABS-2591 
Programme N°: PTU-110 
Date of poster presentation:  Tue 15. 03. 2011 
Time of poster round: Please stand next to your poster board 
between 12:30 and 14:00 
Hanging of poster: 09. 30 on the morning of the presentation 
day 
Removal of poster: Before exhibition close on the same day 
Poster Board size: 2m wide by 1m high (landscape format) 
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BSG ANNUAL MEETING 14 - 17 MARCH 2011 
ICC Birmingham 
Dear John GIANNIOS,  
We are pleased to inform you that your abstract has been accepted for poster presentation 
at this meeting. Below you find instructions regarding necessary preparation. The details of 
your presentation are as follows: 
Title: LIP-RMDVA COMPOSED OF LIPOSOMAL CDNA ENCODING RECOMBINANT 
MULTIMODULAR PROTEINS RMDVA COMPRISING DISINTEGRIN/CYSTEINE RICH 
DISULFIDE BOND 2RGD, C-TERMINAL DOMAIN, METALLOPROTEASE-DOMAIN, AND 
DIMERIC DISINTEGRIN/MLD-VGD DOMAIN ERADICATED CRC 
BSG11-ABS-2592 
Programme N°: PTU-111 
Date of poster presentation:  Tue 15. 03. 2011 
Time of poster round: Please stand next to your poster board between 12:30 
and 14:00 
Hanging of poster: 09. 30 on the morning of the presentation day 
Removal of poster: Before exhibition close on the same day 
Poster Board size: 2m wide by 1m high (landscape format) 
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Presenting Author: John Giannios 
BSG ANNUAL MEETING 14-17 MARCH 2011 
ICC Birmingham 
Dear John GIANNIOS,  
We are pleased to inform you that your abstract has been accepted as a poster at this 
meeting. Furthermore, we have the pleasure to inform you that your poster is among the 
10% best posters. It is therefore classified as a  
Poster of Distinction and will be highlighted with a rosette at the meeting to make sure it 
gets the appropriate attention. Your abstract will also be highlighted as a ‘poster of 
distinction’ in the abstract book. The details of your presentation are as follows: 
Title: CETUXIMAB COMBINED WITH MULTI-TARGETED SIRNA AGAINST HSP90, 
UBCH5, AND SRC CIRCUMVENTED ONCOGENE ADDICTION, TRANSACTIVATION, 
AND ACQUIRED RESISTANCE AS A RESULT OF EGFR UBIQUITINATION, AND 
MUTATIONS/DELETIONS IN THE KINASE DOMAIN OF EGFR IN COLORECTAL CA 
BSG11-ABS-2500 12 January 2011 
Dear John GIANNIOS,  
We are pleased to inform you that your abstract has been accepted as a poster at this 
meeting. Furthermore, we have the pleasure to inform you that your poster is among the 
10% best posters. It is therefore classified as a  
Poster of Distinction and will be highlighted with a rosette at the meeting to make sure it 
gets the appropriate attention. Your abstract will also be highlighted as a ‘poster of 
distinction’ in the abstract book.  
The details of your presentation are as follows: 
Title: LNA-MODIFIED OLIGONUCLEOTIDES TARGETING MRNA OF DICER IN 
PEGYLATED COLLOIDAL NANOPARTICLES WITH LINKED ABS AGAINST CD44 
ERADICATE ESOPHAGEAL CANCER STEM CELLS (ECSC) BY INDUCTION OF PCD 
AFTER INHIBITION OF ONCOMIR MACHINERY.  
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BSG11-ABS-2509 
Programme N°: PTU-107 
Date and time of poster 
presentation:  
Tue 15. 03. 2011 
Time of poster round: Please stand next to your poster board 
between 12:30 and 14:00 
Place of poster presentation: Poster Area 
Hanging of poster: 09. 30 on the morning of the presentation day 
Removal of poster: Before exhibition close on the same day 
Poster Board size: 2m wide by 1m high (landscape format) 
 
PL07 Plenary Session 
ADVANCES IN THE TREATMENT OF ANEURYSM / THORACIC AORTIC PATHOLOGY 
GENE REPLACEMENT THERAPY INDUCES DEVELOPMENT OF NEW CORONARY 
ARTERIES CIRCUMVENTING CORONARY ARTERY DISEASE  
J. Giannios, N. Liasis, N. Alexandropoulos, Erasinio Hospital, Athens, Greece 
 
15th World Congress on Heart Disease - Advance Program 
26 Jul 2010 . . . International Academy of Cardiology Awards . . . . . REGENERATION OF 
INFRACTED MYOCARDIUM WITH NUTRITIONALLY MODIFIED CARDIAC STEM CELLS. 
. . by JOHN GIANNIOS 
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13th Biennial Meeting of the International Gynecological Cancer Society  
Prague, October 23-26, 2010  
Dear John Giannios 
1. On behalf of the Scientific Program Committee, we are pleased to inform you that your 
abstract A-214-0003-00178 entitled ‘COLLOIDAL-CDNA ENCODING RECOMBINANT 
PROTEINS-RMDVA COMPRISING DISINTEGRIN/CYSTEINE-RICH-DISULFIDE 
BOND 2RGD, AND C-TERMINAL DOMAIN, METALLOPROTEASE-DOMAIN, AND 
DIMERIC DISINTEGRIN/MLD-VGD DOMAIN (VADD) INDUCED APOPTOSIS IN 
OVARIAN CA’ has been accepted for POSTER PRESENTATION at the 13th Biennial 
Meeting of the International Gynecological Cancer Society (IGCS 2010). Details of your 
schedule can be found below. In addition, please refer to the IGCS 2010 scientific 
program and instructions for presenters for more information.  
2. On behalf of the Scientific Program Committee, we are pleased to inform you that your 
abstract A-214-0003-00175 entitled ‘ADMINISTRATION OF GENE-MODIFIED-
CELLULAR-VACCINE COMPOSED OF AUTOLOGOUS- ADIPOSE-DERIVED 
MESENCHYMAL-STEM-CELLS TRANSFECTED WITH LIPID-CATION-HSP70 
ACTIVATES INNATE AND ADAPTIVE IMMUNITY ERADICATING METASTATIC 
OVARIAN CARCINOMA’ has been accepted for POSTER PRESENTATION at the 13th 
Biennial Meeting of the International Gynecological Cancer Society (IGCS 2010). Details 
of your schedule can be found below. In addition, please refer to the IGCS 2010 
scientific program and instructions for presenters for more information.  
3. On behalf of the Scientific Program Committee, we are pleased to inform you that your 
abstract A-214-0003-00174 entitled ‘LNA MODIFIED OLIGONUCLEOTIDES 
TARGETING MRNA-DICER IN PEGYLATED COLLOIDAL NANOPARTICLES WITH 
LINKED ABS AGAINST CD44 ERADICATE OVARIAN CANCER STEM CELLS 
(OCSCS)’ has been accepted for POSTER PRESENTATION at the 13th Biennial 
Meeting of the International Gynecological Cancer Society (IGCS 2010). Details of your 
schedule can be found below. In addition, please refer to the IGCS 2010 scientific 
program and instructions for presenters for more information 
4. On behalf of the Scientific Program Committee, we are pleased to inform you that your 
abstract A-214-0003-00162 entitled ‘IMMUNOCHEMOGENIC TREATMENT WITH 
STEALTH NANOPARTICLE FORMULATION CONSISTING OF CLAMP PNA 
AGAINST MRNA-FOXC2, ANTI-CD44 CHIMERIC-MAB, AND TAXOTERE 
ERADICATED ADVANCED OVARIAN EPITHELIAL CA’ has been accepted for 
POSTER PRESENTATION at the 13th Biennial Meeting of the International 
Gynecological Cancer Society (IGCS 2010). Details of your schedule can be found 
below. In addition, please refer to the IGCS 2010 scientific program and instructions for 
presenters 
137 
 
5. On behalf of the Scientific Program Committee, we are pleased to inform you that your 
abstract A-214-0003-00161 entitled ‘PEGYLATED-NANOPARTICLES OF CDP BOUND 
TO MULTITARGETED SIRNA AGAINST BMI1 AND SURVIVIN CONJUGATED WITH 
MIR-373 (SEVIN-A) ERADICATES METASTATIC OVARIAN CARCINOMA’ has been 
accepted for POSTER PRESENTATION at the 13th Biennial Meeting of the International 
Gynecological Cancer Society (IGCS 2010). Details of your schedule can be found 
below. In addition, please refer to the IGCS 2010 scientific program and instructions for 
presenters for more information.  
6. On behalf of the Scientific Program Committee, we are pleased to inform you that your 
abstract A-214-0006-00177 entitled ‘ANTISENSE TREATMENT WITH PEGYLATED 
LIPOSOMAL MULTITARGETED SIRNA AGAINST UBCH5, C-SRC, AND HSP90 
COMBINED WITH BEVACIZUMAB ERADICATED HORMONE REFRACTORY 
BREAST CA(HRBC) BY INDUCTION OF APOPTOSIS/PCD TYPEI’ has been accepted 
for POSTER PRESENTATION at the 13th Biennial Meeting of the International 
Gynecological Cancer Society (IGCS 2010). Details of your schedule can be found 
below. In addition, please refer to the IGCS 2010 scientific program and instructions for 
presenters for more information.  Session title: Poster Session I 
Session date: Saturday, October 23 - Sunday, October 24, 2010 
7. On behalf of the Scientific Program Committee, we are pleased to inform you that your 
abstract A-214-0006-00167 entitled ‘LIPOSOMAL TAXOTERE WITH LINKED-PYMT-
MABS INHIBITED VEGF-MEDIATED-HUMAN-TELOMERASE-REVERSE- 
TRANSCRIPTASE (HTTTERT), C-SRC, PI3K, VEGF-A, MMP-2, AND INTEGRINS- A1- 
2-6 INDUCING APOPTOSIS IN HRBC’ has been accepted for POSTER 
PRESENTATION at the 13th Biennial Meeting of the International Gynecological Cancer 
Society (IGCS 2010). Details of your schedule can be found below. In addition, please 
refer to the IGCS 2010 scientific program and instructions for presenters for more 
information.  Session title: Poster Session I 
Session date: Saturday, October 23 - Sunday, October 24, 2010 
8. On behalf of the Scientific Program Committee, we are pleased to inform you that your 
abstract A-214-0001-00166 entitled ‘HUMORAL AND CELLULAR IMMUNITY 
INDUCES APOPTOSIS(PCD) IN CIN2-3, HPV16+ CERVICAL CA AFTER DIVALENT 
GENETIC VACCINATION WITH CRS TARGETING P53 AND RB’ has been accepted 
for an oral presentation in a FREE COMMUNICATION SESSION at the 13th Biennial 
Meeting of the International Gynecological Cancer Society.  
Session title: Free Communication Session: Cervical, Vulvar, and Vaginal Cancer 
Session date: Monday, October 25, 2010 
Session time: 08:00 – 10:00Abstract Presentation Notification  
9. On behalf of the Scientific Program Committee, we are pleased to inform you that your 
abstract A-214-0003-01402 entitled ‘OVARIAN TUMOR MULTITARGETING WITH 
MABS AGAINST GP38, MUC1, AND TAG72 ON PEGYLATED NANODELIVERY 
PLATFORM OF CYLD AND RIP-1 LEADS TO NECROPTOSIS/ APOPTOSIS’ has 
been accepted for an oral presentation in a FREE COMMUNICATION SESSION at the 
13th Biennial Meeting of the International Gynecological Cancer Society. Details of your 
schedule can be found below. In addition, please refer to the IGCS 2010 scientific 
program and instructions for presenters for more information.  
 
Session title: Free Communication: Young Investigator Oral Presentations 
Session date: Monday, October 25, 2010 
Session time: 08:00-10:00  
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Chemoradioimmunotherapy for advanced breast cancer: hope for the future? 
7 July, 2004  
A successful, and novel, technique to kill metastatic breast cancer cells by circumventing 
their chemo- and radioresistant mechanisms was by presented by Dr John Giannios, Head 
of Radiotherapeutic Cancer Research at the IASO Hospital, Athens, Greece at the 18th 
Annual Meeting of the European Association of Cancer Research today (Tuesday 6 July 
2004).  
Advanced breast cancer, with metastases to lung and bone, has a very poor prognosis and 
current treatment protocols for this stage of disease generally result in survival periods of 
less than two years. One of the reasons for this poor prognosis is that metastatic cancer 
cells are less responsive to treatment than primary tumour cells.  
This is partly caused by the fact that the normal cell death process (apoptosis) is repressed 
by the overexpression of oncogenes such as bcl-2, HER-2, Raf-1 and cdc25c (these 
oncogenes are expressed more strongly in metastatic tumour cells), which means that the 
cells fail to die following treatment with chemotherapy drugs and radiation therapy.  
Using metastatic tumour tissue taken from a patient with advanced breast cancer, Giannios's 
team analysed the cells to determine if known oncogenes were being overexpressed. In 
addition to finding overexpression of the oncogenes bcl-2, HER-2, Raf-1 and cdc25c they 
also detected overexpression of DNMT1 (a DNA methyltransferase, involved in DNA 
replication during cell division, and implicated in cancer development) and they also detected 
methylation of BRCA1 promoter (a process implicated specifically in the development of 
breast cancer tumours).  
The experimental treatment, termed 'chemoradioimmunotherapy', combined chemotherapy, 
radiation therapy and immunotherapy in one. The chemotherapy component consisted of 
vinorelbine tartrate (a cytotoxic drug used in the treatment of breast (and other) cancers), the 
radiotherapy component was provided through the addition of high-energy radioisotopes, 
whilst the immunotherapy aspect was achieved by attaching an antibody specific to HER-2 
to those radioisotopes, as well as through the inclusion of a separate 21-nucleotide double 
stranded siRNA ('small interfering RNA') generated against DNMT1.  
It was hoped that the novel treatment regime would effectively target the tumour cells by 
blocking the genetic mechanisms that protect the cells from conventional treatment thereby 
allowing the chemotherapy and radiation therapy components to exert their cytotoxic effects.  
By 24 hours post-treatment there was clear evidence that the treated tumour cells were 
undergoing significantly greater apoptosis than the untreated controls.  
Apoptosis was confirmed by the detection of activation of caspase-3-9 (an enzyme involved 
in apoptosis), inhibition of DNA synthesis and metabolic activity in the tumour cells and the 
formation of apoptotic bodies. These apoptotic bodies were seen to be phagocytosed 
(absorbed) by adjacent tumour cells, which resulted in the subsequent apoptosis of the 
tumour cells through a 'bystander' killing effect.  
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Several diagnostic tests were employed to determine the molecular basis for the observed 
success of the chemoradioimmunotherapy treatment. The tests proved that the novel 
regimen had specifically impacted on the identified oncogenes that are essential to the 
propagation and perpetuation of the tumour cells. Evidence was found to show 1) there was 
clear downregulation of HER-2 as a consequence of the action of antiHER-2 scFv antibody; 
2) there was re-expression of the tumour suppressor gene BRCA1 as a consequence of the 
inhibition of the DNMT1 mRNA and; 3) the radioisotopes had induced DNA double strand 
breaks in the tumour cells.  
The combination of these molecular actions was responsible for circumvention of chemo- 
and radioresistant mechanisms in the tumour cells, allowing them to be effectively targeted 
and damaged by the chemotherapy and radiation therapy components leading to induction 
of apoptosis.  
According to John Giannios, ‘This technique will be very applicable in a clinical setting where 
treatment difficulties will be limited because, as a tailored and targeted anti-cancer 
treatment, the treatment will reduce systemic toxicity whilst enhancing the therapeutic index.  
‘Introducing the radiation by linking the radioisotopes to the anti-HER-2 antibody is more 
efficient than conventional external beam radiotherapy because the radiation is targeted 
specifically to those breast cancer cells that over-express HER-2/neu, leaving normal cells 
unaffected and thereby reducing system toxicity’, he added.  
‘These results open the possibility of combining targeted immunotherapy with chemotherapy 
and radiation therapy to successfully kill metastatic tumour cells’, said Dr Giannios. 
‘Theoretically this novel technique should be as effective in other types of cancer that are 
characterised by hypermethylation of tumour suppressor genes and the overexpression of 
oncogenes such as HER-2 and bcl-2. Our next step will be to develop the treatment in 
patients, and on a bigger scale, in a Phase I clinical trial’.  
Note: The Federation of European Cancer Societies (FECS) is the Brussels-based 
organisation that represents the interests of almost 18,000 cancer professionals in Europe. 
FECS promotes the multidisciplinary aspect of cancer care through political and scientific 
activities.  
The European Association for Cancer Research (EACR) is the pan-European organisation 
representing the scientists and researchers involved in the basic science and research in the 
field of oncology.  
Contact: Stuart Bell 
stuart@fecs.be 
00-32-0-495-27-2838 
Federation of European Cancer Societies  
Article URL: http://www.medicalnewstoday.com/articles/10412.php 
Main News Category: Cancer/Oncology 
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Formulation SEVIN-A composed of Pegylated-Nanoparticles of CDP bound to 
multitargeted siRNA molecules against BMI1 and Survivin conjugated with miR-373 
which targets CD44 overexpressing cancer stem cells (CSCs) of metastatic ovarian 
carcinoma induces Apoptosis/PCD type-I (D2 Stage) circumventing potent 
Chemoresistant-Multifactors caused by Vinorelbine 
John Giannios • Erasinio Oncology Hospital (Greece 
 
 
 
In addition to those listed below are many new, unmentioned presentations in oncology 
congresses: 
Giannios, J. et al., Induction of PCD in ALL cells after combined wtp53 lipofection 
vinorelbine treatment and radiation, 40th Annual American Society of Hematology Meeting, 
4-8 December, 1998, Miami Beach, Florida.  
Giannios, J. et al., Eradication by ADCC and p53 indept. PCD of chemoresistant 
esophageal squamous cell carcinoma (ESCC) overexpressing c-erbB2 after adm. of 
vinorelbine encapsulated in pegylated immunoliposomes consisting of Mab-antiHER2/neu 
and hexadecyl-PC, downregulating c-erbB2, (Immunobiology and Biologic Therapy 
Session) 36th ASCO Annual Meeting, 20-23 May, 2000, New Orleans, Louisiana.  
Giannios, J., Immunochemogene Tx consisting of recombinant adenovirus transfection of wt 
PTEN/MMAC1/TEP1 and PEGylated liposomal transfer of vinorelbine with linked anti-
HER2/Neu Mabs induced ADCC, complement dept. cytotoxicity and PCD in breast Ca 
overexpressing AKT2 and HER2/neu (Experimental/Molecular Therapeutics), 92nd AACR 
Annual Meeting, March 24-28, 2001, New Orleans, LA, 42, March 2001.  
Giannios, J. et al., Chimeric antibodies targeting the SH2 domain of Grb2 and p85a of PI3-K 
linked on PEG-SUVs with entrapped vinorelbine induced ADCC, ADMC, complement 
fixation, anoikis, apoptosis and inhibition of Ras/Raf/MEK/MAPK and PI3K/Akt pathways in 
chemoresistant breast Ca overexpressing HER-2/neu, Proceedings of American Society of 
Clinical Oncology, Volume 20, Part 1, 37th Annual Meeting, 12-15 May, 2001, San 
Francisco, CA.  
Giannios, J. et al., RhuMAb anti-HER-2/neu pegylated immunoliposomes with incorporated 
vinorelbine tartrate induces p53 indept. PCD and ADCC in chemoresistant NSCLC, ASCO, 
18, 1999.  
141 
 
Giannios, J. et al., HMG-CoA inhibitor lovastatin sensitizes highly aggressive breast 
carcinoma to PCD induced by vinorelbine, upregulating BAX, p53 and downregulating 
RhoA-GTPase, bcl-2, ECCO 10, 12-16 September. 1999, Vienna.  
Giannios, J. et al., A phase II study with vinorelbine, gemcitabine and cisplatin in the 
treatment of patients with stage IIIb-IV NSCLC, Lung Cancer, 23(1999), 31-37.  
Giannios, J. et al., Carcinoembryonic antigen and CA19-9 expression in primary and 
metastatic histological specimens of colorectal cancer, Annual Panhellenic Oncology 
Congress, 1999.  
Giannios, J. et al., Paclitaxel and carboplatin in advanced NSCLC:a phase II study, Eur. J. 
Oncol., 4(1), 15-20, 1999.  
Giannios et al., ScFv antibody fragments directed against intracellular HER-2/neu has 
blocked synthesis of membrane HER-2/neu (c-erbB2) proto-oncogene product p185 leading 
to induction of PCD, International Conference on Advances in Cancer Immunotherapy, New 
Jersey, March 4, 2000.  
Giannios et al., Induction of PCD in human chemoresistant breast carcinoma after 
combined adm. of Gene and Cytotoxic treatments, 10th International Congress on Senology 
(Breast diseases) of the Senologic International Society (S. I. S.), 31 May-4 June 1998, 
Oporto, Portugal.  
Giannios, J. et al., Induction of PCD in chemoresistant NSCLC after combined adm. of 
cytostatic paclitaxel, cytotoxic etoposide and colloidal plasmid pCB6+wtp53, 17th 
International Cancer Congress, UICC, Rio de Janeiro, Brazil, 24-28 August, 1998.  
Giannios, J. et al., Combined adm. of vinorelbine, wtp53cDNA and mitoxantrone treatment 
induces PCD in chemoresistant cervical carcinoma, Pharmacology and Experimental 
Therapeutics, AACR, April 1, 1998.  
Giannios, J. et al., Apoptotic-induced vinorelbine delivery (AIDD) mediated by 
electrochemotherapy (ECT) under hyperthermic conditions and radiation induced apoptosis 
(RIA) caused by IR (x-ray) enhanced wtp53 cDNA gene-transfer (REGT) and subsequent 
ROS formation by p53 induced genes (PIGs) eradicated radioresistant advanced breast Ca 
(aBRCa) with mutant p53, III International Symposium:Changes in the Treatment of Breast 
Cancer, 2-4 June, 1999, Madrid, Spain.  
Giannios, J. et al., ASA sensitizes advanced breast carcinoma to apoptotic-induced drug 
delivery by vinorelbine exerting synergestic down-modulation of bcl-2 oncogene and 
upregulation of Bax-gene, III International Symposium:Changes in the Tx of Breast Cancer, 
2-4 June, 1999, Madrid, Spain.  
Giannios, J. et al., Eradication of post-menopausal cervical carcinoma after adm. of 
combined gene therapy and chemotherapy, EMAS, 5th European Congress on Menopause, 
1-5 July, 2000,Copenhagen.  
Giannios, J. et al., Induction of D2 stage of PCD in Intraductal Breast Ca via ADCC and 
CPP32/caspase 2 pathway after adm. of antiHER-2 Mab plus calicheamicin 
immunoconjugate linked on liposomal vinorelbine (LVI), I European Spring Oncology 
Conference (ESOC-1), 28-30 April-1 May, 2000,Malaga, Spain.  
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Giannios, J. et al., Downregulated HER-2 as an apoptotic marker in intraductal breast Ca 
after combined adm. of colloidal paclitaxel with linked rhuantiHER-2 Mabs, Oncology from 
Molecules to Management Congress, 23-24 March 2000, Hong Kong.  
Giannios, J. et al., Adenoviral hairpin ribozyme (rAd-HER2-Rz) plus paclitaxel causes 
zeiosis with subsequent BKE in overexpressing HER-2 DCIS, 1st International Symposium 
on Genetic Anticancer Agents (Session:Apoptosis and Angiogenesis), 8-9 March, 2000,Vrije 
Universiteit Amsterdam, The Netherlands.  
Giannios, J. et al., Antisense adenoviral gene therapy against VEGF mRNA blocks 
angiogenesis and subsequent metastatic tumour growth in-vivo after open surgery in 
animals with primary invasive breast cancer, ESSO 2000, Federation of European Cancer 
Societies, The Netherlands, 5-8 April 2000.  
Giannios, J. et al., Bystander killing effect after induction of D2 apoptotic signs of invasive 
ductal breast cancer via ADCC and CPP32 cleavage after colloidal antisense ODN 
suppression of MT-tubulin-Bm mRNA, downmodulation of c-erbB2 by rhuMAb-HER2/neu, 
bcl-2 phosphorylation and cytochrome-c upregulation by paclitaxel, 91st Annual Meeting of 
American Association for Cancer Research, 1-5 April, 2000, San Francisco, CA.  
Giannios, J., p53 tumour suppressor gene therapy for breast cancer and induction of 
apoptosis, plenary session III: Markers for breast Ca differentiation and malignancy-
Apoptosis, 22nd Congress of the International Association for Breast Cancer Research, 25-
28 September, 1998, Athens, Greece.  
Giannios, J., Molecular Aspects of Breast and Ovarian Cancer, Eur. J. Gynaecol. Oncol. 
1997, 18(5), 387-393.  
Giannios, J. et al., Induction of apoptosis in chemoresistant acute lymphocytic leukemia 
(ALL) cells bycombined administration of pCB6+wtp53 lipofection, G1 blocker taxol and 
DNA intercalator doxorubicin, (Signaling and Gene Regulation) 11th Symposium in 
Molecular Biology of Hematopoiesis, 25-29 June, 1998, Bormio, Italy.  
Giannios, J., Eradication of HCC by induction of ADCC and subsequent apoptosis, Institut 
fur tumor Biologie-Krebs forschung der Universitat Wien, 6th European Meeting on 
Hepatocarcinogenesis: From Basic Research to Treatment, 25 September, 1999.  
Giannios, J. et al., A phase II study with vinorelbine, gemcitabine and cisplatin in the 
treatment of patients with stage III b-IV non-small cell lung carcinoma (NSCLC), Lung 
Cancer 1999 January, 23(1), 31-7.  
Giannios, J., Fab fragments of humanized antiHER2 IgG pegylated immunoliposomes 
(SUVs) with encapsulated vinorelbine tartrate induce PCD in human metastatic mtp53 
invasive ductal carcinoma cells of ipsilateral axillary nodes, Ninth International Congress on 
Anticancer Treatment, Paris, 2-5 February, 1999.  
Giannios, J., Induction of ADCC and subsequent apoptosis in CaP after adm. of vinorelbine 
encapsulated in pegylated immunoliposomes consisting of Mab-antiHER2/neu (c-erbB2) 
and hexadecyl-PC, altering expression in c-erbB2/neu, bax, bcl-2, PKC, JNK, p53 and 
VEGF, 17th World Congress on Endourology and SWL, 2-5 September, 1999, Rodos, 
Greece.  
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Giannios, J., Vinorelbine-tartrate eradicates resistant to anoikis prostate carcinoma (CaP) 
by downmodulation of bcl-2, VEGF/VPF and upregulation of bax, junN-terminal kinase, 
inhibiting angiogenesis and metastasis, 17th World Congress on Endourology and SWL, 2-5 
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